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Abstract
With the advent of combinatorial chemistry, the number of novel synthetic chemicals has
skyrocketed over the past three decades, bringing about tremendous advances in medicine and
material science. At the same time, the massive libraries of existing chemicals coupled with the
unprecedented rate of new chemical generation presents a unique and costly challenge to toxicity
testing in the 21 st century. In recent years, the United States has seen large coordinated efforts
across governmental agencies to shift from expensive and slow traditional in vivo tests to more
affordable and higher throughput in vitro methods.
For each human cell, about 100,000 DNA lesions occur every day. Unrepaired DNA
damage can lead to deleterious health consequences, including cancer and aging. Therefore, an
essential endpoint in cell-based chemical safety testing is the assessment of a compound's
genotoxic potential. In this work, we developed a CometChip platform that addresses two major
areas that are lacking in genotoxicity testing: 1. rapid and sensitive detection of bulky DNA
adducts, and 2. robust and physiologically relevant metabolism of test compounds. The assay uses
two DNA repair synthesis inhibitors, hydroxyurea and I-p-D-arabinofuranosyl cytosine, to cause
strand-break accumulation and HepaRGTM cells to provide high levels of liver-specific functions.
We also conducted extensive validation studies and a small chemical screen to demonstrate the
platform's applicability in genotoxicity testing.
One of the most important decisions of proliferating cells under stresses is to divide,
senesce, or die. Therefore, in vitro measurements of cell survival after a toxic exposure are among
the most fundamental and broadly used endpoints in biology. The gold standard for cell survival
testing is the colony forming assay, which is exquisitely sensitive but sees limited uses due its low-
throughput nature and requirement of large dishes. We have developed MicroColonyChip as a
high-throughput platform that can directly measure a cell's ability to divide and has the potential
to provide highly sensitive and rapid toxicity assessment of chemicals of interest. The technology
is based on the use of a microcolony array where the size distributions for different conditions
provide a direct measure of cell survival. We have results showing that MicroColonyChip is as
sensitive as the gold standard assay, reduces -80% incubation time, and requires -250x less
surface area for cell growth.
In addition to detecting genotoxic agents, it is also important to understand how an
individual responds to internal and external assaults to DNA as a necessary first step for assessment
of human health outcomes. There is a high variability in DNA repair capacity among people, and
more studies are needed to elucidate whether a causal relationship between DNA repair capacity
and clinical outcomes exists. We applied CometChip to study repair kinetics in human primary
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lymphocytes. In order to account for the extensive crosstalk and competition between different
repair pathways, repair of different types of DNA damage was measured. To test the assay's
sensitivity and reproducibility, a small population of 56 healthy volunteers were recruited to give
blood samples. Isolated lymphocytes from different individuals show significant differences in
repair kinetics of oxidative damage and a sevenfold variation in repair rates.
Taken together, the work described here represents significant technological advances in
addressing a number of major challenges in chemical toxicity testing as well as in the evaluation
of health outcome variability across populations. The technologies also open doors to exciting
opportunities in personalized strategies for disease prevention and intervention.
Thesis Supervisor: Bevin P. Engelward
Title: Professor of Biological Engineering
Thesis Supervisor: Leona D. Samson
Title: Professor of Biological Engineering and Biology
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Chapter 1
Background and Introduction
The large number of novel compounds produced every year and the vast reservoir of existing
chemicals pose an enormous public health challenge that traditional approaches for chemical safety testing
have failed to meet. Recent coordinated efforts from governmental programs recognize this challenge and
are working to change the way safety testing is conducted. More than ever, innovations that enable rapid
and reproducible analyses of large numbers of samples are needed. As a contribution to this effort, this
dissertation focuses on the development of two high-throughput platforms for assessment of genotoxicity
as well as cellular sensitivity to test compounds.
The effect on human health is the net result of the interactions between the chemicals and the
individual's molecular responses, which can vary widely across the population. In order to fully assess the
consequences of an exposure, it is therefore crucial to understand the differences in molecular responses
among individuals. DNA damage is a fundamental step toward a number of human diseases and aging, and
there is increasing evidence showing that the ability to repair DNA damage is one of the key determining
factors for health outcomes. This work demonstrates a potential use of CometChip, a high-throughput
platform for DNA damage detection, to assess the differences in individuals' repair capacity in response to
DNA damaging agents.
1.1. DNA DAMAGE AND HUMAN HEALTH
For each human cell, about 100,000 DNA lesions occur every day (1, 2), and the majority come
from three different sources. First, spontaneous chemical reactions, such as hydrolysis, can result in base
losses and deamination. Examples are the loss of purines due to hydrolysis of their N-glycosyl linkages
(depurination) and deamination of cytosine to uracil (3). Endogenous metabolism and inflammation are the
second and main source of DNA damage via reactive metabolites, such as reactive oxygen and nitrogen
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species (RONS), lipid peroxidation products, and reactive aldehydes (4, 5). The third source comes from
exogenous physical and chemical agents (5), such as ultraviolet light, pollutants, and ionizing radiation.
Paradoxically, a large number of cancer therapies kill tumor cells by inducing DNA damage, which can
result in secondary cancers.
Unrepaired DNA damage can lead to deleterious consequences (5). Damaged bases that mispair
during replication leave a permanent change in the genetic material (a mutation), which increases the risk
of cancer. DNA nicks and DNA lesions may stall replication, causing fork collapse that can lead to large
genomic changes (e.g. deletions/insertions, translocations, and amplifications) and increased cancer risk.
On the other hand, DNA damage that blocks replication may trigger either cell death or cell senescence,
contributing to aging (5).
To maintain genomic stability, the cells have evolved six major pathways for DNA repair (6, 7)
(Fig. 1-1). Some base modifications can be directly reversed by several proteins, such as the ALKBH family
and MGMT. Bases that mispair due to replication errors can be removed by mismatch repair (MMR). Base
excision repair (BER) or nucleotide excision repair (NER) are also involved in the removal of DNA lesions.
BER recognizes and removes bases with small adducts that minimally distort the double helix structure. In
addition, BER is involved in the repair of single-strand breaks (SSBs) and abasic sites. NER is capable of
removing bulky adducts that thermodynamically destabilize the DNA duplex. In addition to helix-distorting
lesions, a sub-pathway of NER, transcription-coupled repair (TC-NER), has also been implicated in the
repair of small lesions that block transcription (e.g. 3,N-ethenocytosine (8)). Double-strand breaks are
primarily repaired by non-homologous end-joining (NHEJ) and homologous recombination (HR) (9).
Although each major pathway is specialized to efficiently recognize and repair certain types of DNA
damage, there is extensive overlapping of substrates between the pathways.
Following are descriptions of some of the most common types of DNA damage, their molecular
and cellular consequences, the key repair pathways that act on them, and their effects on human health.
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Types of DNA damage
Single-strand breaks (SSBs)
SSBs are the most common type of DNA damage (10). The main source of SSBs is oxidative attack
by reactive oxygen species (ROS), such as superoxide, hydrogen peroxide, and hydroxyl radical. Heavily
regulated vital processes, such as transcription and translation, employ specialized enzymes (e.g. DNA
topoisomerases) to create SSBs. On the other hand, unregulated SSBs can form as intermediates in DNA
excision repair pathways or via direct breakage of the sugar-phosphate backbone due to oxidative attack.
Most SSBs are repaired by a global SSB repair process, which involves SSB detection, DNA end
processing, DNA gap filling, and DNA ligation steps. Many of the enzymes and processes involved in the
global SSB repair are shared with BER. Unrepaired SSBs can lead to devastating consequences to the cell
(10). In proliferating cells, SSBs can stall the replication fork, causing fork collapse, which results in
double-strand breaks (DSBs). DSBs can result in cell cycle arrest, which may trigger cell death or cellular
senescence. In non-proliferating cells, SSBs block RNA polymerases, triggering cell death (11-13).
Excessive SSBs can lead to cell death via hyperactivation of the protein poly(ADP-ribose) polymerase I
(PARP 1), which depletes cellular NAD+ and ATP and causes energetic failure (14, 15). This type of cell
death contributes to the pathology of conditions associated with oxidative stress, such as post-ischemic
brain or heart damage (10).
Double-strand breaks (DSBs)
DSBs are the most deleterious type of DNA damage (16), being highly cytotoxic and cytostatic (5).
In dividing cells, it is estimated that about 10 DSBs occur per cell per day (17-20). DSBs are introduced
mainly by oxidative attacks that result in breakage of the sugar-phosphate backbone (21). These attacks can
come from exogenous sources, such as ionizing radiation, or endogenous radicals generated during cellular
metabolism (17). DSBs also form as a consequence of replication fork collapse when it encounters SSBs
or unrepaired lesions (16, 17). During meiosis, DSBs are created to facilitate recombination (16, 17).
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Regulated rearrangements, such as V(D)J recombination and immunoglobulin class-switch recombination,
produce DSBs as intermediates (16, 17).
Chromosomal rearrangements that come from misrepair of DSBs lead to large genomic alterations,
such as deletions/insertions, translocations, loss of heterozygosity, and amplifications. Chromosomal
aberration is highly associated with increased risk of cancer. For example, the Philadelphia chromosome
(22) comes from a translocation between chromosomes 9 and 22 that results in a fusion between the BCR
and ABLJ genes. The fusion gene (BCR-ABLJ) codes for a tyrosine kinase that is constitutively active,
leading to unregulated cell division (22). The Philadelphia chromosome is associated with acute
lymphoblastic leukemia and chronic myeloid leukemia.
There are two main pathways that repair DSBs: NHEJ and HR. In recent years, two micro-
homology directed repair pathways have emerged to play important roles in DSB repair and associated
diseases: alternative end joining (alt-EJ) and single-strand annealing (SSA) (23). The molecular mechanism
for the pathway choice decision is not completely understood although recent studies have shed many
insights into the process (23). The initiation of 5'- 3' end resection commits the cell to HR and inhibits
repair by NHEJ. End resection proteins are tightly regulated by the cell cycle. As a consequence, the cell
cycle appears to play a crucial role in pathway choice. NHEJ is favored in non-proliferating cells and during
M/G1 phases while HR and the other two pathways are used primarily during S/G2 phases (24). In addition,
DSBs formed during meiosis are mainly resolved by HR (17).
DNA base damage
A large number of DNA damage involves chemical modifications of the nucleobases. Most DNA
damaging agents induce a spectrum of DNA lesions with diverse chemical structures and biological
consequences. Following is a discussion of a few groups of DNA base damage that are both prevalent and
important in the context of human health.
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Base oxidation comes predominantly from ROS induced by oxidative stress. The main endogenous
sources of ROS are cellular metabolisms, including oxidative phosphorylation by mitochondria,
metabolism by cytochrome P450s, and inflammatory cell activation (25). ROS are also produced in
response to exogenous sources, such as ionizing radiation (IR), ultraviolet light, chlorinated compounds,
and metal ions (25). Dietary intakes have also been shown to modulate the level of ROS in the body and
subsequently the level of oxidative damage. For example, consumption of kiwifruit (26) and carotenoids
(27, 28) significantly reduces the level of 8-oxoguanine (8-oxoG), an established biomarker for oxidative
stress.
Examples of common oxidative base lesions are shown in Fig. 1-2 (29, 30) . High levels of 8-oxoG
and thymine glycol have been used as biomarkers of persistent oxidative stress, which is associated with
aging and human diseases, including chronic inflammation, neurodegenerative diseases, and cancer (31).
Unrepaired, these lesions are also highly mutagenic (31). For example, 8-oxoG can mispair with A, causing
G-to-T transversion mutations (30, 31). The majority of oxidative base lesions are corrected by base
excision repair (BER), which has six glycosylases dedicated to the recognition and removal of oxidative
base lesions in mammalian cells (32).
Another prevalent type of base modification is DNA alkylation damage, which is caused by the
transfer of alkyl groups from alkylating agents onto DNA nucleobases or the sugar phosphate backbone.
Alkylating agents are ubiquitous. Endogenous sources include lipid peroxidation (LPO) and cellular methyl
donors, such as S-adenosylmethionine (6). Major external sources of alkylating agents are contaminants in
air or drinking water (e.g. N-nitrosodimethylamine) and pollutants (e.g. polycyclic aromatic hydrocarbons)
(6). Importantly, alkylating agents are routinely used as anticancer drugs, such as temozolomide, bis-
chloroethylnitrosourea (BCNU) (6).
The ring nitrogen (N) and the extracyclic oxygen (0) atoms are particularly vulnerable to reactions
with alkylating agents via either SNI or SN2 nucleophilic substitutions (examples of lesions in Fig. 1-3A).
SN I agents react readily with both N and 0 positions while SN2 agents mainly target the ring nitrogen atoms.
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Examples of strong SNI agents are nitrosoureas, many of which are used in chemotherapy (6). Examples of
SN 2 are alkane sulfonates, such as methyl methanesulfonate (MMS) (33). In addition, alkylating agents can
be either monofunctional or bifunctional. Monofunctional agents have one reactive group while
bifunctional agents have two reactive groups that can form covalent bonds with two DNA bases, generating
intrastrand and interstrand crosslinks (6).
Alkylated lesions have significant biological effects. For example, about 10% of alkylated lesions
are N3-methyl adenine (3meA), which blocks most DNA polymerases, triggering cell death (6, 34, 35).
About 60-80% of lesions are N7-methyl guanine (7meG), which is neither mutagenic nor cytotoxic.
However, 7meG is prone to hydrolysis, generating AP sites that are both mutagenic and cytotoxic (6, 34,
35). SNI agents induce a small number of 0 6 -methyl guanine (O6meG) lesions (-5%), which can mispair
with thymine during replication and cause a G-to-A mutation (6, 34, 35). On the other hand, the O'meG:T
mismatch can activate MMR, which acts on the newly synthesized DNA strand and removes the mispaired
thymine. MMR then reinserts a thymine across O6meG, creating a futile cycle. During the next replication
cycle, the persistent strand break generated by the repeated base removal and insertion process causes fork
collapse, resulting in chromosome aberrations, cell cycle arrest, and cell death (6).
Attacks of RONS on lipids, especially polyunsaturated fatty acids, generate lipid peroxides as
primary products and reactive aldehydes as secondary products (36). These aldehydes are potent DNA
alkylating agents, some examples of which are 4-hydroxy-2-nonenal (4-HNE), malondialdehyde (MDA),
acrolein, and crotonaldehyde. Their reactions with DNA bases can generate mutagenic exocyclic DNA
lesions, such as etheno adducts (five-member ring) and propano adducts (six-member ring) (37). Etheno
adducts (Fig. 1-3B) are highly mutagenic and thought to underlie the carcinogenicity of vinyl chloride and
urethane (37). Bulky adducts that distort the DNA duplex such as those induced by LPO (Fig. 1-3C) block
replication and can also be mutagenic (36, 37).
Alkylated bases are repaired by a number of different pathways. Small N-alkyl lesions (eg. 3meA,
7meG) are removed by the alkyladenine DNA glycosylase (AAG, also known as MPG) in mammalian cells
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as part of BER (32). AP sites are also repaired by BER. O'meG can be directly reversed by the MGMT
alkyltransferase in mammalian cells (6). In fact, increased MGMT expression has been implicated as a
potential mechanism for resistance to alkylating agents in cancer treatment (38-41). Bulky lesions (HNE-
dG and M1dG) are repaired by NER (36, 37). ALKBH enzymes can directly remove the etheno group in
some adducts [e.g, 1,N6-ethenoadenine (FA) and 1,N2-ethenoguanine] (42, 43). EA can also be removed by
AAG (44, 45), and as mentioned above, TC-NER contributes to the repair of EC (8). DNA crosslinks are
removed by a combination of HR and NER components (46).
An important group of DNA damage is comprised of bulky adducts that significantly disrupt base-
pairing and thermodynamically destabilize the DNA duplex. Some alkylated bases, such as the propano
adducts induced by LPO, belong to this group. Bulky lesions underlie the carcinogenicity of many known
environmental carcinogens (Fig. 1-4). Common examples include UV-induced adducts, cyclobutane
pyrimidine dimers (CPDs) and pyrimidine-pyrimidone photoproducts (6-4PPs), which are both cytotoxic
and mutagenic. 6-4PPs are efficiently removed by NER with a half-life of~2-3 hours while it takes ~10-24
hours for NER to remove half of CPDs (47). People diagnosed with xeroderma pigmentosum (XP) disorder
were born with a defect in one of the seven NER proteins or in DNA polymerase ri (48). XP patients are
reported to have 10,000-fold increase in skin cancer under 20 years of age, and 25% of the patients also
develop progressive neurological degeneration (48).
Another important class of DNA modifications is DNA crosslinks, which can be between bases of
opposing strands (interstrand) or between adjacent bases on the same DNA strand (intrastrand). Interstrand
crosslinks (ICLs) are highly toxic DNA modifications because they prevent the separation of DNA strands
in the double helix. Strand separation is essential for many molecular processes, including DNA replication
and transcription, and the blockage of these processes by ICLs triggers cell death (46). Intrastrand crosslinks
are much less cytotoxic because they can be bypassed by translesion DNA synthesis (TLS) (46). However,
they can mispair during this process and result in point mutations. Endogenous sources of DNA crosslinks
come from byproducts of LPO, such as acrolein and crotonaldehyde (49). Consumption of alcohol and a
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high-fat diet is shown to increase LPO and subsequently the level of DNA crosslinks (50-52). Currently,
the most prevalent class of chemotherapeutics is ICL-based, and many are bifunctional alkylating agents.
Some examples are cyclophosphamide, BCNU, and cisplatin. DNA crosslinks induced by ICL-based
chemotherapeutics are mostly intrastrand (e.g. 80-90% by cisplatin), which are partially repaired by NER
or bypassed by TLS (46). In most cases, only a small number of ICLs are induced (e.g. ~5% by cisplatin),
and these are primarily repaired by the Fanconi anaemia (FA) complex, which coordinates components
from HR, NER, and TLS (46). FA disorder results from genetic defects in key components of the FA
complex (46).
Common assays for DNA damage detection
Immunoassays
Antibodies against number of biomarkers for DNA damage provide highly sensitive tools for DNA
damage assessment (53). Some important examples include antibodies against oxidative damage (e.g. 8-
oxoG), alkylation damage (e.g. O'meG, 7meG), bulky lesions (e.g. benzo[a]pyrene-DNA adducts, aflatoxin
Bi-DNA adducts), markers of DSBs [e.g. yH2AX, p53-binding protein 1 (53BP1) (54)], and DNA repair
proteins [e.g. X-ray repair cross complementing 1 (XRCC 1) (55)]. Different types of immunoassays have
been applied in numerous studies where levels of DNA adducts were monitored following specific
environmental or clinical exposures (53). Immunoassays can range from highly quantitative methods, such
as the enzyme-linked immunosorbent assay (ELISA), to mostly qualitative techniques, such as
immunohistochemistry. There are assays that measure the level of DNA damage markers from cell and
tissue lysates, such as immunoblotting and ELISA. On the other hands, methods have been developed to
perform detection and/or quantification directly for each cell, e.g. fluorescent microscopy, fluorescence-
activated cell sorting (FACS) (53). Following is a brief discussion of the most commonly used biomarker
for DNA damage and repair, yH2AX foci, for which many sensitive and robust immunoassays have been
established.
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yH2AX
The most common method for detection and quantification of DSBs is via immunostaining for
yH2AX (56). A crucial component in repair of DSBs is the histone protein H2AX, which becomes
phosphorylated on serine 139 by P13K-like kinases (e.g. ATM, ATR, DNA-PK) to form yH2AX at nascent
DSB sites (54). Within minutes after DSBs arise, a large number of H2AX molecules are phosphorylated
in the chromatin near the break site, covering a stretch of DNA as long as 30 Mbp (54). The amplification
of yH2AX signal serves as a focus to recruit chromatin remodeling and DNA repair proteins. Importantly,
the high concentration of yHA2X near the break site enables the detection of a single DSB using an antibody
for yH2AX.
There are generally two different approaches for quantification of yH2AX levels. The first approach
measures yH2AX levels in cell or tissue lysates. Common techniques for this approach include
immunoblotting and enzyme-linked immunosorbent assay (ELISA) (57, 58). ELISA is a much more
sensitive method, and several high-throughput assays have been adapted to use in genotoxicity screening
and clinical trials (57, 59). The second and most common approach in measuring yHA2X is via
immunofluorescence and based on assessment directly in cells and tissues. The number of yH2AX foci has
been shown to correlate well with the number of DSBs (54, 60, 61), and the fluorescent foci can be counted
for each cell, manually or with a software, via fluorescent microscopy. The total level of yH2AX in each
cell can also be quantified with flow cytometry. While flow cytometry is faster and more quantitative,
fluorescent microscopy provides structural information that is missed in flow cytometry. One important
example is the difference between distinct foci, which are indicative of DSBs, and pan-staining, which is a
characteristic of apoptotic cells (62).
Advantages. A large body of evidence shows that yH2AX is a highly sensitive and robust measure of DSBs.
yH2AX is also an established biomarker for DNA damage (62) and cellular sensitivity to toxic agents (63).
In addition, yH2AX holds powerful potential for use in cancer diagnostics, cancer progression and treatment
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monitoring (54), and clinical pharmacodynamic studies (59). High-throughput and sensitive assays tailored
for different applications have been developed, facilitating ease of use.
Disadvantages. The majority of DNA damaging agents do not directly cause DSBs. In many cases, DSBs
are an indirect consequence of fork collapse due to replication blockage by DNA lesions. In these situations,
the result from yH2AX assay may differ significantly between resting cells and proliferative cells. Another
major concern in using the assay is the interpretation of the foci. It is still unclear whether every yH2AX
focus represents a DSB (64). In fact, formation of yH2AX foci have been observed in cells undergoing
apoptosis (65) as well as cells exposed to UV light (66). Small yH2AX foci also appear in certain cell types
(67, 68) and may interfere with the quantification of DSB-associated yH2AX foci.
Comet assays
Developed in 1984 (69), the comet assay has since become a classic tool in a number of fields,
including environmental biomonitoring, DNA repair studies, and genotoxicity screening (70, 71). The
comet assay is based upon electrophoretic migration of nuclear DNA in the presence of strand breaks (SBs).
DNA from cells exists as supercoiled loops, and a single SB relaxes the supercoiling, enabling the
movement of the free ends under electrophoresis (70). The result is a comet-like shape, where different
parameters of the comet tail can be quantified as a measure of DNA damage level. There are two main basic
versions of the comet assay. The alkaline comet assay detects DNA SSBs and alkali-labile sites while the
neutral comet assay mainly detects DSBs (72). The underlying principle of the comet assay dictates that
detectable DNA lesions must be convertible to SBs chemically, enzymatically, or biologically. Chemical
conversion includes transforming alkali-labile sites to SBs under high pH conditions (pH >13) (72).
Enzymatically, incubation with lesion-specific enzymes to create nicks or generate alkali-labile abasic sites
at the damage positions is an efficient method to improve sensitivity and specificity (e.g. Fpg, Endo III,
hOGG1, T4 Endo V, DpnI, AlkA, UDG) (72). Biological conversion is based on cellular repair of DNA
damage, which often involves multiple steps, including incisions to remove the damage base or a nucleotide
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fragment surrounding the damage site. Repair intermediates that contain DNA SBs are generated through
this process and can be detected by the comet assay (72).
The comet assay has been used with human primary samples to assess DNA damage levels of
people who have been exposed to genotoxic chemicals. The level of DNA damage has been demonstrated
as a sensitive biomarker for several types of exposure (73). For example, antioxidant diet reduces oxidative
damage (26-28) while tobacco smoke increases both oxidative damage (74, 75) and aromatic bulky DNA
lesions (76). In fact, many studies have found that smoking status is highly correlated with the level of
aromatic bulky adducts found in peripheral blood lymphocytes (PBLs), a high level of which is associated
with more than threefold increase in lung cancer risk (77, 78). In addition, concomitant exposure to AFB,
and Hepatitis B synergistically increases risk of liver cancer (79).
Potential clinical applications of the comet assay have been demonstrated in a number of studies.
Specifically, cancer incidence can be monitored using the comet assay to examine DNA damage levels in
PBLs. Supporting evidence for the feasibility of this application includes results showing that PBLs of
cancer patients (e.g. head and neck, breast, bladder, and so on) have elevated basal DNA damage compared
to control groups (80). In addition, high chromosome aberration frequency in PBLs has been established as
a reliable biomarker for cancer incidence (81), suggesting that it is feasible to monitor for cancer incidence
via measures of DNA damage in PBLs. Besides diagnostics, another potential clinical application of the
comet assay lies in early prediction of tumor response to a cancer treatment regimen. Because only a small
number of surviving tumor cells is sufficient for a treatment to fail, it is important to be able to predict early
the tumor response and design an effective treatment regimen accordingly. In fact, strong correlation has
been observed between DNA damage susceptibility measured by the alkaline comet assay and sensitivity
to y-radiation and several chemotherapeutics (e.g. cisplatin, mitomycin C) in cancer cell lines (80, 82).
Advantages. The key advantages of the comet assay include simple procedures, sensitivity to low levels of
DNA damage, affordability, use of a small number of cells, and small amounts of test compounds. In
addition, different versions of the comet assays have been developed tailored for detection of specific types
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of DNA damage. DNA repair synthesis inhibitors have also been used to enhance the sensitivity of strand
break detection.
Disadvantages. The disadvantages of the comet assay lie in its low-throughput nature, poor reproducibility,
and slow image processing and analysis methods. Problems with reproducibility stem from both technical
problems and human errors/bias. Recently, CometChip was invented in the Engelward laboratory to address
these challenges (83, 84). CometChip increases throughput by more than 5,000 fold and also significantly
improves reproducibility (85). Another disadvantage is the potential interference from cytotoxicity. SBs
can arise from cell death processes, such as apoptosis, and comet assays may overestimate the level of DNA
damage-induced SBs.
1.2. CELL SURVIVAL QUANTIFICATION
In vitro measurements of cell survival after a toxic exposure are among the most fundamental and
broadly used endpoints in biology (86, 87). As a basic research tool, cytotoxicity assays enable analysis of
molecular pathways and gene functions (88, 89). Viability assays are also a mainstay assay in the
pharmaceutical industry where they are used to predict adverse effects as well as establishing efficacy of
compounds designed to kill cells, such as chemotherapeutics (90). Furthermore, from the perspective of
environmental health, cytotoxicity assays are critical for identifying agents in our environment that are
potentially toxic. There is an acute need for faster and better cytotoxicity assays by environmental health
sciences given the challenge of the more than 2,000 new compounds that are introduced annually into our
environment by industry (91).
The gold standard for cell survival testing is the colony forming assay, wherein cells are exposed
to a cytotoxic agent and the ability of single cells to form colonies is quantified (92, 93). This assay was
developed decades ago, and is still performed in most laboratories using essentially the same approach
wherein surviving colonies are stained and counted by eye. The power of the colony forming assay is that
it provides a direct measure of the ability of cells to divide, and it has an impressive dynamic range,
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spanning over several orders of magnitude. Nevertheless, this assay is performed relatively infrequently
compared to other cytotoxicity assays (described below) because it is low-throughput (often requiring 10-
21 days of incubation), it is prone to bias, there is significant variation from laboratory to laboratory, and
large dishes with large volumes of media are generally required. Importantly, the requirement for large
plates renders the assay incompatible with high-throughput screening technologies that require a 96 or 384
well format, and also serves as a barrier for analysis of novel compounds wherein only small quantities are
available.
A popular class of viability assays rely upon membrane integrity and mitochondrial functions as
endpoints. Several assays, such as the trypan blue or propidium iodide exclusion assay, quantify the loss in
cell viability by measuring the proportion of cells that have lost membrane integrity. A drawback of this
approach is that membrane permeability does not always accurately reflect cell viability. For example, cells
going through early apoptosis would be counted as viable using this assay.
Another approach for estimating viability is to measure mitochondrial functions via metabolism-
based endpoints. For example, the MTT/XTT assays are based upon the underlying principle that a live cell
can reduce tetrazolium salts to formazan derivatives, accompanied by a change in color that can be
measured by absorbance. Analogously, the CellTiter-Glo@ (CTG®) assay (from Promega) is based on
quantification of intracellular ATP as a measure of viable cells (94). Although these assays are highly
prevalent in toxicity screening (eg. services offered by CROs, drug development in pharma), they have
significant shortcomings, such as artifacts as a result of changes in pH, factors that affect cellular
metabolism, and constituents in cell media (e.g. reducing agents) (86).
1.3. INTERINDIVIDUAL VARIATION IN DNA REPAIR CAPACITY
There is a high variability in how an individual responds to DNA damaging agents. This variation
manifests in several important contexts. First, the risk of cancer associated with environmental and
occupational exposures to genotoxic agents varies widely among individuals. For example, only 10% of
heavy smokers develop lung cancer (95). Second, cancer patients undergoing treatment suffer different
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degrees of side effects, which can be mild or severe. Third, tumor response to a treatment regimen is also
highly variable (96). Therefore, the ability to predict how an individual responds to a DNA damaging agent
may enable more accurate assessment of cancer risk and provide useful information to design tailored
treatment regimens in order to minimize side effects while maximizing treatment effectiveness.
Many lines of evidence point toward an association between aberrant DNA repair capacity and risk
of cancer as well as sensitivity to treatment. Xeroderma pigmentosum represents a classic example where
genetic defects in a major repair pathway, NER, lead to -2,000-fold increased risk of skin cancer (48).
Fanconi anaemia (FA) patients, who carry genetic defects in the FANC repair pathway, are hypersensitive
to chemotherapeutics that induce interstrand crosslinks (ICLs) (46). An example highlighting the role of
DNA repair in treatment efficacy is the case of breast and ovarian cancers, where BRCA 1/2-deficiency
confers sensitivity to PARPT inhibitors (97-99).
Over the past two decades, there is mounting evidence showing significant interindividual
variations in DNA repair capacity, which are associated with differences in disease risk and treatment
outcomes. The evidence has been contributed by methods that indirectly or directly measure DNA repair
capacity. Examples of major indirect methods include gene variant association and gene expression studies.
Important results from gene variant association studies include a large number of correlations between
common single nucleotide polymorphisms in genes in major DNA repair pathways and cancer risks (56).
There are also important examples from gene expression studies. Reduced expression levels of XPG or
CSB are associated with higher risk of lung cancer (100). In some cases, the expression level of a single
DNA repair gene can predict the outcomes for certain cancer treatments [e.g. MGMT (101), ERCCI (102)].
A major challenge with indirect methods of measurement is that they may fail to predict protein functions
due to the complexity of biological processes that govern the transition from a gene to a functional protein.
Direct or functional methods for measurements of DNA repair capacity include enzyme activity
assays performed on cell-free extracts, quantification of DNA damage (e.g. 32P-postlalebling, comet
assays), and quantification of repair efficiency of damaged reporter plasmid DNA [host-cell reactivation
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assays (HCR)]. Activity assays using cell lysates have revealed wide variations among important repair
enzymes. Examples include a tenfold variation in MGMT activity (103) and AAG activity (104) in cell-
free extracts prepared from human lymphocytes. The comet assays allow detection and quantification of
overall DNA damage levels or specific DNA lesions, enabling direct monitoring of DNA damage
disappearance over time as a measure of DNA repair efficiency as well as repair kinetics. A number of
studies using comet assays demonstrate a wide range of variation in repair among people and associated
cancer risks (105-107). Results from studies using HCR assays show interindividual variations across most
of the major DNA repair pathways (108, 109) and provide further evidence of the association between DNA
repair capacity and cancer risks (110-113).
Despite the significance of interindividual variation in DNA repair capacity and the importance of
functional methods, clinical applications have been limited. Specifically, clinical applications of DNA
repair capacity have been realized mostly in genetic testing of known mutations for genes associated with
DNA repair defects and diseases (114). There are only infrequent uses of certain cell-based assays, such as
chromosomal aberration and UV-induced unscheduled DNA synthesis, for diagnostics in the clinics (115,
116). Furthermore, although genetic defects in DNA repair proteins have been exploited to improve cancer
treatment outcomes (102, 117), interindividual variation in DNA repair capacity has not been considered
in cohort selection for clinical trials or in designing treatment regimens.
It is evident that more studies are needed to further elucidate the relationship between DNA repair
capacity and clinical outcomes. Larger and more prospective studies are especially crucial since it is unclear
whether the altered DNA repair capacity associated with cancer risk and response to treatment is the cause
or the effect. The extensive crosstalk and competition between the major DNA repair pathways also needs
to be taken into account in these studies. To these ends, high-throughput assays capable of measuring
multiple repair pathways in parallel, such as CometChip (83, 84) and a multiplexed fluorescence-based
flow cytometric HCR assay (FM-HCR) (109, 118), have been developed. Efforts to demonstrate their
applications in large-scale population studies are under way.
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1.4. OBJECTIVE AND SPECIFIC AIMS
The objective of this dissertation is to establish and validate cell-based platforms for HT evaluation
of chemical toxicity. To that end, the following specific aims are pursued, and the next chapters are devoted
to comprehensive descriptions and in-depth discussions of the experimental results.
Aim 1. Development of a CometChip platform for detection of DNA adducts induced by
metabolic activation. The work detailed in chapter 2 addresses two major areas that are lacking in
genotoxicity testing: 1. rapid and sensitive detection of bulky DNA adducts, and 2. robust and
physiologically relevant metabolism of test compounds. With the advent of the CometChip platform (83,
84), it becomes possible to measure DNA damage in a high-throughput and reproducible fashion (85). To
overcome the first challenge, a technique commonly used to enhance SB persistence in the alkaline sucrose
sedimentation assay is adopted into a CometChip procedure. Bulky DNA adducts are primarily repaired by
the NER pathway, which generates transient SB intermediates (Fig. 1-5). Two DNA repair synthesis
inhibitors, hydroxyurea (HU) and I -p-D-arabinofuranosyl cytosine (ara-C), are used to inhibit the gap
filling step of NER, causing accumulation of SBs easily detectable by the alkaline comet assay. The use of
HepaRGTM, a unique human hepatocyte cell line that maintains high levels of liver-specific functions,
provides a possible solution to the second challenge. Extensive validation studies and results from a small
chemical screen to demonstrate the platform's applicability in genotoxicity testing are also described in
details.
Aim 2. Development of a microarray colony formation platform, MicroColonyChip, for high-
throughput cell survival quantification. Chapter 3 showcases the establishment of a cell survival assay
that addresses major shortcomings of commonly used methods. The gold standard is the colony formation
assay, which is exquisitely sensitive but requires a long incubation and large amounts of valuable test
compounds. On the other hand, many popular assays that are fast and compatible with microtiter plates rely
on indirect biomarkers of cell viability, which can result in lack of sensitivity in addition to viability-
independent interferences. The MicroColonyChip exploits the microarray platform originally developed
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for CometChip to grow non-overlapping colonies that are evenly spaced from one another, substantially
reducing the surface area required for colony formation. The assay also relies on automated analysis of
colony size distributions to measure relative cell survival, achieving similar sensitivity as the gold standard
assay within a few days instead of weeks. This chapter describes how MicroColonyChip works, how it
compares to commonly used assays, and potential applications for toxicity testing.
Aim 3. Application of CometChip in human lymphocytes to study interindividual variation
in DNA repair capacity. Chapter 4 describes the initial efforts to apply CometChip for population studies.
The chapter begins with the work to optimize CometChip assays for measuring DNA repair kinetics in
response to different types of DNA damage, including oxidative damage, alkylation damage, bulky adducts,
and DSBs, in human primary lymphocytes. Next, a small pilot study of ten volunteers comparing
intraindividual and interindividual variations in repair of oxidative damage is described. The chapter ends
with results obtained from lymphocytes isolated from 46 healthy volunteers and preliminary analyses
showing a sevenfold variation in repair rates of oxidative damage.
Chapter 5 offers a discussion of the experimental achievements, the limitations, and future work to
further establish the methods for chemical safety testing and population studies.
29
1.5. REFERENCES
1. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993;362(6422):709-15.
2. Sander M, Cadet J, Casciano DA, Galloway SM, Marnett LJ, Novak RF, Pettit SD, Preston RJ, Skare
JA, Williams GM, Van Houten B, Gollapudi BB. Proceedings of a workshop on DNA adducts:
biological significance and applications to risk assessment Washington, DC, April 13-14, 2004.
Toxicol Appl Pharmacol. 2005;208(1):1-20. doi: 10.1016/j.taap.2004.12.012. PubMed PMID:
16164957.
3. Alberts B. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002. xxxiv, 1463, 86
p. p.
4. De Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data.
Mutagenesis. 2004;19(3):169-85. PubMed PMID: 15123782.
5. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475-85. doi:
10.1056/NEJMraO8O4615. PubMed PMID: 19812404.
6. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating
agents. Nat Rev Cancer. 2012;12(2):104-20. doi: 10.1038/nrc3185. PubMed PMID: 22237395;
PMCID: PMC3586545.
7. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-
94. doi: 10.1038/naturel0760. PubMed PMID: 22258607.
8. Chaim IA, Gardner A, Wu J, Iyama T, Wilson DM, 3rd, Samson LD. A novel role for transcription-
coupled nucleotide excision repair for the in vivo repair of 3,N4-ethenocytosine. Nucleic Acids Res.
2017;45(6):3242-52. doi: 10.1093/nar/gkx0 15. PubMed PMID: 28115629; PMCID: PMC5389632.
9. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature.
2009;461(7267):1071-8. doi: 10.1038/nature08467. PubMed PMID: 19847258; PMCID:
PMC2906700.
10. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet. 2008;9(8):619-31. doi:
10.1038/nrg2380. PubMed PMID: 18626472.
11. Kathe SD, Shen GP, Wallace SS. Single-stranded breaks in DNA but not oxidative DNA base damages
block transcriptional elongation by RNA polymerase II in HeLa cell nuclear extracts. J Biol Chem.
2004;279(18):18511-20. doi: 10.1074/jbc.M313598200. PubMed PMID: 14978042.
12. Zhou W, Doetsch PW. Effects of abasic sites and DNA single-strand breaks on prokaryotic RNA
polymerases. Proc Natl Acad Sci U S A. 1993;90(14):6601-5. PubMed PMID: 8341674; PMCID:
PMC46980.
30
13. Zhou W, Doetsch PW. Transcription bypass or blockage at single-strand breaks on the DNA template
strand: effect of different 3' and 5' flanking groups on the T7 RNA polymerase elongation complex.
Biochemistry. 1994;33(49):14926-34. PubMed PMID: 7993919.
14. Heeres JT, Hergenrother PJ. Poly(ADP-ribose) makes a date with death. Curr Opin Chem Biol.
2007;11(6):644-53. doi: 10.1016/j.cbpa.2007.08.038. PubMed PMID: 17936669.
15. Moroni F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin
Pharmacol. 2008;8(l):96-103. doi: 10.1016/j.coph.2007.10.005. PubMed PMID: 18032109.
16. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat
Genet. 2001;27(3):247-54. doi: 10.1038/85798. PubMed PMID: 11242102.
17. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-
joining pathway. Annu Rev Biochem. 2010;79:181-211. doi:
10.11 46/annurev.biochem.052308.093131. PubMed PMID: 20192759; PMCID: PMC3079308.
18. Lieber MR, Karanjawala ZE. Ageing, repetitive genomes and DNA damage. Nat Rev Mol Cell Biol.
2004;5(1):69-75. doi: 10.1038/nrml281. PubMed PMID: 14708011.
19. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous
DNA end-joining. Nat Rev Mol Cell Biol. 2003;4(9):712-20. doi: 10.1038/nrm1202. PubMed PMID:
14506474.
20. Martin GM, Smith AC, Ketterer DJ, Ogburn CE, Disteche CM. Increased chromosomal aberrations
in first metaphases of cells isolated from the kidneys of aged mice. Isr J Med Sci. 1985;21(3):296-301.
PubMed PMID: 3997491.
21. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res. 2008;18(1):114-
24. doi: 10.1038/cr.2008.3. PubMed PMID: 18166980.
22. Koretzky GA. The legacy of the Philadelphia chromosome. J Clin Invest. 2007; 117(8):2030-2. doi:
10.1172/JC133032. PubMed PMID: 17671635; PMCID: PMC1934583.
23. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair Pathway Choices and Consequences at the Double-
Strand Break. Trends Cell Biol. 2016;26(1):52-64. doi: 10.1016/j.tcb.2015.07.009. PubMed PMID:
26437586; PMCID: PMC4862604.
24. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev
Genet. 2011;45:247-71. doi: 10.1146/annurev-genet-110410-132435. PubMed PMID: 21910633.
25. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol
Toxicol. 2004;44:239-67. doi: 10.1146/annurev.pharmtox.44.101802.121851. PubMed PMID:
14744246.
31
26. Collins BH, Horska A, Hotten PM, Riddoch C, Collins AR. Kiwifruit protects against oxidative DNA
damage in human cells and in vitro. Nutr Cancer. 2001;39(1):148-53. doi:
10.1207/S15327914nc391_20. PubMed PMID: 11588897.
27. Lorenzo Y, Azqueta A, Luna L, Bonilla F, Dominguez G, Collins AR. The carotenoid beta-
cryptoxanthin stimulates the repair of DNA oxidation damage in addition to acting as an antioxidant
in human cells. Carcinogenesis. 2009;30(2):308-14. doi: 10.1093/carcin/bgn270. PubMed PMID:
19056931.
28. Pool-Zobel BL, Bub A, Muller H, Wollowski I, Rechkemmer G. Consumption of vegetables reduces
genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods.
Carcinogenesis. 1997; 18(9):1847-50. PubMed PMID: 9328185.
29. Krokan HE, Bjoras M. Base excision repair. Cold Spring Harb Perspect Biol. 2013;5(4):a012583. doi:
10.1 101/cshperspect.a012583. PubMed PMID: 23545420; PMCID: PMC3683898.
30. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and
significance. Mutat Res. 2004;567(1):1-61. doi: 10.1016/j.mrrev.2003.11.001. PubMed PMID:
15341901.
31. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in
human carcinogenesis. Mutat Res. 2011;711(1-2):193-201. doi: 10.1016/j.mrfmmm.2010.12.016.
PubMed PMID: 21216256.
32. Wallace SS. Base excision repair: a critical player in many games. DNA Repair (Amst). 2014;19:14-
26. doi: 10.1016/j.dnarep.2014.03.030. PubMed PMID: 24780558; PMCID: PMC4100245.
33. Jones GD, Le Pla RC, Farmer PB. Phosphotriester adducts (PTEs): DNA's overlooked lesion.
Mutagenesis. 2010;25(1):3-16. doi: 10.1093/mutage/gepO38. PubMed PMID: 19920061.
34. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with monofunctional
alkylating agents. Mutat Res. 1990;231(1):11-30. PubMed PMID: 2195323.
35. Beranek DT, Weis CC, Swenson DH. A comprehensive quantitative analysis of methylated and
ethylated DNA using high pressure liquid chromatography. Carcinogenesis. 1980;1:595-606.
36. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling
mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev.
2014;2014:360438. doi: 10.1155/2014/360438. PubMed PMID: 24999379; PMCID: PMC4066722.
37. Nair U, Bartsch H, Nair J. Lipid peroxidation-induced DNA damage in cancer-prone inflammatory
diseases: a review of published adduct types and levels in humans. Free Radic Biol Med.
2007;43(8):1109-20. doi: 10.1016/j.freeradbiomed.2007.07.012. PubMed PMID: 17854706.
32
38. Bobola MS, Berger MS, Ellenbogen RG, Roberts TS, Geyer JR, Silber JR. 06-Methylguanine-DNA
methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clin
Cancer Res. 2001;7(3):613-9. PubMed PMID: 11297257.
39. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase
(MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and
immunohistochemistry. Biochim Biophys Acta. 2011;1816(2):179-90. doi:
10.1016/j.bbcan.2011.06.002. PubMed PMID: 21745538.
40. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA,
Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Caimcross JG, Janzer RC, Stupp R.
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med.
2005;352(10):997-1003. doi: 10.1056/NEJMoaO43331. PubMed PMID: 15758010.
41. Hongeng S, Brent TP, Sanford RA, Li H, Kun LE, Heideman RL. 06-Methylguanine-DNA
methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res. 1997;3(12 Pt 1):2459-63.
PubMed PMID: 9815647.
42. Ringvoll J, Moen MN, Nordstrand LM, Meira LB, Pang B, Bekkelund A, Dedon PC, Bjelland S,
Samson LD, Falnes PO, Klungland A. AlkB homologue 2-mediated repair of ethenoadenine lesions
in mammalian DNA. Cancer Res. 2008;68(11):4142-9. Epub 2008/06/04. doi: 68/11/4142 [pii]
10.1158/0008-5472.CAN-08-0796. PubMed PMID: 18519673.
43. Zdzalik D, Domanska A, Prorok P, Kosicki K, van den Born E, Falnes PO, Rizzo CJ, Guengerich FP,
Tudek B. Differential repair of etheno-DNA adducts by bacterial and human AlkB proteins. DNA
Repair (Amst). 2015;30:1-10. doi: 10.1016/j.dnarep.2015.02.021. PubMed PMID: 25797601;
PMCID: PMC4451939.
44. Lee CY, Delaney JC, Kartalou M, Lingaraju GM, Maor-Shoshani A, Essigmann JM, Samson LD.
Recognition and processing of a new repertoire of DNA substrates by human 3-methyladenine DNA
glycosylase (AAG). Biochemistry. 2009;48(9):1850-61. doi: 10.1021/bi8018898. PubMed PMID:
19219989; PMCID: PMC2883313.
45. Saparbaev M, Kleibl K, Laval J. Escherichia coli, Saccharomyces cerevisiae, rat and human 3-
methyladenine DNA glycosylases repair 1,N6 -ethenoadenine when present in DNA. Nucleic Acids
Res. 1995;23(18):3750-5.
46. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11(7):467-
80. doi: 10.1038/nrc3088. PubMed PMID: 21701511; PMCID: PMC3560328.
47. Mitchell DL, Haipek CA, Clarkson JM. (6-4)Photoproducts are removed from the DNA of UV-
irradiated mammalian cells more efficiently than cyclobutane pyrimidine dimers. Mutat Res.
1985;143(3):109-12. PubMed PMID: 4010689.
33
48. DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol.
2012;132(3 Pt 2):785-96. doi: 10.1038/jid.2011.426. PubMed PMID: 22217736; PMCID:
PMC3279615.
49. Kozekov ID, Nechev LV, Moseley MS, Harris CM, Rizzo CJ, Stone MP, Harris TM. DNA interchain
cross-links formed by acrolein and crotonaldehyde. J Am Chem Soc. 2003;125(1):50-61. doi:
10.1021/ja020778f. PubMed PMID: 12515506.
50. Brooks PJ, Theruvathu JA. DNA adducts from acetaldehyde: implications for alcohol-related
carcinogenesis. Alcohol. 2005;35(3):187-93. doi: 10.1016/j.alcohol.2005.03.009. PubMed PMID:
16054980.
51. Folmer V, Soares JC, Gabriel D, Rocha JB. A high fat diet inhibits delta-aminolevulinate dehydratase
and increases lipid peroxidation in mice (Mus musculus). J Nutr. 2003;133(7):2165-70. PubMed
PMID: 12840172.
52. Stone MP, Cho YJ, Huang H, Kim HY, Kozekov ID, Kozekova A, Wang H, Minko IG, Lloyd RS,
Harris TM, Rizzo CJ. Interstrand DNA cross-links induced by alpha,beta-unsaturated aldehydes
derived from lipid peroxidation and environmental sources. Accounts of chemical research.
2008;41(7):793-804. doi: 10.1021 /ar700246x. PubMed PMID: 18500830; PMCID: PMC2785109.
53. Santella RM. Immunological methods for detection of carcinogen-DNA damage in humans. Cancer
Epidemiol Biomarkers Prev. 1999;8(9):733-9. PubMed PMID: 10498391.
54. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y.
GammaH2AX and cancer. Nat Rev Cancer. 2008;8(12):957-67. doi: 10.1038/nrc2523. PubMed
PMID: 19005492; PMCID: PMC3094856.
55. Figueroa-Gonzalez G, Perez-Plasencia C. Strategies for the evaluation of DNA damage and repair
mechanisms in cancer. Oncol Lett. 2017;13(6):3982-8. doi: 10.3892/ol.2017.6002. PubMed PMID:
28588692; PMCID: PMC5452911.
56. Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic
target. Clin Cancer Res. 2011;17(22):6973-84. doi: 10.1158/1078-0432.CCR-11-0761. PubMed
PMID: 21908578; PMCID: PMC3218201.
57. Matsuzaki K, Harada A, Takeiri A, Tanaka K, Mishima M. Whole cell-ELISA to measure the
gammaH2AX response of six aneugens and eight DNA-damaging chemicals. Mutat Res. 2010;700(1-
2):71-9. doi: 10.1016/j.mrgentox.2010.05.009. PubMed PMID: 20580854.
58. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo
AJ, Tomaszewski JE, Doroshow JH, Kinders RJ. Monitoring drug-induced gammaH2AX as a
pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res. 2010;16(3):1073-
84. doi: 10.1 158/1078-0432.CCR-09-2799. PubMed PMID: 20103672; PMCID: PMC2818670.
34
59. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH,
Pommier Y. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Clin Cancer Res. 2010;16(18):4532-42. doi: 10.1158/1078-0432.CCR-10-0523. PubMed PMID:
20823146; PMCID: PMC2940983.
60. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-
strand breaks in vivo. J Cell Biol. 1999;146(5):905-16. PubMed PMID: 10477747; PMCID:
PMC2169482.
61. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced
DNA double-strand breaks with gamma-H2AX antibody. Radiat Res. 2002;158(4):486-92. PubMed
PMID: 12236816.
62. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay to
monitor DNA damage and repair in translational cancer research. Cancer Lett. 2012;327(1-2):123-33.
doi: 10.1016/j.canlet.2011.12.025. PubMed PMID: 22198208; PMCID: PMC3329565.
63. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat
Oncol Biol Phys. 2004;58(2):331-5. PubMed PMID: 14751500.
64. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells
exposed to very low x-ray doses. Proc Natl Acad Sci USA. 2003;100(9):5057-62. PubMed PMID:
12679524.
65. Solier S, Sordet 0, Kohn KW, Pommier Y. Death receptor-induced activation of the Chk2- and histone
H2AX-associated DNA damage response pathways. Mol Cell Biol. 2009;29(1):68-82. doi:
10.1128/MCB.00581-08. PubMed PMID: 18955500; PMCID: PMC2612481.
66. Marti TM, Hefner E, Feeney L, Natale V, Cleaver JE. H2AX phosphorylation within the GI phase
after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc
Natl Acad Sci U S A. 2006;103(26):9891-6. doi: 10.1073/pnas.0603779103. PubMed PMID:
16788066; PMCID: PMC1502549.
67. McManus KJ, Hendzel MJ. ATM-dependent DNA damage-independent mitotic phosphorylation of
H2AX in normally growing mammalian cells. Molecular biology of the cell. 2005;16(10):5013-25.
doi: 10.1091/mbc.E05-01-0065. PubMed PMID: 16030261; PMCID: PMC1237100.
68. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human
cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nature cell
biology. 2004;6(2):168-70. doi: 10.1038/ncb1095. PubMed PMID: 14755273.
69. Ostling 0, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual
mammalian cells. Biochem Biophys Res Commun. 1984;123(1):291-8. PubMed PMID: 6477583.
35
70. Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat
Protoc. 2006; l(1):23-9. doi: 10.1038/nprot.2006.5. PubMed PMID: 17406208.
71. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A,
Speit G, Thybaud V, Tice RR. Recommendations for conducting the in vivo alkaline Comet assay. 4th
International Comet Assay Workshop. Mutagenesis. 2003;18(l):45-51. PubMed PMID: 12473734.
72. Collins A, A. OA, Brunborg G, Gaivao I, Giovannelli L, Kruszewski M, Smith CC, Stetina R. The
comet assay: topical issues. Mutagenesis. 2008;23:143-51.
73. Moller P. The alkaline comet assay: towards validation in biomonitoring of DNA damaging exposures.
Basic Clin Pharmacol Toxicol. 2006;98(4):336-45. doi: 10.1111/j.1742-7843.2006.pto167.x.
PubMed PMID: 16623855.
74. Arora A, Willhite CA, Liebler DC. Interactions of beta-carotene and cigarette smoke in human
bronchial epithelial cells. Carcinogenesis. 2001;22(8):1173-8. PubMed PMID: 11470745.
75. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ
Health Perspect. 1997;105 Suppl 4:875-82. PubMed PMID: 9255574; PMCID: PMC1470037.
76. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke
carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene.
2002;21(48):7435-51. doi: 10.1038/sj.onc.1205803. PubMed PMID: 12379884.
77. Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, Tsai WY, Ma J, Cole KJ, She MN,
Perera FP. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in
the physicians health study. Cancer Res. 2001;61(18):6708-12. PubMed PMID: 11559540.
78. Veglia F, Matullo G, Vineis P. Bulky DNA adducts and risk of cancer: a meta-analysis. Cancer
Epidemiol Biomarkers Prev. 2003;12(2):157-60. PubMed PMID: 12582026.
79. Henry SH, Bosch FX, Bowers JC. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med
Biol. 2002;504:229-33. PubMed PMID: 11922091.
80. McKenna DJ, McKeown SR, McKelvey-Martin VJ. Potential use of the comet assay in the clinical
management of cancer. Mutagenesis. 2008;23(3):183-90. doi: 10.1093/mutage/gemO54. PubMed
PMID: 18256034.
81. Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C. Chromosomal
aberrations in lymphocytes predict human cancer: a report from the European Study Group on
Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 1998;58(18):4117-21. PubMed PMID:
9751622.
82. Bowman KJ, Al-Moneef MM, Sherwood BT, Colquhoun AJ, Goddard JC, Griffiths TR, Payne D,
Singh S, Butterworth PC, Khan MA, Summerton DJ, Steward WP, McKelvey-Martin VJ, McKeown
SR. Kockelbergh RC, Mellon JK, Symonds RP, Jones GD. Comet assay measures of DNA damage
36
are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo. Int J Cancer.
2014;134(5):1102-11. doi: 10.1002/ijc.28437. PubMed PMID: 23959905.
83. Weingeist DM, Ge J, Wood DK, Mutamba JT, Huang Q, Rowland EA, Yaffe MB, Floyd S, Engelward
BP. Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and
DNA repair inhibitors. Cell Cycle. 2013;12(6):907-15. doi: 10.4161/cc.23880. PubMed PMID:
23422001; PMCID: PMC3637349.
84. Wood DK, Weingeist DM, Bhatia SN, Engelward BP. Single cell trapping and DNA damage analysis
using microwell arrays. Proc Natl Acad Sci U S A. 2010;107(22):10008-13. doi:
10.1073/pnas.1004056107. PubMed PMID: 20534572; PMCID: PMC2890454.
85. Ge J, Chow DN, Fessler JL, Weingeist DM, Wood DK, Engelward BP. Micropatterned comet assay
enables high throughput and sensitive DNA damage quantification. Mutagenesis. 2015;30(1):11-9.
doi: 10.1093/mutage/geuO63. PubMed PMID: 25527723; PMCID: PMC4272061.
86. Sumantran VN. Cellular chemosensitivity assays: an overview. Methods Mol Biol. 2011;731:219-36.
doi: 10.1007/978-1-61779-080-5 19. PubMed PMID: 21516411.
87. Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L, Storts D, Reid Y. Cell Viability
Assays. In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, Bejcek B,
Glicksman M, Inglese J, Iversen PW, Li Z, McGee J, McManus 0, Minor L, Napper A, Peltier JM,
Riss T, Trask OJ, Jr., Weidner J, editors. Assay Guidance Manual. Bethesda (MD)2004.
88. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev
Cancer. 2005;5(3):231-7. doi: 10.1038/nrcl560. PubMed PMID: 15738985.
89. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG,
Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA,
Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS,
Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G,
Hardwick JM, Hengartner MO, Ichijo H, Jaattela M, Kepp 0, Kimchi A, Klionsky DJ, Knight RA,
Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ,
Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nunez
G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich
GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp
J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer
G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.
Cell Death Differ. 2009;16(8):1093-107. doi: 10.1038/cdd.2009.44. PubMed PMID: 19373242;
PMCID: PMC2757140.
37
90. Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo
chemosensitivity testing. Mol Biotechnol. 2007;35(2):185-97. PubMed PMID: 17435285.
91. Shukla SJ, Huang R, Austin CP, Xia M. The future of toxicity testing: a focus on in vitro methods
using a quantitative high-throughput screening platform. Drug Discov Today. 2010; 15(23-24):997-
1007. doi: 10.1016/j.drudis.2010.07.007. PubMed PMID: 20708096; PMCID: 2994991.
92. Puck TT, Marcus Pl. A Rapid Method for Viable Cell Titration and Clone Production with Hela Cells
in Tissue Culture: The Use of X-Irradiated Cells to Supply Conditioning Factors. Proc Natl Acad Sci
U S A. 1955;41(7):432-7. PubMed PMID: 16589695; PMCID: 528114.
93. Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med. 1956;103:653-66.
94. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell
proliferation and cytotoxicity. J Immunol Methods. 1993;160(1):81-8. PubMed PMID: 7680699.
95. Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene.
2004;23(38):6500-23. doi: 10.1038/sj.onc.1207811. PubMed PMID: 15322521.
96. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and
the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol
Phys. 1995;31(5):1341-6. doi: 10.1016/0360-3016(95)00060-C. PubMed PMID: 7713792.
97. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M,
Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young
women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol.
2010;28(3):375-9. doi: 10.1200/JCO.2008.20.7019. PubMed PMID: 20008645.
98. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A,
O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of
poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med.
2009;361(2):123-34. doi: 10.1056/NEJMoa0900212. PubMed PMID: 19553641.
99. Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer:
current practice and future directions. Br J Cancer. 2016; 115(10):1157-73. doi: 10.1 038/bjc.2016.311.
PubMed PMID: 27736844; PMCID: PMC5104889 participated in advisory boards for Genentech,
Clovis Oncology, and Medivation. RSK was involved in the development of rucaparib, participated
in olaparib trials, and served an advisory role to Clovis Oncology.
100. Li C, Wang LE, Wei Q. DNA repair phenotype and cancer susceptibility--a mini review. Int J Cancer.
2009;124(5):999-1007. doi: 10.1002/ijc.24126. PubMed PMID: 19065660; PMCID: PMC4349428.
101. Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A,
Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Promoter CpG island hypermethylation of
the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for
38
metastatic colorectal cancer. Clin Cancer Res. 2013;19(8):2265-72. doi: 10.1 158/1078-0432.CCR-12-
3518. PubMed PMID: 23422094.
102. Olaussen KA, Mountzios G, Soria JC. ERCC I as a risk stratifier in platinum-based chemotherapy for
nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007;13(4):284-9. doi:
10.1097/MCP.0b013e32816b5c63. PubMed PMID: 17534174.
103. O'Donnell PN, Barber PV, Margison GP, Povey AC. Association between 06-alkylguanine-DNA-
alkyltransferase activity in peripheral blood lymphocytes and bronchial epithelial cells. Cancer
Epidemiol Biomarkers Prev. 1999;8(7):641-5. PubMed PMID: 10428203.
104. Calvo JA, Moroski-Erkul CA, Lake A, Eichinger LW, Shah D, Jhun I, Limsirichai P, Bronson RT,
Christiani DC, Meira LB, Samson LD. Aag DNA glycosylase promotes alkylation-induced tissue
damage mediated by Parpl. PLoS genetics. 2013;9(4):e1003413. doi: 10.1371/journal.pgen.1003413.
PubMed PMID: 23593019; PMCID: 3617098.
105. Gaivao I, Piasek A, Brevik A, Shaposhnikov S, Collins AR. Comet assay-based methods for
measuring DNA repair in vitro; estimates of inter- and intra-individual variation. Cell biology and
toxicology. 2009;25(1):45-52. doi: 10.1007/si0565-007-9047-5. PubMed PMID: 18058031.
106. El-Zein RA, Monroy CM, Cortes A, Spitz MR, Greisinger A, Etzel CJ. Rapid method for
determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers.
BMC cancer. 2010;10:439. doi: 10.1186/1471-2407-10-439. PubMed PMID: 20718982; PMCID:
PMC2933626.
107. Palyvoda 0, Polanska J, Wygoda A, Rzeszowska-Wolny J. DNA damage and repair in lymphocytes
of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta
Biochim Pol. 2003;50(1):181-90. doi: 035001181. PubMed PMID: 12673358.
108. Nagel ZD, Chaim IA, Samson LD. Inter-individual variation in DNA repair capacity: a need for multi-
pathway functional assays to promote translational DNA repair research. DNA Repair (Amst).
2014;19:199-213. doi: 10.1016/j.dnarep.2014.03.009. PubMed PMID: 24780560; PMCID:
PMC4071454.
109. Nagel ZD, Margulies CM, Chaim IA, McRee SK, Mazzucato P, Ahmad A, Abo RP, Butty VL, Forget
AL, Samson LD. Multiplexed DNA repair assays for multiple lesions and multiple doses via
transcription inhibition and transcriptional mutagenesis. Proc Natl Acad Sci U S A.
2014;111(18):E1823-32. doi: 10.1073/pnas.1401182111. PubMed PMID: 24757057; PMCID:
PMC4020053.
110. Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q. Reduced DNA repair capacity in head and
neck cancer patients. Cancer Epidemiol Biomarkers Prev. 1998;7(6):465-8. PubMed PMID: 9641488.
39
111. Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q. Reduced DNA repair of
benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer
patients. Carcinogenesis. 2004;25(9):1695-700. doi: 10.1093/carcin/bgh167. PubMed PMID:
15090466.
112. Wang L, Wei Q, Shi Q, Guo Z, Qiao Y, Spitz MR. A modified host-cell reactivation assay to measure
repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis.
2007;28(7):1430-6. doi: 10.1 093/carcin/bgmO29. PubMed PMID: 17341660.
113. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos
CI, Spitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant
melanoma. J Natl Cancer Inst. 2003;95(4):308-15. PubMed PMID: 12591987.
114. Ellis CN, SpringerLink (Online service). Obtaining and Using Genetic Information. 2011. In: Inherited
cancer syndromes [Internet]. New York ; London: Springer,. 2nd. [pl- 2 1]. Available from:
SpringerLink http://dx.doi.org/I0.1007/978-1-4419-6821-0 MIT Access Only.
115. Alter BP. Diagnostic evaludation of FA. In: Eiler ME, Frohnmayer D, Larsen K, Owen J, editors.
Fanconi Anemia: Guidelines for Diagnosis and Management. 3rd ed: Fanconi Anemia Reserach Fund,
Inc.; 2008.
116. Bernstam VA. CRC Handbook of Gene Level Diagnostics in Clinical Practice. Boca Raton, FL: CRC
Press; 1992.
117. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP 1 and beyond.
Nat Rev Cancer. 2010;10(4):293-301. doi: 10.1038/nrc2812. PubMed PMID: 20200537; PMCID:
PMC2910902.
118. Chaim IA, Nagel ZD, Jordan JJ, Mazzucato P, Ngo LP, Samson LD. In vivo measurements of
interindividual differences in DNA glycosylases and APEl activities. Proc Natl Acad Sci U S A.
2017;114(48):E10379-E88. doi: 10.1073/pnas.1712032114. PubMed PMID: 29122935.
119. Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JH. Understanding nucleotide excision repair and
its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014;15(7):465-81. doi: 10.1038/nrm3822.
PubMed PMID: 24954209.
120. Li CL, Golebiowski FM, Onishi Y, Samara NL, Sugasawa K, Yang W. Tripartite DNA Lesion
Recognition and Verification by XPC, TFIIH, and XPA in Nucleotide Excision Repair. Mol Cell.
2015;59(6):1025-34. doi: 10.1016/j.molcel.2015.08.012. PubMed PMID: 26384665; PMCID:
PMC4617536.
121. Dunand-Sauthier I, Hohl M, Thorel F, Jaquier-Gubler P, Clarkson SG, Scharer OD. The spacer region
of XPG mediates recruitment to nucleotide excision repair complexes and determines substrate
40
specificity. J Biol Chem. 2005;280(8):7030-7. doi: 10.1074/jbc.M412228200. PubMed PMID:
15590680.
122. Hohl M, Thorel F, Clarkson SG, Scharer OD. Structural determinants for substrate binding and
catalysis by the structure-specific endonuclease XPG. J Biol Chem. 2003;278(21):19500-8. doi:
10.1074/jbc.M213155200. PubMed PMID: 12644470.
41
Base Baeaklto
oxidation nBulky Base mismatches,
OHDSB adducts deletions/insertions
G GT
HRBER DR NHEJ NER MMR
Figure 1-1. Major types of DNA damage and DNA repair mechanisms (adapted from (7)). SSB = single-
strand break, DSB = double-strand break, BER = base excision repair, DR = direct reversal, HR =
homologous recombination, NHEJ = non-homologous end joining, NER = nucleotide excision repair,
MMR = mismatch repair.
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Figure 1-5. Nucleotide excision repair (adapted from (119) by permission from RightsLink Permissions
Springer Customer Service Centre GmbH: Springer Nature, Nature Reviews Molecular Cell Biology).
There are two separate NER subpathways, global-genomic (GG-NER) and transcription-coupled (TC-
NER). The two subpathways differ in the initial damage recognition (steps 1, 2, and 3). GG-NER relies on
the damage sensor XPC in complex with RAD23 and CETN2 to constantly probe for disrupted base-
pairing. Once detected, the XPC complex binds to the DNA strand opposite the lesion. The diversity of
NER substrates is partially due to the fact that the XPC complex does not depend on direct contact with the
lesion for damage recognition. In TC-NER, a damage site is indirectly recognized when transcription is
blocked. The Cockayne syndrome protein CSB transiently interacts with RNA polymerase II during
transcription elongation and binds the stalled RNA polymerase II with a higher affinity. The CSA protein
is recruited to form the CSA-CSB complex, which potentially facilitates the backtracking of the stalled
RNA polymerase II, making the lesion accessible for repair. After damage recognition, the two NER
subpathways converge. The transcriptional initiation factor II helicase (TFIIH) complex is recruited to the
damage site by XPC (step 4). Upon binding, the CAK module dissociates from the TFIIH complex, leaving
behind a seven-subunit core (Core7). In a recent study, the CAK module has been shown to inhibit DNA
binding by TFIIH, thereby enhancing the specificity of XPC-dependent recruitment (120). Core7 includes
two ATP-dependent helicases, XPB and XPD, which are essential in unwinding the DNA around the lesion
to form a DNA bubble. Furthermore, a recent finding shows that XPB and XPD potentially provide an
additional damage verification step since the presence of bulky lesions inhibits their helicase activity (120).
While the same study also finds that AP sites do not inhibit the helicase activity, it is unclear whether this
result applies to other small base lesions. The damage verification step is believed to be further aided by
the XPA protein, which preferentially binds to single-stranded, modified nucleotides (119). TFIIH also
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TC-NERGG-NER
mediates the recruitment of a structure-specific endonuclease, XPG, to the NER preincision complex (121).
Once the lesion is verified, XPA recruits the structure-specific endonuclease complex, XPF-ERCC 1, which
makes a 5' incision to the damage site (step 5). Gap filling DNA synthesis by DNA polymerases 6, K, and
F can happen immediately after this step. XPG is activated, potentially by the conformational change in the
NER complex (122), and cleaves the DNA strand 3' to the lesion site (step 6). Consequently, the lesion is
excised along with a DNA single strand of 22-30 nucleotides. DNA polymerases continue to fill in the gap
(step 7), and the final nick is sealed by DNA ligase 1 or 3 (step 8).
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Chapter 2
High-Throughput Platform for Detection of DNA Adducts Induced by
Metabolic Activation of Xenobiotics
2.1. ABSTRACT
The comet assay is a well-known sensitive method used for measuring DNA damage that can lead
to or can be converted into strand breaks in DNA. One blind spot of the comet assay is its poor sensitivity
to detect bulky DNA adducts induced by the metabolism of xenobiotics, such as benzo[a]pyrene (B[a]P)
and aflatoxin B 1 (AFB1 ). CometChip, a high-throughput comet platform recently invented in the Engelward
laboratory, increases throughput by more than 5,000 fold and also increases reproducibility. The advantages
provided by CometChip enable our work aimed at optimizing conditions for high-throughput detection of
bulky DNA damage. We optimized CometChip conditions using DNA repair synthesis inhibitors
[hydroxyurea (HU) and 1 -p-D-arabinofuranosyl cytosine (ara-C)] to prevent completion of nucleotide
excision repair (NER) of bulky DNA adducts (the HU/ara-C approach). We also leveraged the metabolic
capacity of the HepaRGTM cell line for genotoxic assessment that is relevant in a human context. Here, we
demonstrated the use of our approach for detection of bulky DNA adducts induced by bioactivation in
HepaRGTM cells. We used B[a]P and AFBI as model DNA damaging agents that require bioactivation to
be reactive with DNA. Using specific CYP450 inhibitors, we validated that DNA damage detected is
dependent upon bioactivation of B[a]P and AFB 1. Importantly, inhibiting NER initiation resulted in a
reduction in the detected signal, confirming the mechanism of DNA damage detection in the HU/ara-C
approach is via NER-induced strand-break (SB) intermediates. Taken together, this approach provides a
rapid and sensitive method for genotoxicity assessment of chemicals in human-relevant metabolic
conditions.
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2.2. INTRODUCTION
Injuries to genetic material can lead to debilitating heritable diseases, cancers, and aging (1-4). It
is required that all pharmaceuticals are comprehensively tested for their genotoxic potential (5). On the
other hand, people are exposed to an unknown number of chemicals every day, most of which have not
been tested for safety. Current genotoxicity tests recognized by the regulatory authorities (e.g. Ames test,
chromosome aberration test, in vitro mouse lymphoma thymidine kinase mutation assay) are slow,
laborious, and often require large quantities of expensive test compounds (6). Significantly, there are about
100,000 synthetic chemicals in consumer products (7), and more than 2,000 new chemicals are released
every year (8), increasing the urgent need for testing methods that are not only reliable and sensitive but
also adaptable for high-throughput (HT) screens.
Although there have been many advances in the ability to screen for genotoxicity (6), many HT
technologies depend on indirect measures of DNA damage, such as yH2AX formation (9) or p53 activation
(10). To identify genotoxic agents, a number of methods are used for detecting DNA damage, including the
unscheduled DNA synthesis assay, alkaline elution method, and the single-cell gel electrophoresis assay
(comet assay). Developed in 1984 (11), the comet assay has since become a classic tool in a number of
fields, including environmental biomonitoring, DNA repair mechanisms, and genotoxicity (12, 13). The
key advantages of the comet assay include simple procedures, sensitivity to low levels of DNA damage,
affordability, use of a small number of cells, and small amounts of test compounds. The disadvantages of
the comet assay lie in its low-throughput nature, poor reproducibility, and slow image processing and
analysis methods. Problems with reproducibility stem from both technical problems and human errors/bias.
Recently, CometChip was invented in the Engelward laboratory to address these challenges of the
conventional comet assay (14, 15). CometChip increases throughput by more than 5,000 fold and also
significantly improves reproducibility (16).
The comet assay is based upon electrophoretic migration of nuclear DNA in the presence of SBs.
DNA from cells exists as supercoiled loops, and a single SB relaxes the supercoiling, enabling the
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movement of the free ends under electrophoresis (12). The result is a comet-like shape, where different
parameters of the comet tail can be quantified as a measure of DNA damage level. There are two main basic
versions of the comet assay. In the context of genotoxicity testing, the most relevant version is the alkaline
assay (pH >13) due to its sensitivity to a broader range of DNA damage than the neutral comet assay (13).
The alkaline comet assay detects DNA strand breaks and alkali-labile sites, such as abasic sites. Abasic
sites are the result of spontaneous loss of a damage base (most often alkylated purines) or are intermediates
in the base excision repair pathway (BER) (17). For this study, we opted to use the alkaline comet version
to maximize our platform's sensitivity.
The underlying principle of the comet assay dictates that detectable DNA lesions must be
convertible to SBs chemically, enzymatically, or biologically. Chemical conversion includes converting
alkali-labile sites to SBs under high pH conditions (pH >13) (17). Enzymatically, incubation with lesion-
specific enzymes creates nicks or generates alkali-labile abasic sites at the damage positions, which is an
efficient method to improve sensitivity and specificity (e.g. oxidized bases or alkylated bases) (17).
Biological conversion is based on cellular repair of DNA damage, which often involves multiple steps,
including incisions to remove the damage base or a nucleotide fragment surrounding the damage site.
Repair intermediates that contain DNA SBs are generated through this process and can be detected by the
comet assay (17).
Many environmental carcinogens have been shown to cause bulky DNA adducts (3, 18, 19). DNA
adducts are considered "bulky" when the damage thermodynamically destabilizes the DNA double helix,
distorting the DNA structure (18, 19). Examples are ultraviolet radiation (UVR)-induced lesions, including
cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidones (6-4PPs) (20), and adducts induced by
bioactivated polycyclic aromatic hydrocarbons (PAHs) (21). Unrepaired adducts can block replication and
transcription, which leads to cell-cycle arrest that can result in cell death (22), as well as promote
mutagenesis and carcinogenesis (23-27). In fact, high levels of bulky DNA adducts have been shown to
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correlate with an increased risk of cancer in humans (28, 29). Therefore, a method enabling sensitive and
rapid detection of bulky adducts has the potential to make a positive and significant impact on human health.
The conventional comet assay has relatively poor sensitivity bulky DNA lesions because these
lesions are difficult to convert to SBs. There are currently no robust methods using endonucleases to create
lesion-specific nicks. Therefore, these lesions are often indirectly detected via SB repair intermediates of
NER (17). Having the widest range of substrates among the repair pathways, NER is the main pathway that
recognizes and removes bulky DNA lesions (18-20). NER operates following an efficient "cut-patch-cut-
patch" model, minimizing the presence of SB intermediates (30). The incision 5' to the damage site made
by the ERCC 1 -XPF endonuclease is followed by DNA repair synthesis, which in turn activates 3' incision
by the XPG endonuclease. DNA repair synthesis continues to fill in the resulting gap, and the nick is sealed
by DNA ligases (31, 32).
Importantly, inhibition of DNA repair synthesis has been shown by a number of techniques to
enhance SB accumulation in cells treated with UV light and PAHs, including the alkaline sucrose
sedimentation assay (33, 34), alkaline unwinding (35), alkaline elution assay (36, 37), and the alkaline
comet assay (38-40). A combination of HU and ara-C is often employed. HU depletes the
deoxyribonucleotide triphosphate (dNTP) pool by inhibiting the activity of ribonucleotide reductase (41-
45). Ara-C is a deoxycytidine structural analog (46), which can be incorporated into DNA (47-50),
inhibiting DNA elongation by DNA polymerases and causing early chain termination (47, 51-54)
The HU/ara-C combination enhances the comet assay's sensitivity in detecting DNA damage and
has the potential to be used as an efficient tool in genotoxicity testing (38-40). However, little has been
done to validate the contribution of bulky adducts in the detected signals as well as develop conditions for
a HT approach. Here, we aimed to develop a HT platform based on CometChip for sensitive detection of
bulky DNA adducts by using HU and ara-C to amplify the level of SBs generated by NER.
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In the human body, foreign substances (xenobiotics) are extensively metabolized, mainly by
hepatocytes in the liver (55). Bioactivation is the metabolic process whereby a chemical is converted into
reactive or toxic metabolites. Therefore, in order for chemical toxicity assessment to be physiologically
relevant, it is essential to have a testing system that can provide appropriate levels of xenobiotic metabolism.
Many environmental procarcinogens are hydrophobic, allowing for passive diffusion through the
cell membrane (56). Kidney clearance of the parent chemicals requires that they are converted to a more
hydrophilic form to be soluble in aqueous urine (55). The biotransformation process of xenobiotics is
typically divided into two phases. Phase I includes oxidation/reduction of parent chemicals, increasing their
hydrophilicity by adding polar groups, such as hydroxyl or amine (55, 56). The cytochrome P450 enzymes
(CYP450s), or microsomal mixed-function mono-oxygenases, account for -75% of all phase I enzymes
(56) and are involved in -95% of oxidative biotransformation (55). Phase II further increases the polarity
of the metabolites from phase I (or chemicals containing moieties appropriate for conjugation reactions) by
adding hydrophilic groups (e.g. glucuronic acid, glutathione, and so on) (55). In many cases, the oxidation
products of CYP450s carry highly unstable and reactive moieties (e.g. epoxide) that readily react with
DNA, forming covalent adducts. Therefore, any assessment of chemical genotoxicity needs to take into
consideration the genotoxic potential of both the parent chemicals and their metabolites.
A major drawback of current in vitro genotoxicity assays is the lack of a standard system that can
provide consistent and human relevant levels of metabolic enzymes. In regulatory settings, rat liver S9
fraction is recommended in most in vitro toxicity tests to provide metabolic activation (5). The use of rat
S9 fraction has a few critical disadvantages, including the interspecies difference between rat and human
metabolisms, large batch-to-batch metabolic variability, and overrepresentation of CYP450s (57-61). For
these reasons, a system that uses a human cell model is preferable. Currently, primary human hepatocytes
are considered the gold standard (62). The drawbacks are high costs and low reproducibility due to inter-
individual variation in metabolic capacity (63). To circumvent these advantages, a number of cell lines have
been established, some of which were derived from human liver cancers (e.g. HepG2, Fa2N-4, BC2) while
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some were engineered to express metabolic enzymes (e.g. MCL-5). Human liver-derived cell lines tend to
express very low levels of metabolic enzymes (63). For example, the classic human hepatoblastoma-derived
HepG2 cell line, which was established nearly 40 years ago (64), has been widely used in a large number
of studies with references in more than 9,000 scientific articles (65). Although HepG2 cells retain many
liver specific functions, they exhibit very low basal and inducible levels of P450s, with the exception of
CYPI family. Engineered cell lines, on the other hand, often express a narrow set of CYP450s and do not
exhibit the regulation of gene expression in primary hepatocytes (63, 66).
In 2002, the hepatoma cell line HepaRG was established from a hepatocellular hepatoma as a cell
model for Hepatitis B infection studies (67). HepaRG cells can undergo extensive differentiation, exhibiting
hepatocyte-like morphology as well as displaying substantial liver-specific functions. Differentiated
HepaRG cells (commercialized as HepaRGTM) express broad-spectrum Phase I and Phase II enzymes, many
of which are maintained at levels within the normal range of human hepatocytes and are significantly higher
than in HepG2 cells. Since establishment, HepaRGTM cells have gained popularity as an in vitro model for
a number of drug metabolism and hepatototixicty studies (60, 68-78).
In this study, we developed an alkaline CometChip platform for genotoxicity HT screening by
incorporating the use of two DNA repair synthesis inhibitors, HU and ara-C, and HepaRGTM cells. We
describe here the use of this platform in detection of bulky DNA adducts induced by bioactivation. We used
B[a]P and AFB1 as model DNA damaging agents that require bioactivation to be reactive with DNA. Using
CYP450 inhibitors, we validated that DNA damage detected using our approach is dependent upon
metabolic activation of B[a]P and AFB1 . Importantly, we inhibited NER initiation, which results in a
reduction in SB levels, indicating the contribution of NER intermediates to detected SBs. Furthermore, we
demonstrated that the platform has superior sensitivity compared to the conventional alkaline comet
procedure using a small screen of nine known in vivo genotoxins.
Taken together, we have leveraged the HT advantage of CometChip, the enhanced sensitivity of
the HU/ara-C combination, and the metabolic capacity of HepaRGTM cells to develop a screening platform
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for DNA damage induced by the metabolism of xenobiotics. We believe this platform provides a rapid and
sensitive tool to help overcome an important public health challenge, which is HT genotoxicity assessment
in human-relevant metabolic conditions.
2.3. MATERIAL AND METHODS
Chemicals
Reduced L-glutathione (GSH, G6013), hydroxyurea (HU, H8627), and cytosine arabinoside (ara-
C, C 1768) were obtained from MilliporeSigma, St. Louis, MO. IX GSH solution (10 mM) was prepared
by dissolving GSH powder in warm culture medium and used immediately within 30 minutes of
preparation. 1,000X HU (1 M) and 1,000X ara-C (10 mM) stock solutions were prepared by dissolving
crystal HU and ara-C in cell culture grade water and stored in 30-50 pL aliquots at -20'C for no more than
one year.
30% w/w hydrogen peroxide (H 202 ) solution was obtained from MilliporeSigma, St. Louis, MO
(H1009) and was stored at 4'C, protected from light. H202 dilutions were freshly prepared from the 30%
stock immediately before use. 99% methyl methanesulfonate (MMS) solution was obtained from
MilliporeSigma, St. Louis, MO (129925) and was stored at room temperature. MMS dilutions were freshly
prepared from the 99% stock less than 15 minutes before use. 100% dimethyl sulfoxide (DMSO) was
obtained from MilliporeSigma, St. Louis, MO (D8418).
Other chemicals (Table 2-1) were purchased in powder form and dissolved to prepare stock
solutions, and their aliquots were stored at -20'C for up to one year. To use, an aliquot was slowly thawed
at room temperature.
Cell culture
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Dulbecco's phosphate-buffered saline (DPBS), high-glucose Dulbecco's Modified Eagle's
Medium (DMEM, high glucose, 11965092), RMPI-1640 with GlutaMAX TM (61870), 200 mM L-glutamine
(A2916801), 10,000 U/ml Pen-Strep (15140), lOOX GlutaMAX TM supplement (35050061), William's E
Medium (WEM, A1217601), HepaRGTM Thaw, Plate, & General Purpose Medium Supplement
(HPRG670), HepaRG TM Maintenance/Metabolism Medium Supplement (HPRG620), 0.25% Trypsin-
EDTA with phenol red (25200), and 96-well plate coated with collagen I (Al 142803) were purchased from
ThermoFisher Scientific, Waltham, MA. Fetal bovine serum was obtained from Atlanta Biologicals, Inc.,
Flowery Branch, GA.
All the cells were cultured in an incubator set at 370 C with 5% CO2 .
TK6 (79, 80), a human B-lymphoblastoid cell line, was a gift from W. Thilly. TK6 was cultured in
RPMI 1640 medium with GlutaMAX TM supplemented with 100 U/ml Pen-Strep. TK6 cell suspension was
directly obtained from the suspension culture.
The XPG cell lines were gifts from 0. Scharer. These include XPG-deficient, XPG/WT, and
XPG/E791 A. The XPG-deficient cell line was obtained from SV40-transformation of the primary human
skin fibroblasts from patient XPCS1RO (81). XPG/WT and XPG/E791A cells were obtained from the
stable transfection of the lentiviral vector containing XPG WT cDNA or XPG-E791 A cDNA in the XPG-
deficient cell line (30). The XPG cell lines were cultured in high-glucose DMEM supplemented with 10%
FBS, 2 mM L-glutamine, and 100 U/ml Pen-Strep.
HepG2 (ATCC® HB-8065 TM), an immortalized cell line derived from human hepatocellular
carcinoma, was obtained from the American Type Culture Collection (Manassas, VA). The cells were
cultured in high-glucose DMEM supplemented with 10% FBS, lX GlutaMAX TM, and 100 U/ml Pen-Strep.
For chemical exposures, exponentially growing cells were plated in a tissue cultured treated 96-well plate
two days before treatment. The seeding density was 50,000 cells/well.
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Cryopreserved HepaRGTM (HPRGC 10), a terminally differentiated hepatic cell line, was purchased
from ThermoFisher Scientific (Waltham, MA). HepaRGTM was thawed and cultured according to the
supplier's manual. Briefly, the general purpose working medium was WEM supplemented with IX
GlutaMAXTM and IX HepaRGTM Thaw, Plate, & General Purpose Medium Supplement. The metabolism
working medium was WEM supplemented with IX GlutaMAXTM and HepaRG TM
Maintenance/Metabolism Medium Supplement. HepaRGTM cells were thawed in the general purpose
working medium and plated in a 96-well plate coated with collagen I at 100,000 cells/well. For same-day
chemical treatments, the final volume per well after plating was 50 ptL. Cells were allowed to attach for 1-
1.5 hr. 50 piL of chemical solution in 2X concentration (prepared in the general purpose working medium)
was added to each well to obtain a final concentration of IX and a final volume of 100 ptL. For day-7
chemical treatments, the final volume per well after plating was 100 pL. One day after plating, the general
purpose working medium was changed to the metabolism working medium. The metabolism working
medium was renewed on day 4 and day 6 after plating. On day 7, the cells were treated with 100 pL of IX
test chemical prepared in the metabolism working medium.
To obtain cell suspension for the XP-G cell lines, HepG2, and HepaRG, the monolayer culture was
incubated with 0.25% Trypsin-EDTA at 370 C. For XPG cell lines, the incubation time was 1-2 minutes.
For HepG2 and HepaRG, the incubation time was 5-10 minutes. Detached cells were then suspended in
complete working media. Cell viability and cell number were analyzed using an automated Trypan Blue
exclusion system [Vi-CELLTM cell counter (Beckman Coulter Life Sciences, Brea, CA)].
CometChip fabrication
SylgarTM 184 silicone elastomer kit (102092-312) and bottomless 96-well plates (82050-714) were
purchased from VWR, Radnor, PA. GelBond® Film (53761) was obtained from Lonza, Portsmouth, NH.
UltraPure TM agarose (16500100) and UltraPureTM low melting point agarose (16520100) were purchased
from ThermoFisher Scientific, Waltham, MA.
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The microwells were fabricated as described previously (14-16, 82). Briefly, 1% w/v agarose
solution in DPBS was prepared. A polydimethylsiloxane (PDMS) stamp with an array of micropegs was
fabricated using the SylgarTM 184 kit as described previously (15). The stamp was pressed into the molten
agarose solution on top of the hydrophilic side of a sheet of GelBond® Film. The agarose was allowed to
gel at room temperature for ~15 minutes. The stamp was removed to reveal an array of microwells with
-40-50 tm in both diameter and depth. The microwells were spaced 240 pm apart. A bottomless 96-well
plate was pressed on top of the agarose chip to form 96 macrowells. The bottom of each macrowell was an
array of~-300 microwells.
To load cells into microwells, ~2,000 - 200,000 cells in suspension were placed into each
macrowell, and the chip was incubated at 37'C in the presence of 5% CO 2 for 15 minutes. This time is
sufficient for most cell types to have fully loaded into the microwells by gravity. Excess cells were then
washed off with DPBS by shear force. The chip was covered with a layer of overlay agarose (1% w/v low-
melting point agarose solution in DPBS, kept molten at 43'C until use). For complete solidification of the
overlay agarose, the chip was kept at room temperature for 2 minutes followed by 2 minutes at 4'C.
Alkaline comet assay
Sodium chloride (NaCl, 7581), disodium EDTA (Na2EDTA, 4931), and sodium hydroxide pellets
(NaOH, 7708) were purchased from VWR, Radnor, PA. Trizma@ base (T1503), Trizma@ HCl (T5941),
and Triton X-100 (X-100) were obtained from MilliporeSigma, St. Louis, MO. 10,OOOX SYBRTM Gold
nucleic acid gel stain was obtained from ThermoFisher Scientific, Waltham, MA.
The alkaline lysis buffer (pH ~ 10) was a solution of 2.5 M NaCl, 100 mM Na2EDTA, 10 mM
Trizma@ base, and 1% v/v Triton X-100 dissolved in de-ionized H20 (dI H 2 0). The alkaline unwinding
buffer (pH ~ 13.5) was prepared by diluting NaOH and Na 2EDTA stock solutions in dl H2 0 to final
concentrations of 0.3 M and 1 mM, respectively. The neutralization buffer (pH - 7.5) was prepared by
dissolving Trizma® HCl in distilled H20 to a final concentration of 0.4 M.
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Cells encapsulated in CometChip were lysed in the alkaline lysis buffer overnight at 4'C. The
nuclei were unwound in the alkaline unwinding buffer for 40 minutes at 41C, and the DNA was
electrophoresed in the same buffer at the same temperature for 30 minutes at 1 V/cm and ~300 mA. The
CometChip was then washed three times in the neutralization buffer by submerging for five minutes each
time.
Afterward, the DNA on ComeChip was stained for 15 minutes at room temperature with IX of
SYBRTM Gold diluted in DPBS, protected from light. Fluorescent images of the comets were captured at
40X magnification using an epifluorescence microscope (Nikon Eclipse 80i, Nikon Instruments, Inc.,
Melville, NY) with a 480 nm excitation filter. Image acquisition was achieved by automatic scanning using
a motorized XY stage. Comet images were automatically analyzed using Guicometanalyzer, a custom
software developed in MATLAB (The MathWorks Inc., Natick, MA) as previously described (15). Outputs
from Guicometanalyzer were processed and imported to a spreadsheet (Microsoft Excel, Microsoft Office
Suite 2016) using Comet2Excel, an in-house software developed in Python (Python Software Foundation,
Python version 2.7.10).
Liver perfusion and hepatocyte culture on CometChip
100X Gibco@ Antibiotic-Antimycotic (15240) was purchased from ThermoFisher Scientific,
Waltham, MA. Insulin-transferrin-sodium selenite supplement (ITS) (11074547001), aprotinin (A3428),
HEPES (H4034), dexamethasone (D4902), and Percoll® (P4937) were obtained from MilliporeSigma, St.
Louis, MO.
Isolation medium was WEM supplemented with IX GlutaMAX TM, lX Gibco@ Antibioti-
Antimycotic, 10 ptg/mL IST, 1 tg/mL aprotinin, 10 mM HEPES, 0.1 1iM dexamethasone, and 10% FBS.
Maintenance medium was isolation medium without 10% FBS.
Primary mouse hepatocytes were obtained from 10-14 week old C57B16 mice using a standard two-
step collagenase liver perfusion procedure with minor changes (83, 84). The isolated cells were suspended
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in the isolation medium and were enriched for viable hepatocytes by centrifugation using a 45% Percoll®
solution. Cell viability and cell number were analyzed using an automated Trypan Blue exclusion system
[Vi-CELLTM cell counter (Beckman Coulter Life Sciences, Brea, CA)]. The perfusion procedure yielded
-20-50 million cells per liver and ~80-90% cell viability.
Microwell array in agarose chip was fabricated as described in the Alkaline CometChip section
with some changes. Specifically, the 1% w/v agarose solution and the overlay agarose solution were
supplemented with 2X Gibco@ Antibiotic-Antimycotic. Hepatocytes in suspension were loaded into
microwells by incubating at 37'C for a maximum of 10 minutes. After the agarose overlay step, cells were
incubated in isolation medium (50 ptL/macrowell) at 37'C in the presence of 5% CO 2. After four hours,
isolation medium was exchanged for maintenance medium, and cells were incubated overnight at 37'C in
the presence of 5% CO2. After the overnight incubation, chemical treatments were performed by exposing
cells to IX solution of test compounds diluted in the maintenance medium (50 pL/macrowell).
Ultraviolet (UV) light exposure
Prior to UV irradiation, cells embedded in CometChip were incubated for 40 minutes at 37'C in
working medium supplemented with 10 mM GSH. Exposure to 254 nm UV light radiation (UVC) was
administered via a handheld UV lamp that had a dose-rate of 14 J/m 2 /s at a distance of 7.6 cm (UVP
95001614, ThermoFisher Scientific, Waltham, MA). The UV irradiation procedure was carried out in the
dark at 4'C.
To query the level of bulky adducts induced by UV exposure, we used a combination of 1 mM HU
and 10 pM ara-C to inhibit NER repair synthesis. Specifically, 50OX HU/ara-C solution was prepared by
combining one volume of I M HU and one volume of 10 mM ara-C. Before UV exposure, cells were
pretreated with IX HU/ara-C prepared in working medium supplemented with 10 mM GSH for 40 minutes
at 37'C. Following UV exposure, cells were incubated in working medium supplemented with 10 mM GSH
59
and 1X HU/ara-C for one hour and four hours at 37'C. Cells were lysed in the alkaline lysis buffer and the
level of DNA strand breaks were analyzed following the alkaline comet assay described above.
To study NER efficiency, we examined the the repair rate of CPDs induced by UV irradiation. The
bacterial T4 endonuclease V (M0308S, New England BioLabs, Ipswich, MA) was used in combination
with the alkaline comet assay to query the level of CPDs (85) over 24 hours of repair. Briefly, UV-exposed
cells were incubated in working medium supplemented with 10 mM GSH for one hour, four hours, and 24
hours. Cells embedded in CometChip were lysed overnight in the alkaline lysis buffer. The CometChip was
then washed three times with the enzyme reaction buffer (1 mM EDTA, 100 mM NaCl, 25 mM Na2HPO 4 ,
100 ptg/mL BSA, pH 7.2) by submerging for 15 minutes each time. The enzyme reaction was performed by
incubating the CometChip with 50 U/mL T4 Endonuclease V in the enzyme reaction buffer for 15 minutes
at 37'C. Afterward, the CometChip was placed in the alkaline unwinding buffer and processed following
the remaining steps of the alkaline comet assay.
AFB1 and Bla]P treatments
For each dose of the test compound, a 200X solution was prepared by diluting the stock solution
(4 mM AFB1 or 20 mM B[a]P) in DMSO. The IX solution was prepared by diluting the 200X with cell
culture medium. A vehicle control condition was included by diluting DMSO in cell culture medium to get
a final concentration of 0.5%. Cells were incubated with the IX solution for 24 hours at 37'C in the presence
of 5% CO2. To reveal the level of DNA damage induced by the test compound, cells were also exposed to
IX HU/ara-C at the same time. After treatment, cells were analyzed with the alkaline comet assay.
Inhibition of AFBI or BjaJP bioactivation
5 pM KET or 25 ptM ANF was added to culture medium at the start of the AFB1 or B[a]P treatment
to inhibit AFB1 or B[a]P bioactivation, respectively. The maximum final concentration of DMSO was 0.6%.
The remaining steps were similar to the AFBI and B[a]P treatments.
Inhibition of NER initiation with spironolactone (SP)
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Cells were pretreated with 20 pM SP for 5 hours at 370 C. For UV-treatment, 20 piM was also added
to the 40-min incubated period prior to UV exposure and in the medium for repair following the irradiation.
The maximum concentration of DMSO was 0.1%, and the remaining steps were similar to the UV exposure
experiment. For AFB1 and B[a]P, 20 pM SP was also added to the culture medium during the treatment
period. The maximum final concentration of DMSO was 0.6%. The remaining steps were similar to the
AFBI and B[a]P treatments.
CellTiter-Glo® assay (CTG®) for cell viability
The CellTiter-Glo® luminescent cell viability assay kit (G7570) was obtained from Promega,
Madison, WI. Cell viability after 24 hours of chemical treatment was measured according to the
manufacturer's manual. Luminescent signals were recorded using a SpectraMax M2e microplate reader
(Molecular Devices, Sunnyvale, CA). Control wells with no cells were included to obtain background
luminescence, which was then subtracted from the signals measured in the sample wells.
P450-GloTM assays for CYP3A4 and CYP1A2 activity
The P450-GIOTM CYP3A4 assay with luciferin-IPA (V9001) and the P450-GIOT M CYPI A2 assay
with luciferin-1A2 (V8421) were purchased from Promega, Madison, Wi. The activity levels of CYP3A4
and CYP1A2 in cells were measured according to the manufacturer's protocol for non-lytic cell-based
assays. Luminescent signals were recorded using a SpectraMax M2e microplate reader (Molecular Devices,
Sunnyvale, CA). Control wells with no cells were included to obtain background luminescence. The net
signal for each sample was obtained by subtracting the background luminescence value.
CYP3A4 or CYP1A2 activity per cell can be obtained by normalizing P450-GIO TM values with cell
numbers. After a sample was analyzed for CYP3A4 or CYPlA2 activity, the CTG® assay was performed
to obtain an estimate of the number of viable cells in the sample. The result from P450-GloTM was then
divided by the CTG@ value to obtain CYP3A4 or CYPIA2 activity per cell.
Hydrogen peroxide (H20 2) treatment
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Doses of H202 were prepared immediately before use by diluting 30% stock solution (10 M) with
cold PBS. Suspension of TK6 cells was obtained directly from exponentially growing culture and loaded
onto CometChip (see "CometChip fabrication"). A new bottomless 96-well was placed on top of the
CometChip. 100 ptL of H202 solution was pipetted into each well, and the CometChip was incubated at 4'C
for 20 minutes, protected from light. Afterward, the H 202 solution was aspirated, and the bottomless plate
was taken off. The CometChip was rinsed by submerging in cold PBS. To analyzed DNA damage
immediately after treatment, the CometChip was placed in cold alkaline lysis buffer and processed
following the remaining steps of the alkaline comet assay. To study repair kinetics, the CometChip was cut
into -5 cm x 5 cm pieces using a pair of sterile surgical scissors and incubated in culture medium at 37'C
for up to two hours. At each time point, a piece of CometChip was removed and placed in cold alkaline
lysis buffer. The remaining steps followed the alkaline comet assay procedure.
Methylmethane sulfonate (MMS) treatment
Doses of MMS were prepared -15 minutes before use by diluting 99% stock solution (11.8 M)
with warm serum-free media (pre-warmed by incubation at 37C). Suspension of TK6 cells was obtained
directly from exponentially growing culture, and 1 mL of cell suspension was placed in a 15 mL conical
tube. The tube was centrifuged (200 x g, 5 minutes), and the supernatant was aspirated. The cell pellet in
each well was re-suspended in 1 mL of MMS solution, and the tube was incubated for 30 minutes or one
hour at 370 C. Next, the tube was again centrifuged (200 x g, 5 minutes), and MMS supernatant was
aspirated. Each cell pellet was washed three times by re-suspending in 1 mL PBS, spinning down (200 x g,
5 minutes), and aspirating the supernatant. After the last wash, each pellet was re-suspended in 1 mL culture
medium. To analyzed DNA damage immediately after treatment, 50 pL of cell suspension was transfer to
a macrowell on CometChip. After the cells loaded into the microwells (see "CometChip fabrication"), they
were immediately placed in cold alkaline lysis buffer and processed following the remaining steps of the
alkaline comet assay. To analyze repair kinetics, remaining cells in the tube were incubated at 37C for up
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to 24 hours. At each time point, 50 ptL of cell suspension was transfer to a macrowell on CometChip and
processed as above.
2.4. RESULTS
Modification of alkaline CometChip for sensitive detection of bulky DNA adducts (HU/ara-C
approach)
Many environmental carcinogens, such as ultraviolet light, aflatoxins, PAHs, and heterocyclic
amines, induce DNA lesions that are considered "bulky" (18, 19). Bulky adducts thermodynamically
destabilize the double helix, making them good substrates of NER (19). After the damage site is recognized
and verified, dual incisions are made to excise a 22-30 nucleotide fragment surrounding the damage site
(20). As a consequence, NER produces a number of SB intermediates as part of the repair pathway. These
intermediates are, in principle, detectable by the alkaline comet assay. However, it has been reported that
the frequency of SBs is relatively low in high UV doses (86), which suggests that NER SB intermediates
are transient and difficult to detect with the alkaline comet assay.
To improve throughput and reproducibility, in this study we performed the alkaline comet
procedure using CometChip as described previously (15, 16, 82) (Fig. 2-1, see Methods). In order to
investigate the sensitivity of the alkaline CometChip in detecting bulky DNA lesions, we exposed
immortalized human fibroblasts with UV-C, which is known to induce mostly CPDs and 6-4PPs (20), as
well as oxidative damage (87, 88). Both CPD and 6-4PP are known to destabilize the DNA duplex and are
substrates for NER (18-20). To minimize oxidative damage induced by UV radiation, the cells were pre-
treated with reduced glutathione (10 mM GSH). After exposure to UV-C, the cells were allowed to repair
for up to four hours in fresh medium supplemented with GSH. As shown in Fig. 2-2A, the level of DNA
SBs analyzed by the alkaline comet assay increases following UV exposure, reaching a maximum of~20%
tail DNA after one hour and slowly going down to ~15% at the 4-hour time point. Both of these numbers
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are only slightly above the basal damage level (-10% tail DNA) and well below the alkaline comet assay's
saturation level (-75% tail DNA), indicating that the assay is relatively insensitive to bulky adducts.
SB intermediates from DNA repair are transient, and the level of SBs is a function of both break
generation (incision) and gap filling (DNA repair synthesis and ligation). Therefore, slowing down or
inhibiting gap filling can theoretically enhance the level of SBs, thereby improving the assay's sensitivity.
To test this hypothesis, we irradiated XPG/E791A cells (30) with UV-C and measured the resulting SBs.
The E791A mutation renders the XPG enzyme catalytically inactive but still allows DNA binding (30, 89).
Because the 5' incision by ERCCI-XPF is not affected (30) XPG/E791A cells are able to generate NER
SB intermediates. However, XPG-E791A is not able to cleave 3' to the damage site, leading to a 5'
overhang and preventing ligation. In fact, we observed that SBs accumulate in XPG/E791A cells overtime
following UVR, exhibiting >2.5-fold the level of SBs in XPG/WT (Fig. 2-2B).
An implication from Fig. 2-2B is that NER's efficient gap filling contributes to the transient state
of the SB intermediates. As a consequence, the result suggests that it is possible to increase the assay's
sensitivity by inhibiting gap filling. In fact, classic SB detection methods, such as the alkaline sucrose
sedimentation technique (33, 34) and alkaline elution assay (36), employ the use of DNA repair synthesis
inhibitors to obtain more SBs for DNA repair studies of UV-induced damage. We adapted this technique
and employed a combination of the inhibitors HU and ara-C. In the presence of HU/ara-C (short for "a
mixture of 1 mM HU and 10 ptM ara-C"), the level of accumulated SBs reaches a steady state of -73-78%
tail DNA after one hour following UVR (Fig. 2-2C), which is -four times higher than the control condition
without HU/ara-C (Fig. 2-2A). Since 75% tail DNA is the alkaline comet assay's saturation limit, it is
possible that a higher number of SBs are generated but not reflected in the comet result.
HU/ara-C eliminates strand break formation by NER
To validate that the use of the HU and ara-C combination inhibits NER gap filling while allowing
NER incision, we compared the results from XPG-deficient and XPG/WT cells (see Methods). Cells
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defective in XPG are unable to initiate NER and generate SB intermediates in the presence of DNA lesions
(30). Here, we show that SB accumulation in XPG-deficient cells is significantly less than in XPG/WT in
both the absence and presence of HU and ara-C (Fig. 2-2D). The difference is revealed to be more than
three-fold in the presence of the repair synthesis inhibitors, showing that most of the detected SBs using
HU/ara-C are NER intermediates.
Dose-response to UV treatment using HU/ara-C approach
We also investigated the ability to study dose-response to a genotoxic agent using HU/ara-C. TK6
(human lymphoblastoid) and HepG2 (human hepatocyte cell line) were incubated in medium supplemented
with GSH, HU, and ara-C for ~40 minutes and irradiated with various doses of UV-C. The cells were
allowed to repair in the same medium for one hour after UV exposure to facilitate maximum SB
accumulation. The HU/ara-C combination displays a strong dose-response to UV-C treatment in both cell
lines, ranging from the basal level of~-10% to -75% tail DNA (Fig. 2-2E). In contrast, the control condition
without HU/ara-C shows significant increase in SBs only at the highest dose in HepG2 cells (-20% tail
DNA).
Application of the HU/ara-C method to detect damage induced by metabolic activation of AFB1 and
Bja]P
Many environmental carcinogens are metabolically activated upon entering the body, mainly by
hepatocytes in the liver (55). To study DNA damage in physiologically relevant metabolism conditions, we
aimed to optimize an alkaline CometChip procedure using the HU/ara-C method together with
metabolically competent human cell lines. We demonstrated the efficacy of the method by treating
HepaRGTM, HepG2, and primary mouse hepatocytes with the carcinogens aflatoxin Bi (AFB1 ) and
benzo[a]pyrene (B[a]P), both of which are known to become DNA reactive upon metabolic activation by
CYP450s. To control for bioactivation, we included a negative control cell line, TK6, which has been shown
to have no expression of CYP450s (90).
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Aflatoxin B1 treatment in cell lines
The mycotoxin AFBi is a potent environmental human carcinogen (91). It is produced by the molds
Aspergillus flavus and A. parasiticus, which are frequent contaminants in peanuts and maize in certain
regions of the world (92). Exposure to AFBI increases the risk of hepatocellular carcinoma (HCC) about
three times, and co-exposure with hepatitis B elevates the risk approximately 60-fold (23). AFBi requires
bioactivation to become reactive to DNA. Several CYP450 enzymes (93), such as CYP3A4 and CYP IA2,
are known to oxidize AFBI, producing a number of metabolites (94-97). The highly mutagenic metabolite,
AFBI-exo-8,9-epoxide, is very unstable, with a half-life of ~1 s in neutral pH at room temperature (98).
The metabolite readily reacts with the N7 position of guanine to form DNA adducts. The most ubiquitous
are AFBi-N7-dG and AFB 1-Fapy-dG, both of which can lead to G-to-T transversions (24, 25). AFBi-N7-
dG highly distorts the double helix and has been shown to be excised by NER (99). In addition, a recent
study shows that AFBi-Fapy-dG is partially repaired by BER (recognized and excised by the glycosylase
NEIL 1) in mammalian cells (100).
Because CYP3A4 and CYP IA2 are essential in bioactivation of AFB1 , we compared the activity
levels of these two enzymes in HepaRGTM and HepG2 cells using the P450-GloTM assay (see Methods).
As expected, HepaRG TM exhibits much higher activity levels for both of these P450s. Specifically,
HepaRG TM shows >100-fold higher CYP3A4 activity (Fig. 2-SI) and >10-folder higher CYP1A2 activity
compared to HepG2 cells (Fig. 2-S2). Consistent with the difference in P450 activity, HU/ara-C reveals a
strong dose-response relationship to AFBI treatment in HepaRGTM cells while HepG2 cells show relatively
little increase in SBs (Fig. 2-3A). The negative control cell line for bioactivation, TK6, has CYP3A4 and
CYP 1A2 activity levels below the detectable range of the P450-Glo assay and shows no response to AFB,
treatment in both the absence and presence of HU/ara-C, further supporting the role of metabolic activation
in SB formation. In addition, while HepG2 cells display a slight trend toward increased DNA damage with
higher doses of AFBI, no such trend is observed in TK6 cells (Fig. 2-3A). In the presence of HU/ara-C,
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there is -2-fold increase in background damage in TK6 cells, potentially due to either background NER
activity or because of the cells' sensitivity toward the repair inhibitors themselves.
Benzo[alpyrene treatment in cell lines
B[a]P, another human carcinogen (91), is the best known PAH. Many other PAHs are known
carcinogens (26, 27). PAHs naturally occur in coal, oil, and gasoline and are produced by incomplete
combustion of organic material. Common routes of exposure include breathing in fuel exhaust, cigarette
smoke, and burning wood smoke, or consuming charred meat or other types of charred food (27). B[a]P,
like other PAHs, is an inducer of the aryl hydrocarbon receptor (AHR), which is a transcription factor
regulating a number of phase I and phase 1I enzymes, including the CYPI family (CYPIA1, CYPIA2, and
CYP1Bl) (101). B[a]P is bioactivated by the CYPI family. The most genotoxic metabolite is the
diolepoxide (+)-anti-B[a]P-7,8-diol-9,lO-epoxide (BPDE), which is formed in a series of reactions: B[a]P
-> B[a]P-7,8-oxide (by CYPIs) -> B[a]P-7,8-diol (by epoxide hydrolase) -* B[a]P-7,8-diol-9,10-epoxide
(by CYP 1 s). BPDE covalently binds to the exocyclic N2 of guanine, forming DNA adducts that can lead to
G-to-T transversions (27).
In both HepaRGTM and HepG2 cells, HU/ara-C reveals dose-dependent increase of SBs with B[a]P
treatment (Fig. 2-3B). HepaRGTM cells display overall higher levels of strand breaks, consistent with higher
CYP 1A2 activity level (Fig. 2-S2). For example, exposure to 1 pM B[a]P induces -3 times more breaks in
HepaRG than in HepG2. On the other hand, B[a]P treatment does not induce additional strand breaks in
TK6 cells, which are consistent with the lack of an inducible CYP450 system in TK6 cells (90).
Application of HU/ara-C in primary mouse hepatocytes
Primary hepatocytes are the gold standard for metabolism studies. We wanted to show that HU/ara-
C works well with these cells. Mouse hepatocytes were isolated using a standard two-step collagenase liver
perfusion (see Methods). The cells were immediately loaded into CometChip microwells and allowed to
recover overnight before AFB1 or B[a]P treatment. HU/ara-C is able to show consistent dose-responses to
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both chemicals (Fig. 2-3C and 3D). AFBI appears to induce SBs that are detectable even in the absence of
HU and ara-C although the use of the repair inhibitors still improves the overall level of detected SBs. In
contrast, B[a]P shows a strong dose-response in the presence of HU and ara-C while displaying a minimal
increase in SBs in the absence of the inhibitors.
Bioactivation modulates the level of strand breaks detected using HU/ara-C approach
To further validate that strand breaks induced by AFB, and BaP using HU/ara-C in the alkaline
CometChip are due to bioactivation of the carcinogens, we exploited the use of P450 inhibitors. We
expected that inhibiting the key P450 enzyme responsible for the metabolism of each chemical would
reduce the level of DNA adducts, which in turn would suppress the formation of NER SBs.
To reduce metabolic activation of AFB1 , we treated cells with ketoconazole (KET), a potent
inhibitor of CYP3A4 (38, 102-105). At 5 pM KET, CYP3A4 activity level in HepaRG TM cells is reduced
by ~100-fold and HepG2 level is reduced by ~10-fold (Fig. 2-Si). By itself, 5 pM KET does not induce
detectable DNA damage in TK6, HepaRGTM , and HepG2 (Fig. 2-4A, 4B, and 4C). When HepaRG TM cells
are exposed to AFBI in the presence of KET, the level of SBs across all AFB1 doses is reduced to near the
background level (Fig. 2-4B). There is no apparent effect of KET in TK6 and HepG2 cells (Fig. 2-4A and
4C), which is most likely because the AFB 1 induces no damage in TK6 cells and minimal damage in HepG2
cells (Fig. 2-3A). The results show that HepaRGTM cells have the ability to metabolically activate AFB1
and that the vast majority of AFBi-induced damage is due to CYP3A4 activity.
To inhibit the metabolism of B[a]P, we used the small molecule a-naphthoflavone (ANF), a potent
antagonist of CYP1A2 (106, 107). In addition, ANF also binds to AHR and inhibits its activation, thereby
preventing the upregulation of AHR targets, including the CYPI family (101, 108, 109). B[a]P induces
CYP I A2 activity in a dose-dependent manner (Fig. 2-S2), consistent with activation of the AHR pathway
by PAHs. Interestingly, B[a]P increases CYP1A2 activity in HepG2 cells up to ~12 times above the
background level while the induction is only -three times in HepaRGTM cells. Treatment of the cells with
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25 tM ANF leads to -40% reduction in background CYPIA2 activity in HepaRG TM cells and no apparent
reduction in HepG2 cells. Furthermore, ANF completely suppresses the induction of CYP 1 A2 activity by
B[a]P in both cell lines (Fig. 2-S2). Significantly, we observed in parallel that the same dose of ANF reduces
the level of B[a]P-induced SBs to near the background level in both HepaRGTM and HepG2 (Fig. 2-4D, 4E,
and 4F). Taken together, these results show that both HepaRGTM and HepG2 cells are capable of inducible
metabolic activation of B[a]P and that CYP1A2 activity is essential for B[a]P's genotoxicity.
Contribution of NER to strand break formation
In the case of UV exposure, we have shown that the majority of SBs detected by HU/ara-C are
NER intermediates (Fig. 2-2D), indicating the repair synthesis inhibitors can be used to reveal bulky lesions.
Similarly, we wanted to investigate whether bulky lesions induced by AFB1 and B[a]P contribute to
detected SBs by HU/ara-C. To do this, we studied the contribution of NER SB intermediates following
exposure to AFB1 and B[a]P.
Our approach was to inhibit NER initiation and query whether SB formation is affected. Recently,
the small molecule pharmaceutical spironolactone (SP) has been shown to inhibit the repair of 6-4PP
induced by UV light via induction of XPB degradation (110). XPB is an essential component of the
transcription factor 2 helicase complex (TFlIH) (11). The TFIIH complex plays a key role in the damage
verification step of NER, which takes place prior to DNA incisions (18-20, 111). Consequently, we
expected a reduction in SBs generated by NER in cells treated with SP, which would result in an overall
reduction of SBs detected by HU/ara-C.
To investigate the effect of SP on SB generation by NER, we irradiated cells with UV-C to induce
bulky adducts. Prior to UV-C exposure, cells were treated for five hours with 20 ptM SP. Following UV-C
irradiation, cells were allowed to repair in the presence of 20 pM SP for one hour. The results show that
cells treated with SP exhibit more than three-fold reduction in SBs in both TK6 and HepG2 (Fig. 2-S3),
indicating that the number of NER incision events is significantly reduced. On the other hand, there are
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residual SBs revealed by HU/ara-C that are significantly higher than the basal levels in both cell types (Fig.
2-S3C and S3D). These results together show that SP partially inhibits NER initiation and can be used to
reveal the contribution of NER intermediates to detected SBs in the presence of HU/ara-C.
We employed SP to explore the role of NER in SBs induced by AFB1 and B[a]P. Similar to the UV
experiment described above, HepaRGTM, HepG2, and TK6 cells were pretreated with SP for five hours
before exposure to AFBI or B[a]P for 24 hours. To maintain inhibition of NER initiation, SP was also added
to the treatment solution.
In AFBI treatment, SP significantly reduces the level of SBs in HepaRGTM cells incubated with
HU/ara-C, revealing that ~25-50% of detected SBs are NER intermediates (Fig. 2-5B). This result is
potentially an underestimation of NER contribution since SP inhibition of NER is likely partial (Fig. 2-S3C
and S3D). Therefore, residual NER activity may account for the remaining SBs. In addition, since the DNA
damage spectrum of AFBI is complex and the mechanisms of HU and ara-C are not specific to NER, it is
likely that other repair pathways partially contribute to the detected SBs. Furthermore, SP appears to have
a relatively small, although not statistically significant, inhibitory effect on CYP3A4 activity in HepaRGTM
cells (Fig. 2-S4A), which may contribute to the observed reduction in SBs in Fig. 2-5B. Finally, because
the negative control cells, TK6 and HepG2, display no additional SB formation in response to AFB1 , SP
shows no inhibitory effect in these cells (Fig. 2-5A and 5C).
Results from B[a]P treatment show that SP displays no inhibition of B[a]P-induced SB formation
in HepaRGTM cells (Fig 2-5E) whereas SP reduces SBs to near the background level in HepG2 cells (Fig.
2-5F). The results in HepG2 indicate that the majority of strand breaks detected by HU/ara-C come from
NER of B[a]P-induced bulky adducts. There appears to be a relatively small but significant reduction of
CYP IA2 activity by SP in HepG2 cells (Fig. 2-S5B), which may partially account for the reduction in SB
formation. The dramatic difference in the effect of SP in HepaRGTM and HepG2 may be due to a difference
in the levels of NER suppression achieved by SP in the two cell lines. SP is known to be extensively
metabolized in the liver to produce metabolites that are active for treatment of hypertension and congestive
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heart failure (112). Although SP has been shown to induce XPB degradation (110), the effects of SP's
metabolites on NER machinery are unknown. Since HepaRGTM cells have a much higher metabolic
capacity than HepG2, it is possible that there is less available NER-inhibiting SP in HepaRGT M compared
to HepG2.
Altogether, the results from SP treatment suggest at least a partial contribution of NER to SBs
induced by AFBI and potentially B[a]P. To accurately quantify the contribution of NER SB intermediates,
we used an Xpa- mouse model to completely abolish NER (113). The XPA protein is an essential
component of the NER preincision complex, interacting with a number of NER proteins (e.g. TFIIH, RPA,
ERCCI-XPF, and PCNA) and facilitating the correct formation of the complex so that incision can occur
(19). Therefore, XPA deficiency results in a complete loss of NER. As a consequence, Xpa-'- mice are prone
to developing tumors upon UV exposure (113) and have been a popular mouse model for NER studies.
In order to provide the necessary metabolism, we used primary mouse hepatocytes for AFB, and
B[a]P treatments. For AFB, doses higher than 1 pIM, the SB level in WT hepatocytes is more than twice
the level in Xpa' cells in the presence of HU/ara-C (Fig. 2-6A). These results indicate that NER
intermediates contribute more than half of the SBs induced by AFBI, which is consistent with the results
obtained in HepaRG TM cells using SP (Fig. 2-5B). Significantly, the results also show that a significant
portion of SBs are NER-independent and therefore likely intermediates from other repair pathways.
Furthermore, a similar dose-response to AFB1 is observed in both WT and Xpa- in the absence of HU and
ara-C, which strengthens the argument that some of AFB i-induced damage is repaired by NER-independent
pathways. Our most likely candidate is BER with NEIL 1 as the glycosylase that can recognize and excise
a portion of AFBi-Fapy-dG adducts (100). Alkali-labile abasic sites formed by spontaneous hydrolysis of
AFB1 -Fapy-dG adducts may also contribute to detected strand breaks (114). In addition, the process of
AFB1 metabolic activation by CYP450s is also known to produce reactive oxygen species and induce lipid
peroxidation (115-117), which can result in a mixture of DNA lesions (117) that require the participation
of different DNA repair pathways.
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For B[a]P treatment, while WT hepatocytes show a dose-dependent increase in SBs, there is
virtually no SB formation in Xpa- - hepatocytes in the presence of HU/ara-C (Fig. 2-6B). These results are
consistent with the data obtained from HepG2 cells (Fig. 2-5F), further supporting that the majority of SBs
detected in the presence of HU/ara-C are NER intermediates and that the lack of SB reduction by SP
observed in HepaRGT M cells (Fig. 2-5E) may be due to insufficient reduction of NER activity.
HU/ara-C inhibits repair of oxidative and alkylation damage
We have demonstrated that the use of HU and ara-C is efficient at inhibiting the gap-filling step of
NER. However, the molecular mechanisms of HU and ara-C suggest that gap filling of BER, particularly
long-patch BER, may also be affected. Specifically, HU leads to a depletion of the dNTP pool (41-45),
which is likely to affect any DNA synthesis-dependent process. There is a body of evidence showing that
ara-C blocks DNA repair synthesis by Pol P (47, 51-53), which participates in BER (118). Therefore, we
postulated that the HU/ara-C combination can also be used to enhanced sensitivity for detection of oxidative
and alkylation damage, both of which are mainly repaired by BER in mammalian cells (118).
To investigate the effect of HU/ara-C on SBs induced by oxidative damage, we treated TK6 cells
with hydrogen peroxide (H 202 ) for 20 minutes at 4*C to minimize repair activity. Cells were then allowed
to repair for one hour. Immediately after the H202 challenge, TK6 cells show a dose-dependent increase in
SBs (Fig. 2-7A, left - gray line). Interestingly, immediately after H202 treatment, HU/ara-C leads to a small
but statistically significant increase in SBs for the top three H 20 2 doses (Fig. 2-7A, left - red line). The
most striking result is observed after one hour of repair following the H 20 2 challenge. In the absence of the
repair synthesis inhibitors, SBs are rapidly rejoined, and by one hour of repair, their level has reduced to
near the basal level across all doses (Fig. 2-7A, right - gray line). In contrast, cells incubated with HU and
ara-C maintain the same initial level of SBs, suggesting that oxidative damage repair is inhibited (Fig. 2-
7A, right - red line).
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To induce alkylation damage, we challenged TK6 cells with the chemotherapeutic methyl methane
sulfonate (MMS) for 30 minutes at 37'C. While a dose-response to MMS treatment is observed in the
absence of HU/ara-C, the presence of the repair inhibitors increases the SB level by -2-fold (Fig. 2-7B, left
- red line). A significant observation is that while 0.5 mM MMS does not appear genotoxic in the absence
of HU and ara-C, the addition of the repair synthesis inhibitors reveals a damage level more than twice the
background level. After one hour of repair following MMS treatment, the damage level is maintained in
both the absence and presence of HU/ara-C. In fact, the repair of MMS-induced damage in TK6 cells is
relatively slow, with a half-time of -6 hours, which is ~12 times slower than the repair of H202-induced
damage (half-time ~28 min) (Fig. 2-S6).
All in all, we conclude that the combination of the repair synthesis inhibitors HU and ara-C can be
used to improve the overall sensitivity of the alkaline comet assay for DNA damage detection by amplifying
the number of SBs induced by the repair of bulky DNA adducts, oxidative damage, and alkylation damage.
The implication is that not only a broader range of genotoxic agents can be uncovered but a wider range of
genotoxic doses can also be revealed.
HU/ara-C improves overall detection sensitivity for DNA damaging agents
For performance assessment of in vitro genotoxicity tests, the European Reference Laboratory for
Alternatives to Animal Testing (EURL ECVAM) published recommendations of chemicals that should
give either positive results or negative results in an in vitro test (119, 120). To assess the sensitivity of the
alkaline CometChip using HU/ara-C, we treated HepaRGTM cells with nine known in vivo genotoxins from
Group I of the ECVAM's recommendation (120) (Table 2-1, No. 5 - 13) and compared the results of the
alkaline CometChip assay in the absence and presence of HU/ara-C.
The identities of the test compounds were blinded until all data were collected and analyzed. Stock
solutions were prepared to be I OOX of the top doses recommended for in vitro genotoxic assessment (120).
The treatment time was 24 hours for all chemicals. In parallel, cell viability for each condition was also
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collected using CTG@ (see Methods). Remarkably, whereas only one chemical shows positive results for
DNA damage [N-nitrosodimethylamine (NDMA)] in the absence of HU/ara-C, the presence of the repair
inhibitors reveal significant DNA damage for seven (out of nine) compounds (Table 2-2, second and third
columns). In addition, four of the test compounds are known to be metabolically activated
[cyclophosphamide, B[a]P, NDMA, and 2,4-diaminotoluene (2,4-DAT) (120)], and all four are scored as
positives in the presence of HU/ara-C.
Hydroquinone (HQ) and chloramphenicol (CAM) induce high levels of cytotoxicity for doses that
show significant DNA damage in the presence of HU/ara-C. Specifically, the highest dose for HQ exhibits
significant increase in SBs but kills more than 50% of the cells (Fig. 2-S7F). Similarly, the two highest
doses for CAM (3.1 and 6.2 mM) induce high levels of cytotoxicity (-53% and -3% survival, respectively
- Fig. 2-S7H) as well as significant DNA damage. There is no formal threshold for cell viability in scoring
the comet assay. Nonetheless, cytotoxicity may contribute to DNA fragmentation, which can lead to
overestimation of genotoxicity (13). Therefore, cytotoxicity needs to be considered in assessing comet data.
In the cases of HQ and CAM, because there appear to be dose-response trends (although not all doses reach
statistical significance), we decided to score both chemicals as positives. However, if a 50% cell viability
threshold is applied, then HQ and the highest CAM dose will be excluded from the positive results.
The two compounds with definite negative results are para-chloroaniline (PCA) and cisplatin. PCA
is used in a number of industrial processes, such as dye production (121). It is extensively metabolized in
the body as part of the detoxification process, but it is unclear whether genotoxic metabolites are generated
(121). Although PCA is an in vivo genotoxin (119, 120), a rodent carcinogen (121), and a possible human
carcinogen (91) (Table 2-2), there are conflicting data about PCA's in vitro genotoxic potential (121, 122).
Notably, although the highest dose (5 mM) induces ~50% cell death, no significant increase in DNA
damage is detected (Fig. 2-S7D). The implication is that PCA induces cell death via a DNA damage-
independent pathway.
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Cisplatin is a commonly used platinum-based chemotherapeutic for different types of cancers,
including bladder cancer, ovarian cancer, head and neck cancer, and non-small-cell lung cancer (123-126).
Upon entering the cell, the chloride ligands hydrolyze, generating aquated cisplatin that can bind to the N7
atom of purine bases in DNA to form monoadducts and subsequent crosslinks (123). Notably, more than
85% of the adducts are intrastrand crosslinks, and about 4-5% are interstrand crosslinks (123, 124).
Although crosslinks can be repaired by NER, our results show no increase in DNA migration with cisplatin
treatment (Fig. 2-S71). These observations indicate that despite their small number, the interstrand
crosslinks are able to prevent migration of DNA ends generated by NER, possibly by holding the two DNA
strands of the double helix together (127).
In the absence of HU and ara-C, only N-nitrosodimethyl amine (NDMA) shows positive results for
DNA damage (Table 2-2). NDMA is bioactivated in the body mainly by CYP2E1 (128) to yield an a-
hydroxymethyl nitrosamine that forms a reactive methyl diazonium ion (129), which alkylates nucleobases
irreversibly via SNI nucleophilic substitution (130). Unlike MMS, which is an SN2 alkylator (131), NDMA
does not exhibit additional increase in SBs in the presence of HU/ara-C (Fig. 2-S7E).
In summary, the repair synthesis inhibitors HU and ara-C significantly improve the sensitivity of
the alkaline comet assay. In the context of chemical genotoxicity testing, we propose the use of the alkaline
CometChip with HepaRGTM cells in the presence of HU/ara-C as a screening platform to achieve high
throughput and low false positive rates. To further assess the platform, we will proceed to test its specificity
with non-genotoxic chemicals from the ECVAM's recommendations (chemicals from Group 2 and Group
3) (119, 120).
2.5. DISCUSSION
Although DNA damage can drive the initiation and progression of carcinogenesis and other
diseases (1-4), there have been relatively few advances in techniques for detection of DNA damage. There
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is currently no HT assay for detection of bulky DNA adducts, and metabolic activation of chemicals is still
routinely achieved through incubation with liver S9 fractions (5, 57). The most commonly used is the comet
assay, which relies on DNA strand breaks to measure the level of DNA damage. However, it is low-
throughput, has high laboratory variation, and is relatively insensitive toward bulky DNA lesions. To
overcome these challenges, we combined the HT nature of CometChip, the metabolic capacity of
HepaRGTM cells, and enhanced sensitivity for DNA damage using DNA repair synthesis inhibitors. We
demonstrated in this study a platform for genotoxicity screening that is significantly more sensitive and
>5,000 fold faster compared to the conventional comet assay.
With its broad spectrum metabolism and its high basal and inducible metabolic enzyme levels,
HepaRGTm has the potential to be the gold standard as a robust and reliable cell model for genotoxicity
testing. We compared HepaRG TM with HepG2, a classic human hepatocyte cell line, and found that
HepaRGTM exhibit orders of magnitude higher activity levels of CYP3A4 and CYPI A2, which is consistent
with the difference in gene expression levels found in other studies (70, 71, 76). We found that the higher
CYP3A4 and CYP IA2 activities in HepaRG TM cells translate to higher levels of DNA damage induced by
AFB1 and B[a]P compared to HepG2. Significantly, the difference in DNA damage between the two cell
lines is revealed only in the presence of the repair synthesis inhibitors HU and ara-C.
Using the alkaline CometChip, we showed here that the HU/ara-C combination enables superior
sensitivity to bulky DNA adducts induced by metabolic activation. Specifically, the HU/ara-C combination
elevates the level of SBs in cells upon exposure to UV, AFB1, and B[a]P. Using CYP450 inhibitors in
HepaRGTM and HepG2 cells, we verified that formation of SBs upon AFBI and B[a]P treatments is
dependent on specific CYP450 enzyme activity. Furthermore, we confirmed that the majority of SBs
induced by UV, AFB1 , and B[a]P treatment in the presence of HU/ara-C are intermediates of NER by
inhibiting NER incisions. These results indicate that HU/ara-C is sensitive for detection of NER substrates,
which include a wide range of DNA lesions (19).
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In addition, we demonstrated that the HU/ara-C combination can be applied to inhibit completion
of the repair of oxidative damage (H 202 treatment), resulting in sustained SB level after one hour of repair.
Because oxidative base lesions (e.g. 8-oxoG) are primarily repaired by the BER (132), it is likely that
HU/ara-C inhibits the gap filling step of BER. On the other hand, there is evidence that NER also
participates in removing oxidative "non-bulky" adducts, such as 8-oxoG and thymine glycol (133).
Furthermore, reactive oxygen species can initiate lipid peroxidation, which produces a number of
unsaturated aldehydes or enals (134). Some of these products (e.g. trans-4-hydroxynonenal,
crotonaldehyde, acetaldehyde (117, 134)) react with DNA to forr bulky adducts (e.g. 1,N2-propano-2'-
deoxyguanosine) (135), which can be repaired by NER (136). It is therefore possible that NER
intermediates also contribute to the observed SBs induced by H2 0 2 .
While we have not yet tested the level of DNA damage in MMS-treated cells after a sufficient
repair period in the presence of HU/ara-C (e.g. 24 hours), we were able to show that the inhibitors HU and
ara-C enhance the initial damage by a factor of-two. The reason is likely because during the 30 minutes of
MMS treatment, DNA repair by BER is active. The presence of HU/ara-C likely inhibits the gap filling step
of BER during this period, resulting in SB accumulation. On the other hand, while HU/ara-C leads to
additional MMS-induced SBs, the same effect is not observed in another alkylating agent, NDMA. Both
NDMA and MMS are alkylating agents, capable of methylating the ring nitrogen atoms in DNA bases
(130). On the other hand, as an SNI alkylator, NDMA is more likely to target both the extracyclic oxygen
groups in the DNA bases (130) and the oxygen atoms of the sugar-phosphate backbone (131, 137).
Therefore, the relationship between alklation damage repair and HU/ara-C is potentially complicated and
dependent on the types of alkalyted lesions.
Despite high variability in metabolic enzyme expressions in primary hepatocytes obtained from
different individuals, primary hepatocytes remain an essential tool in toxicity testing and metabolism
studies. We demonstrated here a procedure where primary mouse hepatocytes are loaded onto CometChip
immediately following isolation, exposed to genotoxins in the presence of HU/ara-C, and analyzed for SBs
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directly on chip. This procedure significantly simplifies cell handling and eliminates the need to detach the
cells from culturing vessels (usually via trypsinization), minimizing the stress on the cells. We demonstrated
here that the hepatocytes recovered on CometChip maintained their ability to bioactivate the carcinogens
AFBI and B[a]P, indicating that CometChip can potentially be used as a suitable culturing vessel for
primary hepatocytes. Further studies are needed to characterize the viability of the cells as well as
quantifying liver-specific protein levels over time. On the other hand, because CometChip is fabricated
with agarose, which provides a hydrophilic and neutrally charged surface, we expect that the effect is similar
to the ultra-low attachment plates (e.g. Corning® Ultra-Low Attachment Spheroid Microplates) that are
routinely used for hepatocyte spheroid formation and culture (138).
As demonstrated in the study with cisplatin, the platform developed here is potentially insensitive
to some DNA crosslinking agents. Although DNA crosslinks induced by cisplatin can be repaired by NER
(124), the results suggest that perhaps a small portion of unrepaired interstrand crosslinks (ICLs) holds the
DNA ends generated from NER in place, preventing electrophoretic migration. There is already an
established comet procedure to detect ICLs, where the reduction in DNA migration after treatment with a
SB-inducing agent, such as y-radiation, is a measure of the level of ICLs (127). We envision that this
approach can be easily incorporated into our platform as an additional step in the procedure to verify the
existence of the highly toxic ICLs.
The comet assay is a popular tool in human biomonitoring studies, where DNA damage can be
used as a biomarker for occupational and environmental exposures and dietary effects (139-145). The HT
nature of CometChip and the enhanced sensitivity for DNA damage using the HU/ara-C combination can
be a valuable tool for these types of studies. There is one caveat, which is that a difference in the level of
SBs across samples may reflect the inter-individual variation in both DNA damage level and NER or BER
incision activity. Therefore, to quantify the contribution of the variation in DNA repair capacity, we
recommend including an independent assay to monitor DNA repair capacity in parallel (e.g. fluorescence-
based multiplex host cell reactivation assay (146)).
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Because an understanding of the types of DNA lesions helps elucidate a chemical's mode of
actions, it can be useful to learn if bulky adducts are formed. The use of HU/ara-C is sensitive but not
specific to bulky adducts, so the technique itself is not capable of discerning whether a chemical induces
bulky adducts. However, as demonstrated in this work, it is possible to determine the presence of bulky
adducts by including a condition where NER incision is inhibited either by a small molecule (e.g. SP) or
by deleting key proteins of the preincision complex (e.g. XPA, XPG). The resulting reduction of strand
breaks indicates participation of NER and therefore supports the presence of bulky adducts.
Determining whether the metabolism of a compound results in genotoxic metabolites is important
in the contexts of both environmental exposures and drug development. We showed here that inhibitors for
specific CYP450s can be employed in our platform to investigate the role of the enzymes in producing the
genotoxic effect of test compounds. As a potential application, our platform can be used to screen a panel
of CYP450 inhibitors to differentiate between parent- and metabolite-based genotoxicity and to determine
the contribution of specific CYP450s for novel compounds with unknown metabolisms.
In conclusion, using a combination of the DNA repair synthesis inhibitors HU and ara-C and a
metabolically competent human cell line HepaRGTM, we developed a CometChip platform for HT
genotoxicity testing that has enhanced sensitivity to a broad range of DNA damaging agents. The platform
can be used as a powerful HT tool for screening of large chemical libraries, which finds applications in both
the pharmaceutical industry and the chemical industry. The use of HU/ara-C together with CometChip is
also a promising tool for clinical applications, where DNA damage level can be monitored as an early
surrogate endpoint for tumor response. In addition, CometChip is compatible with HT screening facilities,
enabling testing of thousands of treatment conditions at the same time in a matter of 2-3 days.
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Figure 2-1. CometChip for high-throughput assessment of DNA damage. A. CometChip fabrication. 1. A
PDMS stamp with an array of micropegs is pressed into molten agarose. Once the agarose cools down and
solidifies, the stamp is lifted to reveal an array of microwells (-40-50 im in both diameter and depth, spaced
240 ptm from each other). 2. Cells in suspension are loaded directly into microwells via gravity. 3. Excess
cells are washed off by shear force, revealing an array of micropatterned cells. 4. Low-melting point (LMP)
agarose kept molten at -37*C is placed on top of the micropatterned cells and allowed to solidify by a brief
incubation at 4*C (-two minutes). B. Macrowells are formed by clamping a bottomless 96-well plate on
top of a microwell array. The bottom surface of each macrowell contains up to 300 microwells. Macrowells
can be used both to load multiple cell types at the same time and to perform parallel treatments. C. Example
fluorescent images of comets on alkaline CometChip. Images were taken at 40X magnification (see
Methods). Each frame can capture -60 to more than 100 comet images. Left: untreated TK6 cells yield
comets with little to no tail. Right: comets from TK6 cells treated with a high dose of a DNA damaging
agent (50 pM H202 ) have visibly large tails.
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Figure 2-2. Analysis of strand breaks (SBs) by the alkaline CometChip as a measure of UV-induced lesions.
Cells were pre-incubated with 10 mM GSH for 40 minutes at 37*C before UV irradiation and kept in the
presence of 10 mM GSH for any subsequent incubation following UV exposure. A. Comparison of SB
levels in human skin fibroblast cell line (XPG/WT) between untreated cells (-UV) and cells irradiated with
5 J/m2 UV-C (+UV). B. SB levels in XPG/WT and XPG/E791A cells up to four hours following 5 J/m2
UV-C exposure. C. SBs in XPG/WT cells incubated with DNA repair synthesis inhibitors, HU and ara-C.
Cells were pre-incubated with 1 mM HU, and 10 pM ara-C for 40 minutes at 37*C, irradiated with 5 J/m
2
UV-C (dark red line), and then incubated with the same HU and ara-C concentrations for up to four hours
after exposure. Untreated control cells were kept in the same HU and ara-C conditions (light red line). D.
Contribution of NER SB intermediates to detected SBs. XPG/WT and XPG-deficient cells were exposed
to 5 J/m2 UV-C and allowed to repair for one hour following irradiation. Cells were either incubated with
the repair synthesis inhibitors (1 mM HU, 10 pM ara-C) for 40 minutes prior to UV irradiation and one
hour of repair after exposure (+) or were incubated in regular medium without the inhibitors (0). *p < 0.05,
Student's t-test, 2-tailed, paired (between the two cell lines for each inhibitor condition). E. HU/ara-C
approach reveals dose-response to UV exposure. TK6 and HepG2 cells were irradiated with different doses
of UV-C and analyzed for SBs one hour following exposure. Cells were either incubated with the repair
synthesis inhibitors (1 mM HU, 10 pM ara-C) for 40 minutes prior to UV irradiation and one hour of repair
after exposure (+) or were incubated in regular medium without the inhibitors (0). *p < 0.05, Student's t-
test, 2-tailed, paired (between each UV dose and the untreated control). All data represent the average of
> 3 independent experiments. Error bars are standard errors of the means.
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Figure 2-3. Application of HU/ara-C approach on alkaline CometChip to detect DNA damage induced by
bioactivation of AFBI and B[a]P. Cells were treated with either AFBI or B[a]P in the absence (0) or
presence (+) of 1 mM HU and 10 ptM ara-C for 24 hours at 37'C and analyzed with the alkaline CometChip.
A. Dose-response to AFBI in TK6, HepaRGTM (same-day treatment, see Methods), and HepG2. All three
cell lines were treated in parallel. B. Dose-response to B[a]P in TK6, HepaRG TM (day-7 treatment, see
Methods), and HepG2. HepaRGTM and HepG2 cells were treated on different days. TK6 was analyzed in
parallel as a control for each treatment. n 3. Error bars are standard errors of the means. C and D. Dose-
response to AFBI (C) and B[a]P (D) in primary mouse hepatocytes (see Methods). All data represent the
average of six mice (C57B16, 10-14 weeks old). Error bars are standard errors of the means. *p<0.05,
Student's t-test, 2-tailed, paired [between treated dose and vehicle control (0.5% DMSO)].
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Figure 2-4. Role of metabolic activation in induction of SBs by AFBI and B[a]P. Cells were treated with
AFBi or B[a]P for 24 hours in the absence or presence of 1 mM HU and 10 pM ara-C and analyzed with
the alkaline CometChip. To inhibit AFB, metabolic activation, 5 pM KET was added to AFBI treatment
(blue lines in A, B, and C). To inhibit B[a]P bioactivaion, 25 pM ANF was added to B[a]P treatment (teal
lines in D, E, and F). Gray lines represent treatment conditions without KET and ANF. A and D. TK6 cells.
B. HepaRGTM cells (same-day treatment). E. HepaRGTM (day-7 treatment). C and F. HepG2 cells. n > 3.
Error bars are standard errors of the means. *p<0.05, Student's t-test, 2-tailed, paired.
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Figure 2-5. Using SP to study contribution of NER intermediates to SBs detected by HU/ara-C approach.
Cells were treated with AFB1 or B[a]P for 24 hours in the absence or presence of 1 mM HU and 10 pM
ara-C and analyzed with the alkaline CometChip. To inhibit NER initiation, cells were incubated with 20
pM SP for five hours are 37C prior to AFB1 and B[a]P challenge. 20 pM SP was also added during AFBI
and B[a]P treatment. Gray lines represent treatment conditions without SP. Purple lines represent treatment
conditions with 20 pM SP. A and D. TK6 cells. B. HepaRG TM cells (same-day treatment). E. HepaRG TM
(day-7 treatment). C and F. HepG2 cells. n > 3. Error bars are standard errors of the means. *p<0.05,
Student's t-test, 2-tailed, paired.
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Figure 2-6. Using Xpa-/- mouse hepatocytes to study contribution of NER intermediates to SBs detected by
HU/ara-C approach. Primary hepatocytes from six pairs of WT and Xpa"- mice (C57B16, 10-14 weeks old)
were isolated via two-step collagenase liver perfusion and incubated at 37*C overnight on CometChip (see
Methods). Cells were then treated with AFBI (A) or B[a]P (B) for 24 hours in the absence or presence of
1 mM HU and 10 p.M ara-C and analyzed with the alkaline CometChip. Gray lines represent the average
of six WT mice. Purple lines represent the average of six Xpa-l~ mice. Error bars are standard errors of the
means. *p<0. 05, Student's t-test, 2-tailed, paired.
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Figure 2-7. Testing the effects of HU/ara-C on repair of oxidative damage and alkylation damage in TK6
cells using the alkaline CometChip. Cells were incubated in culture medium in the absence or presence of
1 mM HU and 10 ptM ara-C for 40 minutes at 37'C prior to H2 02 and MMS treatment. A. Cells were
incubated with H2 02 for 20 minutes at 4*C, protected from light, in the absence or presence of 1 mM HU
and 10 pM ara-C. After treatment, H202 was rinsed off. Half of the cells were placed in regular culture
medium and the other half in medium supplemented with 1 mM HU and 10 pM ara-C for one hour at 37'C.
n = 3. Error bars are standard errors of the means. *p<. 05, Student's t-test, 2-tailed, paired. B. Cells were
incubated with MMS for 30 minutes at 37'C in the absence or presence of 1 mM HU and 10 pM ara-C.
After treatment, MMS was rinsed off. Half of the cells were placed in regular culture medium and the other
half in medium supplemented with 1 mM HU and 10 pM ara-C for one hour at 37'C. n = 2. Error bars are
standard errors of the means. "0 hour" are cells analyzed immediately after treatment. "I hour" are cells
analyzed after one hour of repair. Gray lines are cells unexposed to HU/ara-C, and red lines are cells treated
with HU/ara-C.
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Table 2-1. List of chemicals used in this study that were prepared from powder form.
No. Chemical Abbreviation Source Catalog StockSolvent
number concentration
I Aflatoxin B, AFBI MilliporeSigma, AFI0 4 mM DMSOSt. Louis, MO
2 Ketoconazole KET MilliporeSigma, K1003 20 mM DMSOSt. Louis, MO
3 a-naphthoflavone ANF MilliporeSigma, N5757 20 mM DMSOSt. Louis, MO
4 Spironolactone SP MilliporeSigma, S3378 20 mM DMSOSt. Louis, MO
5 Benzo[a]pyrene B[a]P MilliporeSigma, B1760 20 mM and DMSO5 Bezo~apyrne Ba]P St. Louis, MO BI76 mM
6 Etoposide MilliporeSigma, E 1383 1 mM DMSOSt. Louis, MO
7 2,4-Diaminotoluene 2,4-DAT TCI America, DO 123 1 M DMSO2,4-iamnotouen 2,4DAT Portland, OR
8 Cyclophosphanide CP MilliporeSigma, C0768 1 M DMSO
nonohydrate St. Louis, MO
9 para-Chloroaniline PCA MilliporeSigma, C224 15 500 mM DMSOSt. Louis, MO
10 N- NDMA MilliporeSigma, 48552 1 M H20Nitrosodimethylamme St. Louis, MO
11 Hydroquinone HQ MilliporeSigma, 1117902 100 mM H2 0St. Louis, MO
12 Chloramphenicol CAM MilliporeSigma, C0378 200 mg/mI DMSOSt. Louis, MO (619 mM)
cis-
13 Diamineplatinum(II) cisplatin MilliporeSigma' 479306 1 mM H20
dichloride St. Louis, MO
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Table 2-2. Results of alkaline CometChip for genotoxicity screen of nine known in vivo genotoxins (120)
and summary of known information about these toxins. "-" means no statistically significant measure of
DNA damage. "+" means at least one dose shows statistically significant DNA damage. Numbers in
parentheses represent the range of doses that score "+".
Genotoxicity Carcinogenicity
In vivo Alkaline Alkaline IARC
genotoxins Ames CometChip CometChip classification
test Cet THepaRG T M  (91)+ HU + ara-C
Etoposide + (147) - + (10 ptM) Group 1
2,4-DAT +(148) - + (10 mM) Group 2B
CP +(148) - + (5-10 mM) Group 1
PCA +(148) - Group 2B
NDMA + (148) + (2.5 - 20 mM) + (2.5 - 20 mM) Group 2A
HQ -(148) - + (0.33 mM) Group 3
B[a]P +(148) - + (5-10 pM) Group 1
CAM - (149) - + (3.1 mM) Group 2A
Cisplatin + (150) - Group 2A
IARC classification (91): Group 1:
possible human carcinogen, Group
human carcinogen, Group 2A: probably human carcinogen, Group 2B:
3: not classifiable as to its carcinogenicity to humans.
102
0 HU, 0 AraC
10000
1000
100
10
It] 1
No DMSO 0.5% DMSO
L..
C.u
+ HU, + AraC
x10-6
No DMSO 0.5% DMSO
x10-6
0000 -
+ HU, + AraC
1000
100
1N
No DMSO 0.5% DMSO
Figure 2-SI. Effects of ketoconazole (KET) on CYP3A4 activity per cell measured by P450-GloTM assay
(see Methods). Cells were incubated with 5 ptM KET for 24 hours at 37*C in the absence or presence of 1
mM HU and 10 ptM ara-C. Gray bars: basal CYP3A4 activity levels for both untreated (No DMSO) and
vehicle control (0.5% DMSO). Blue bars: CYP3A4 activity levels in the presence of 5 piM KET. A.
HepaRGTM cells. B. HepG2 cells. rlu: relative light unit. All data represent the average of three independent
experiments. Error bars are standard errors of the means.
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Figure 2-S2. Effects of a-naphthoflavone (ANF) on CYP 1 A2 activity per cell measured by P450-GIOTM
assay (see Methods). Cells were incubated with B[a]P together with 25 ptM ANF for 24 hours at 37'C in
the absence or presence of 1 mM HU and 10 ptM ara-C. Gray bars: CYPIA2 activity levels corresponding
to untreated control (UT), vehicle control (0.5% DMSO), and B[a]P doses. Teal bars: CYPIA2 activity
levels in the presence of 25 pM ANF. A. HepaRG TM cells. B. HepG2 cells. rlu: relative light unit. All data
represent the average of three independent experiments. Error bars are standard errors of the means.
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Figure 2-S3. A and B. Effects of spironolactone (SP) on NER initiation. Cells were exposed to UV light
and allowed to repair for one hour at 37*C. SBs were analyzed using the alkaline CometChip. 1 mM HU
and 10 pM ara-C were either absent or present at all time in the experiment. Purple: 20 pM SP (see
Methods). Dark gray: vehicle control (0.1% DMSO). Light gray: untreated control (no DMSO). A. TK6
cells. B. HepG2 cells. All data represent the average of four independent experiments. Error bars are
standard errors of the means. *p<0.05, Student's t-test, 2-tailed, paired (between 20 pM SP and vehicle
control).
C and D. UV-induced SBs in the presence of 20 pM SP. C. TK6 cells. D. HepG2 cells. All data represent
the average of four independent experiments. Error bars are standard errors of the means. *p<0.05,
Student's t-test, 2-tailed, paired (between each UV dose and untreated control (0 J/m2 )).
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Figure 2-S4. Effects of spironolactone (SP) on CYP3A4 activity per cell measured by P450-Glo TM assay
(see Methods). Cells were incubated with 20 ptM SP for 24 hours at 37*C in the absence or presence of 1
mM HU and 10 ptM ara-C. Gray bars: basal CYP3A4 activity levels for both untreated (No DMSO) and
vehicle control (0.5% DMSO). Purple bars: CYP3A4 activity levels in the presence of 20 piM SP. A.
HepaRGTM cells. B. HepG2 cells. rlu: relative light unit. All data represent the average of three independent
experiments. Error bars are standard errors of the means.
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Figure 2-S5. Effects of SP on CYP1A2 activity per cell measured by P450-GbO TM assay (see Methods).
Cells were incubated with B[a]P together with 20 pM SP for 24 hours at 37*C in the absence or presence
of 1 mM HU and 10 pM ara-C. Gray bars: CYP I A2 activity levels corresponding to untreated control (UT),
vehicle control (0.5% DMSO), and B[a]P doses. Purple bars: CYP1A2 activity levels in the presence of 20
gM SP. A. HepaRGTM cells. B. HepG2 cells. rlu: relative light unit. All data represent the average of three
independent experiments. Error bars are standard errors of the means.
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Figure 2-S6. DNA repair kinetics of oxidative damage and alkylation damage in TK6 cells. A. TK6 cells
were loaded onto CometChip and exposed to 50 pM H2 02 for 20 min at 4*C, protected from light. After
treatment, cells were allowed to repair in culture medium at 37*C. Cells were analyzed for SB levels using
the alkaline CometChip for basal damage (UT), immediately after treatment (0 min), and at 15, 30, 60, and
120 min of repair. B. TK6 cells in suspension were treated with 0.5 mM MMS for one hour at 37*C. After
treatment and washing, cells in suspension were allowed to repair in culture medium at 37*C. Cells were
loaded onto CometChip and analyzed for background SB level (UT), SBs immediately after treatment (0
hour), and 1, 4, 6, and 24 hours of repair. All data represent the average of three independent experiments.
Error bars are standard errors of the means.
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Figure 2-S7. DNA damage in HepaRGTM cells induced by nine in vivo genotoxins, measured by the alkaline
CometChip using the repair synthesis inhibitors HU and ara-C. HepaRGTM cells were exposed to test
compounds for 24 hours at 370 C using the same-day treatment procedure (see Methods). 1 mM HU and
10 p.M ara-C were either absent (0) or present (+) in the same treatment. At the end of the exposure period,
half of the cells were analyzed for SB levels with the alkaline CometChip (left plot of each figure), and the
other half were analyzed for cell viability using the CTG® assay (see Methods) (right plot of each figure).
"UT" represents background damage. Vehicle controls are "1% DMSO" or "H 20". A. Etoposide. B. 2,4-
Diaminotoluene. C. Cyclophosphamide. D. para-Chloroaniline. E. N-Nitrosodimethylamine. F.
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Hydroquinone. G. Benzo[a]pyrene. H. Chloramphenicol. I. cis-Diamineplatinum (II) dichloride. rlu:
relative light unit. All data represent the average of three independent experiments. Error bars are standard
errors of the means. *p<0.05, Student's t-test, 2-tailed, paired (between a treatment dose and the
corresponding vehicle control).
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Chapter 3
Novel Microarray Colony Formation Platform for High-Throughput Cell
Survival Quantification
3.1. ABSTRACT
Quantification of cell survival is one of the most fundamental and broadly used endpoints in
biology. The gold standard for cell survival quantification is the colony formation assay. While the assay
has an impressive dynamic range over several orders of magnitude, it is relatively low-throughput (10-21
days), laborious, and consumes large amounts of test compounds. On the other hand, XTT and CellTiter-
Glo® (CTG@), two of the most popular high-throughput assays, use indirect measures of cell viability to
estimate the extent of cytotoxicity. The XTT assay suffers from low sensitivity and an inferior dynamic
range compared to the colony formation assay. In addition, because indirect markers do not always correlate
directly with viability, both XTT and CTG@ are susceptible to viability-independent interferences. To
overcome the major limitations of commonly used assays, we developed MicroColony Chip (pCC) to
measure directly a cell's ability to divide (similar to the colony formation assay) with the scale and speed
of microtiter assays. pCC is a miniaturized colony formation platform, wherein microcolonies grow in an
array and toxicity is calculated based on the change in the distribution of the microcolony sizes. We show
here that pCC achieves the same sensitivity as the colony formation assay with -250-fold reduction in
growth surface area and -80% reduction in incubation time. We also show that pCC is more sensitive than
the XTT assay and that it has comparable sensitivity to CellTiter-Glo@ while being more robust. Finally,
we show that the pCC can be used for studies of xenobiotics in metabolically relevant conditions.
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3.2. INTRODUCTION
Quantification of cell survival is one of the most fundamental and broadly used endpoints in
biology. Cell viability assays are a basic research tool enabling molecular pathway analysis and definition
of gene function. Cell survival assessment is also essential in chemical safety studies. There are more than
100,000 synthetic chemicals used in consumer products, many of which have not been tested for safety (1).
In addition, more than 2,000 new compounds are introduced each year (2), increasing the urgent need for
sensitive, reliable, and rapid methods for toxicity assessment. Viability assays are also a mainstay assay in
the pharmaceutical industry where they are used to predict adverse effects as well as establishing efficacy
of compounds designed to target cancer cells (3). In these contexts and others, accurate cell survival testing
has significant implications. For example, in terms of public health, a false negative for toxicity could mean
that hundreds of people are exposed to a hazardous chemical. For the pharmaceutical industry, a false
positive could mean that an effective drug does not make it to the market, while a false negative could mean
that patients get exposed to toxic pharmaceuticals.
The gold standard for cell survival quantification is the colony formation assay (4), wherein cells
are exposed to a toxic agent and the ability of single cells to form colonies is quantified (5, 6). About 2-3
weeks following exposure, the surviving cells form colonies that can be counted by eye when stained.
Comparison of the colony numbers between the treated and untreated cells yields the relative toxic.ity of
the treatment condition. While the assay has an impressive dynamic range over several orders of magnitude,
it is inconvenient and relatively low-throughput due to long incubations. In addition, to prevent colony
overlapping, cells are plated in large dishes, which require large amounts of media. High volumes of media
consume more test compounds. Small molecule libraries are generally limited in quantities, and therefore
the colony formation assay cannot be used. Further, manual colony counting is time consuming and can be
prone to bias (4).
Due to the significant limitations of the colony formation assay, viability assays that are compatible
with microtiter plates or have a rapid assay time of 1-4 days have become popular alternatives. Loss of
112
membrane integrity has been the most common indicator of cell death for many viability assays, such as
the trypan blue and propidium iodide exclusion assays (3). Cells considered viable are those with intact
membrane and can exclude the stains. A drawback of this approach is that membrane integrity does not
always accurately reflect viability. Cells going through early stage programmed cell death may still have
intact plasma membrane (4, 6). On the other hand, severely damaged cells can disintegrate before the assay
is performed and will not be counted (7).
Another approach for estimating viability is to measure mitochondrial function via metabolism-
based endpoints. For example, tetrazolium assays (eg. MTT and XTT) are based upon the underlying
principle that a live cell can reduce tetrazolium salts to formazan derivatives, accompanied by a change in
color that can be measured by absorbance (8-11). Because of its relative ease of use and affordability,
tetrazolium assays are commonly used despite their low sensitivity (4, 9, 10). Importantly, artifacts can
arise from spontaneous reduction of the tetrazolium salts by reducing agents in cell media (4) or changes
in the absorbance spectrum of the formazan products induced by pH changes in the culture medium (12,
13). Analogously, intracellular ATP levels can be quantified as a measure of viable cells (14-18). The most
popular assay for this approach is the CellTiter-Glo® (CTG®) assay (Promega), which quantifies ATP
levels with luciferin-luciferase luminescence. CTG® is exquisitely sensitive and is able to measure ATP
levels in a single mammalian cell (6). However, ATP assays are affected by viability-independent
perturbations, such as nutrient depletion and pH changes (3, 13, 19), and can underestimate toxicity for
short incubation periods (6). Importantly, we have found in this work that CTG@ can yield highly different
results depending on initial cell density (described in detail below).
Here, we aimed to create an alternative approach to cell survival testing that combines the
advantages of existing assays. The result is "MicroColonyChip" (piCC), which requires ~250 times less
surface area than the colony formation assay and reduces -80% incubation time while achieving similar
sensitivity. ptCC is based upon the ability of microcolonies to grow in a microarray, enabling the
miniaturization of the traditional colony formation assay. Specifically, being able to grow cells in a
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microarray suppresses colony overlap, making it possible to move from large dishes to a 96-well plate
format. Rather than manual counting of colonies, ptCC uses DNA fluorescent staining combined with an
in-house software to measure microcolony sizes, enabling a significant reduction of assay time. For most
cell types, it takes -2-3 weeks for colonies to be countable by eye. On the other hand, after -3-4 days we
have observed significant differences between the distributions of microcolony sizes in the untreated control
and in the exposed population. Based on this observation, we developed methods to extract key parameters
that reflect the portion of surviving cells. These variables form the basis of a highly sensitive toxicity test.
We demonstrate in this work that the pCC has sensitivity comparable to the gold standard colony
formation assay. Furthermore, we find that the tCC is significantly more sensitive than the XTT assay, and
that it has comparable sensitivity to CTG@, while being more robust against culturing conditions. Finally,
we show that the tCC can be applied for studies of xenobiotics in metabolically relevant conditions.
3.3. MATERIAL AND METHODS
Chemicals
1,3-Bis(2-chloroethyl)-l-nitrosourea (BCNU) was obtained from Sigma-Aldrich, St. Louis, MO
(C0400) and dissolved in 100% ethanol to make a 99 mM stock solution. Aflatoxin B1 from Aspergillus
flavus (A6636) and ketoconazole (K1003) were purchased from Sigma-Aldrich, St. Louis, MO (A6636)
and dissolved in 100% dimethyl sulfoxide (DMSO) to make 20 mM stock solutions. 10% formalin, RPMI
1640 medium with GlutaMAX TM, and Pen-Strep were obtained from Thermo Fisher Scientific, Waltham,
MA (61870). Fetal Bovine Serum (FBS) was obtained from Atlanta Biologicals, Inc., Flowery Branch, GA.
Cell culture
TK6 (20, 21), TK6+MGMT (22), and MCL-5 (23) human B-lymphoblastoid cell lines were
cultured in IX RPMI 1640 medium with GlutaMAXTM supplemented with 10% FBS and 1% Pen-Strep.
All cell lines were incubated in an incubator set at 37'C with 5% atmospheric CO 2. Cell growth in liquid
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culture was measured by counting cell density of the same culture every day for four days using the Vi-
CELL'M cell counter (Beckman Coulter Life Sciences, Brea, CA).
pCC fabrication
The microwells were fabricated as described previously (24-27). Briefly, 1% w/v agarose solution
in phosphate-buffered saline (PBS) was prepared. When the molten agarose solution cooled down to ~65'C,
Pen-Strep was aseptically added to a final concentration of 2%. A polydimethylsiloxane (PDMS) mold with
an array of micropegs was pressed into the molten agarose solution on top of the hydrophilic side of a sheet
of GelBond® Film (Lonza, Hopkinton, MA). The agarose was allowed to gel at room temperature for -15
minutes. After the mold was removed, a bottomless 96-well plate was pressed on top of the agarose chip.
A 0.6% w/v low melting point agarose stock solution in PBS was kept molten at 43'C. A culture
medium stock (RPMI 1640 with GlutaMAX"M supplemented with 20% FBS and 2% Pen-Strep) was kept
at 370 C. To prepare the 0.3% w/v overlay agarose solution, one volume of the agarose stock solution was
combined with one volume of the culture medium stock.
Cells were loaded into the microwells by gravity, and the gel was then covered with a thin layer of
0.3% w/v overlay agarose prepared as described above. The gel was kept at room temperature for 15
minutes and another layer of the overlay agarose was added. After 15 more minutes at room temperature,
the gel was transferred to 4'C for 15 minutes to ensure maximal solidification of the overlay agarose.
Microcolony culture and treatment with DNA damaging agents
The pCC gel attached to GelBond@ Film was cut into 5 cm x 5 cm pieces using a pair of sterile
surgical scissors. The pCC pieces were submerged in fresh culture medium and incubated at 370 C and 5%
atmospheric CO 2 overnight before toxic treatments.
For chemical treatments, the compounds were added to the medium at different concentrations, and
the pICC pieces were then submerged in the medium. Immediately after the treatment time, an unexposed
piCC piece was removed from culture medium and placed in 10% formalin (starting population). The rest
of the pCC pieces were allowed to recover in fresh culture medium with no compounds for three or four
additional days before fixation in 10% formalin.
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ptCC pieces were submerged in 10% formalin for cell fixation and kept at 40 C for at least 2 hours
before staining for DNA content. After fixation, ptCC pieces were transferred to PBS and kept at 4'C until
staining.
y radiation treatment
While submerged in culture medium, cells encapsulated in gCC were irradiated at room
temperature using y-rays from a 13 7Cesium source at I Gy/min (Gammacell 40 Exactor, Best Theratronics
Model C-440).
N,N'-bis (2-chloroethyl)-N-nitrosourea (BCNU) treatment
pCCs were removed from culture medium and rinsed by submerging in PBS for 5 minutes. PBS
was aspirated and replaced with BCNU diluted in warm RPMI 1640 (+ GlutaMAXT M ) supplemented with
I% Pen-Strep. The maximum final concentration of ethanol was 0.1%. BCNU exposure was for one hour
at 370 C with 5% atmospheric C0 2; the BCNU solution was aspirated and residual BCNU was rinsed off
twice by submerging the ptCC pieces in PBS for 5 minutes each time.
Aflatoxin B1 (AFBj) treatment
ptCCs were submerged in culture medium supplemented with AFBI and incubated at 370 C and 5%
atmospheric CO 2. The maximum final concentration of DMSO was 0.5%. After 24 hours of incubation, the
AFB i-supplemented medium was removed. The pCC pieces were washed three times by submerging in
PBS for 5 minutes.
Inhibition of AFB1 metabolism with ketoconazole (KET)
To inhibit AFB, metabolism, 5 ptM KET was added to culture medium at the start of AFB,
treatment. The maximum final concentration of DMSO was 0.53%. The remaining steps were similar to
the AFB, treatment.
Fluorescence imaging and analysis
After cell fixation with 10% formalin, the [iCCs were rinsed once with PBS solution and stained
with Vybrant® DyeCycle TM Green (Thermo Fisher Scientific, Waltham, MA) (dissolved in PBS to a final
concentration of 1.5 ptM) at 4'C overnight. As a membrane permeable dye, Vybrant® DyeCycle TM Green
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maximizes the chance of capturing the total DNA content of a microcolony, which may contain both live
and dead cells. Fluorescent images were captured using an epifluorescence microscope (Nikon Eclipse 80i,
Nikon Instruments, Inc., Melville, NY) with a 480 nm excitation filter and automatically analyzed using a
custom software written in MATLAB (The MathWorks Inc., Natick, MA) as previously described (24)
with modifications to enable quantification of integrated fluorescence intensity per microcolony (F/M)
(Figure 2A). Distributions of F/M values were automatically generated and exported into spreadsheet files
using a custom software written in Python (Python Software Foundation, Python version 2.7.10). Analyses
of F/M distributions for excess microcolonies and excess growth were performed in Microsoft Excel
(Microsoft Office Suite 2016).
Colony formation assay in microtiter plates
The colony formation assay in microtiter plates was performed as previously described (28, 29) to
determine survival of TK6 cells 3 weeks after ionizing radiation treatment. Briefly, TK6 cells growing in
suspension were analyzed for viability and cell number using an automated Trypan Blue exclusion system
[Vi-CELL TM cell counter (Beckman Coulter Life Sciences, Brea, CA)]. A fixed number of TK6 cells were
distributed over U-bottom 96-well plates after ionizing radiation treatment. After 3 weeks, the wells were
scored for absence of colony growth, and the fraction of wells with no growth was calculated (a best
estimate for P(0), the probability of any well having no colony). The number of viable cells per 96 well
follows a Poisson distribution, therefore the mean number of viable cells per well can be calculated from
the estimated P(0). The surviving fraction was then calculated by dividing by the number obtained for
untreated cells and multiplying by a dilution factor. Bright field pictures of the bottom of 96-well plates
were taken with an Olympus TG-860 Tough Stylus Digital Camera (Olympus America, Inc., Center Valley,
PA) at 5X magnification.
XTT assay
The XTT cell viability kit was purchased from Cell Signaling Technology® (Danvers, MA). Three
days after ionizing radiation treatment, the viability of TK6 cells was measured using the XTT kit according
to the manufacturer's manual.
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CellTiter-Glo@ assay (CTG®)
The CTG@ luminescent cell viability kit was purchased from Promega (Madison, WI). 3 days after
ionizing radiation treatment, the viability of TK6 cells was measured using the CTG@ kit according to the
manufacturer's manual.
3.4. RESULTS
Patterning of cells using a microwell array platform
Arraying cells in a micropattern makes it possible to measure colony formation using a small area.
Specifically, the microarray increases the density of colonies per cm2 by ~250 times while eliminating most
of colony overlap. In order to array cells, we use a cell microarray approach that has previously been
described by our laboratory (24). Briefly, a PDMS mold (created by photolithography and soft lithography)
is pressed into molten agarose. The agarose is allowed to gel, and the mold is removed to reveal an array
of microwells. For the experiments described here, each microwell is -40 pim in both diameter and depth,
spaced 240 ptm apart from one another. The microwell array platform provides a tunable physical distance
between microcolonies and tunable well sizes. A bottomless 96-well plate is then compressed on top of the
microwell array to create macrowells with about 300 microwells each. A suspension of cells is then placed
in each macrowell and the cells are loaded into the microwells by gravity. Removal of excess cells by sheer
force reveals a microarray of cells (Fig. 3-1A). Cells are then trapped by adding low melting point agarose
in a layer above the cells. Due to the nature of the loading conditions where excess cells are washed away,
we find that the wells work equally effectively across a remarkably broad range of cell numbers (2,000-
200,000 cells/macrowell).
Non-adherent cells, such as lymphoblastoid cells, can be micropatterned using the microwell array
(Fig. 3-1B). After the cells are loaded into the microwells, we observe a range between one and seven TK6
cells per microwell, using phase-contrast microscopy at 40X magnification (Fig. 3-1B - Day 0). To learn
about the ability of the arrayed cells to form microcolonies, TK6 cells were incubated in cell culture media
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at 37'C. Suspension cells that naturally grow without attachment have previously been shown to form
colonies in soft agar (5, 30, 31). Consistent with these studies, here we show that TK6 cells also grow on
the microwell array platform. Appearance of cells growing out of the microwell boundary was noted as
soon as two days in culture (Fig. 3-B, Day 2). By day four, most microwells had formed larger
microcolonies with approximately more than ~60 cells, which is consistent with about a 20-hour doubling
time and an average of three cells/well on Day 0 (manual approximation using phase-constrast) (Fig. 3-1B,
Day 4) (28).
High-throughput quantification of microcolony size via nucleic acid fluorescence staining
We estimated individual microcolony sizes based on the total DNA content for each microcolony,
since DNA content is a useful indicator of cell number (32-35). Although DNA content depends on the cell
cycle phase, in a non-synchronous cultures, the average DNA content per cell stays relatively constant over
time (34). We therefore labeled the DNA of the microcolonies (example in Fig. 3-C, left) using a
fluorescent nucleic acid stain that is membrane permeable (Vybrant® DyeCycle Green; see Methods).
Fluorescent images of microcolonies were then captured (example in Fig. 3-IC, middle). To quantify total
DNA staining for each microcolony, we used an in-house MATLAB program that integrates the
fluorescence intensity for a given area (adapted from previous in-house software (24), see Methods). The
program detects the locations of the microcolonies and generates images of individual microcolonies
(example in Fig. 3-C, middle). The software integrates the total fluorescence intensity for each
microcolony (F/M) (example in Fig. 3-C, right).
To validate the F/M parameter, the number of distinct fluorescent nuclei in a microcolony was
counted manually as an estimate of total cell number for that microcolony (examples in Fig. 3-2A, see
Supplementary Procedures). As shown in Fig. 3- 2B, the number of cells per microcolony increases linearly
with the microcolony's F/M value (R2 = 1), indicating F/M is a sensitive and robust measurement of cell
number up to seven cells. F/M for a single cell, or fluorescence intensity per cell (F/C), is calculated to be
2300 500 (arbitrary fluorescence unit).
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We further tested the linearity of the F/M parameter for microcolony size beyond the cell number
countable under phase-contrast microscopy (seven cells). We monitored the change in the median F/M
value over four days in culture (Fig. 3-2C). Regression analysis shows that the median F/M for TK6
microcolonies increased exponentially between day 0 and day 4 (R2 = 0.95) with a doubling time of
approximately 21 hours. Similarly, we observed a doubling time of -21 hours in TK6 cells growing in
liquid culture (Fig. 3-2C, see Methods). We concluded that F/M is a sensitive and robust measurement of
microcolony size and that the doubling time of TK6 cells cultured on pCC is not significantly altered.
Construction of microcolony size distribution using F/M values
To construct the distribution of microcolony sizes, we calculated the relative frequency of
microcolonies with the same number of TK6 cells (Fig. 3-SlA). We monitored the growth of the TK6
microcolonies over the course of four days. Initially, the number of cells per microwell ranged between one
and seven cells. On each day, a plate was removed for analysis, and microcolonies were stained for DNA
content (Fig. 3-2D). As expected, some microcolonies remained very small while others had grown
extensively. After four days, microcolony F/M values ranged from 1 F/C to 150 F/C, corresponding to ~one
cell up to ~150. It is important to note that a colony that initially had seven cells could readily double to
form a colony of more than 150 cells over the course of four days (approximately 4.5 doubling times). Fig.
3-2D shows that the F/M distribution of TK6 microcolonies is very tight on day 0 and that as the
microcolonies grow, the distribution both shifts to the right and broadens. One can see more easily the
extent to which the populations become broader when all plots have the same scale for the y-axis (Fig. 3-
S2). We postulate that the broadening of F/M distributions is attributable to the difference in starting
microcolony sizes, growth rates, and potential effects of cell-cell interactions.
Toxicity measurement with pCC.
To perform a toxicity assay, cells embedded in a pCC are exposed to a toxic agent for a fixed time
(treatment period) and allowed to recover in fresh culture for at least three cell divisions following treatment
(recovery period). As shown in Fig. 3-2D, microcolony growth leads to a shift of the microcolony size
distribution toward higher frequencies of larger microcolonies compared to the initial microcolony
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population. We define Excess Microcolonies to be the microcolonies that have grown beyond the starting
population in size, and Excess Growth (EG) to be the total number of cells in Excess Microcolonies (Fig.
3-3 A, Supplementary Procedures).
To explore the sensitivity of EG as a metric for toxicity, we treated micropatterned TK6 cells with
y-radiation. Exposure to y-rays directly causes DNA single strand breaks and double strand breaks, which
can be highly cytotoxic. Previous studies using the colony formation assay have shown that TK6 cells are
highly sensitive to y-radiation (36-39). We examined the microcolony size distributions for TK6
microcolonies three or four days after y-radiation. Fig. 3-3B shows examples of TK6 microcolony size
distributions in untreated condition (left) and after 3 Gy of yIR (right). As expected, non-irradiated cells
(Fig. 3-3B, left) from small microcolonies (starting population - light green) readily grew into larger
microcolonies after three days (dark green). They gave rise to a broad distribution of microcolony sizes
with approximately a nine-fold increase in median colony size. In contrast, Fig. 3-3B (right) shows an
example of microcolonies that were exposed to 3 Gy of yIR. Many of the irradiated cells were growth
inhibited, due to either cell death or inability to divide, leading to overall smaller microcolonies after 3 days
(dark green).
Having established EG as a new parameter for toxicity, we compared it to a more established metric
of toxicity, the median microcolony size. In Fig. 3-3C, we detected more than two-log of killing using EG
but only one-log using median size, establishing that EG is the more sensitive metric. For all the subsequent
studies, all the microcolony size distributions are analyzed for EG values, and the method will simply be
referred to as "pCC".
yIR Survival Curves: Comparison of pCC, XTT, CellTiter-Glo® (CTG®) and Colony Formation
Assay
To investigate the sensitivity of pCC in measuring toxicity, we compared tCC and other assays for
TK6 cells' sensitivity to yIR. Specifically, we compared ptCC with the colony formation assay (28, 29) and
two commercially available methods, XTT and CTG@. y-irradiated TK6 microcolonies on pCC were
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analyzed 3-4 days after exposure. The recovery periods for the other methods were varied to maximize their
sensitivity.
We performed a direct comparison between the jtCC approach to the gold standard colony
formation assay (28, 29) (see Methods). y-irradiated TK6 cells were analyzed for colony formation in
microtiter plates three weeks after exposure. We tracked the appearance of colonies in 96-well plates over
18 days and observed that some colonies were not obvious until the last day (Fig. 3-S3). Therefore, we
decided on a timescale of three weeks before counting the colonies in order to maximize the assay's
sensitivity. In contrast, piCC data were obtained three days after yIR. ptCC yields an exponential toxicity
curve undistinguishable from the survival curve obtained from the colony formation assay (Fig. 3-4A). The
result from ptCC is also remarkably consistent with previously published studies using the colony formation
assay (36-39). Specifically in 1998 study (36), the same cell type was analyzed using the traditional colony
formation approach. Importantly, the pCC assay yielded nearly identical data (Fig. 3-4B). We conclude
that the pCC assay is as sensitive as the colony formation assay while being ~80% faster.
Many microtiter-plate methods for measuring cell survival have been developed as faster and more
convenient alternatives to the colony formation assay. We sought to compare pCC with two of the most
popular assays, XTT and CTG@. The XTT method is a widely used colorimetric assay that estimates the
number of viable cells by measuring the ability of cells to reduce the faint yellow salt (2,3-bis-(2-methoxy-
4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) (XTT) to a bright orange water-soluble formazan
dye (40). y-irradiated TK6 cells on microtiter plates were analyzed with XTT or ptCC three days after
exposure. Remarkably, the pCC assay is orders of magnitude more sensitive than the popular XTT assay
(Fig. 3-4C).
The CTG® assay (from Promega) is based on luminescent quantification of cellular ATP as a
measure of metabolically active cells (14). Specifically, beetle luciferin is added to lysed cells. ATP is rate
limiting for beetle luciferin to be enzymatically converted to oxyluciferin by firefly luciferase, with the
output of light. Thus, the amount of ATP in a sample (proportional to number of metabolically active cells)
can be estimated by the extent to which light is emitted. We performed the CTG@ assay with different
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starting cell densities. Unexpectedly, the results are highly dependent on the initial cell number, which
implies that there can be considerable variation in the results from one laboratory to another Fig. 3-S4A,
Fig. 3-4D). Unlike CTG®, the pCC is highly consistent across cell loading densities ranging over two
orders of magnitude (Fig. 3-S4B, Fig. 3-4E). The number of days in culture also changes the results of
CTG@ while having minimal effects on pCC (Fig. 3-S4).
Use of pCC to study the effects of a DNA repair gene on chemotherapeutic sensitivity
There is a great interest in DNA damaging agents because they can both cause cancer and be used
to treat cancer. To combat problems posed by DNA damage, cells have evolved a network of DNA repair
responses. Here, we explored the utility of pCC for studies of the role of DNA repair in preventing
cytotoxicity caused by an important DNA damaging agent used for chemotherapy.
In this study, we used iCC to measure toxicity induced by N,N'-bis (2-chloroethyl)-N-nitrosourea
(BCNU) and ylR using cells with different DNA repair capacity. BCNU is an chemotherapeutic alkylating
agent used to treat brain cancers (31, 41, 42). BCNU induces highly cytotoxic DNA interstrand crosslinks
(43). The DNA crosslinks are formed via a series of chemical reaction steps that start with the generation
of 0 6-chloroethylguanine lesions, which then react a second time with bases on the opposite strand (44). It
is known that the 06 -methylguanine methyl transferase (MGMT) protein prevents the formation of the
highly toxic interstrand crosslinks (45, 46).
The lymphoblastoid TK6 cells are deficient in MGMT and have been shown to be very sensitive
to BCNU toxicity (31). The TK6+MGMT cells are TK6 cells stably transfected with cDNA expressing the
MGMT protein and have been reported to be significantly more resistant to BCNU than the TK6 cells (31,
45, 46). As a control, we studied the effects of y-radiation, for which MGMT is not expected to play a role.
Results show that TK6 and TK6+MGMT are similarly sensitive to yIR-induced toxicity (Fig. 3-5A),
consistent with the fact that MGMT is not involved in strand break repair induced by y-radiation. In contrast,
there is a significant difference in sensitivity to BCNU between TK6 and TK6+MGMT (Fig. 3-5B) (22,
31). This results shows that pCC can be used to reveal the role of DNA repair genes in modulating the
sensitivity to chemotherapeutic agents.
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Use of pCC to study toxicity of a metabolically activated carcinogen
In the human body, xenobiotics are extensively metabolized, mainly by hepatocytes in the liver
(47). This process can result in reactive intermediates that can form adducts with DNA that may lead to
mutations, tumorigenesis, and cell death (48). While viability assays are widely used to monitor potential
health impact of industrial and pharmaceutical chemicals, a major drawback of current in vitro viability
assays is the lack of an appropriate cell model that can provide capacity for metabolisms of foreign
substances (xenobiotics). It is, therefore, essential to assess the toxicity of chemicals in metabolically
relevant conditions. The cytochromes P450 (CYP450s) are a superfamily of metabolizing enzymes,
responsible for -70-80% of phase I metabolism in the liver (49). To provide ptCC with the ability to measure
toxicity of both parent chemicals and their metabolites, we incorporated a metabolically competent cell
line, MCL-5. MCL-5 is an engineered human B-lymphoblastoid cell line that can stably express human
cytochrome P450 CYPlAl, CYPIA2, CYP2A6, CYP2EI, CYP3A4, and microsomal epoxide hydrolase
(mEH) (23). Together, these metabolic enzymes are responsible for approximately 50% of P450 activity in
phase I metabolism (49).
In this study, we focus on aflatoxin B1 (AFB1 ). Millions of people worldwide are exposed to AFB1,
a procarcinogen present in the molds Aspergillus flavus and A. parasiticus usually found in grains. In
combination with hepatitis B infection, AFB1 has been reported to increase the risk of liver cancer
approximately 60-fold and is thus the major cause of cancer in many regions of the world (50). Studies
have shown AFB1 is metabolized by a number of P450 enzymes (51). The most genotoxic metabolite, AFBI
exo-8,9-epoxide, is generated via oxidation of AFB1 mainly by CYP3A4 and CYPI A2 (52-55). AFB1 exo-
8,9-epoxide is highly unstable and readily reacts with guanine to form a number of bulky DNA adducts that
can lead to mutations and carcinogenesis (56-58).
We applied pCC to measure the toxicity level of AFB1 in MCL-5 cells three days following
exposure. To control for the effects of metabolism, we included TK6 as a negative control cell line. As
expected, TK6 cells are insensitive to AFB1 due to their low metabolic capacity. In contrast, MCL-5 cells
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are significantly more sensitive than TK6 to AFB, (more than two-log difference at the highest dose) (Fig.
3-5C). We were able to further test the hypothesis that MCL-5 sensitivity is due to metabolic activation of
AFB1 by using ketoconazole (KET). KET is a well-known potent inhibitor of CYP3A4 activity (59-61).
Whereas MCL-5 cells are extremely sensitive to AFB1 , inhibition of metabolism by KET leads to significant
rescue of MCL-5 cells (Fig. 3-5D). Taken together, the incorporation of MCL-5 cells into the tCC platform
yields a rapid and sensitive method to test for toxicity of xenobiotics in a metabolically relevant context.
3.5. DISCUSSION
Despite the fact that millions of cytotoxicity tests are performed every year, there have been relatively
few fundamental advances in cytotoxicity testing. The gold standard is the colony formation assay, which
is slow, laborious, and not compatible with high-throughput screening. Alternative faster approaches have
been developed, but they rely on indirect measures of cell viability. With nearly identical sensitivity and
higher throughput, we show here that pCC rivals the colony formation assay, with the potential to become
the new gold standard. The results presented in this work highlight a few important advantages of the pCC
assay: (i) analysis of microcolony size distribution is a direct measure of cells' ability to divide, enabling
quantification of toxicity using the same testing parameter as the colony formation assay in -3-4 days
instead of -2-3 weeks; (ii) by arraying cells in microwells, pCC shrinks the colony formation assay to
~1/250 its area, enabling compatibility with the microtiter plate format; (iii) pCC is capable of measuring
cell survival on a multi-log scale, enabling sensitive quantification of toxicity; (iv) pCC is robust against
experimental noise introduced by differences in initial cell numbers. Perhaps the most important
observation is that results from pCC are nearly identical to data from the traditional colony formation assay
performed in our laboratory. Furthermore, the same experiment performed 20 years ago by a different
laboratory yielded essentially the same results (36).
Today, commonly used assays are the tetrazolium assays and ATP assays. The underlying principle
for these assays is that the number of viable cells is estimated by the cells' mitochondrial functions, either
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to reduce a tetrazolium salt or to maintain intracellular ATP level. Developed in 1980s, tetrazolium assays
have enjoyed popularity in academic labs as well as industry due to the convenient microtiter plate format
and the wide availability of colorimetric plate readers. Tetrazolium assays, however, are known to be
limited in sensitivity (4, 9, 10). On the other hand, pCC is capable of measuring multi-log survival levels.
As demonstrated in this work, ptCC is far more sensitive than the XTT assay, one of the most common
tetrazolium assays, with more than 10-fold difference in dynamic range. Importantly, iCC relies solely on
DNA content, which is a reliable and robust measure of cell number (32-35). In contrast, tetrazolium assays
depend on mitochondrial activity, which can vary due to factors unrelated to cell division (4, 12, 13).
Similar to tetrazolium assays, ATP assays are also a staple in cell viability testing. The CTG® assay
is amendable to microtiter plate format, highly sensitive, and the luminescence output is very convenient
to measure. In this work, we observe that pCC yields consistent results across a 100-fold range of initial
cell densities while CTG@ results are highly susceptible to changes in both initial cell number and the
number of days in culture. This observation is consistent with the fact that metabolic functions are highly
influenced by non-lethal changes in culture conditions (3, 6, 13, 19, 62). In addition, the relationship
between intracellular ATP level and cell viability is not always linear (63). Finally, ATP-based assays are
not appropriate to assess toxicity of chemicals that interfere with ATP biosynthesis [e.g., atractyloside
inhibits ADP/ATP translocases, inhibiting ATP biosynthesis (64)].
The advantages of pCC over commonly used cell viability assays can be leveraged to provide an
efficient and sensitive screening platform in drug discovery. Quantification of cell survival provides a
critical endpoint because the ability to modulate cell death is an effective therapeutic strategy. For example,
in cancer therapy large chemical libraries are screened for their ability to induce cancer cell death or inhibit
cell growth (65). On the other hand, cytoprotective compounds are selected for their ability to attenuate cell
death in the context of ischemia and neurodegeneration (66). In these cases, ptCC can provide highly
sensitive and robust quantification of cell survival, which is critical in assessing the efficacy of a potential
candidate drug. The short assay time and the compatibility with the microtiter-plate format also make pCC
adaptable for high-throughput drug discovery screens.
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In drug development, it is also important to understand the underlying cell death mechanism
induced by a potential candidate (3). With their critical roles in human diseases, cell death modalities, such
as apoptosis and necroptosis, and can be exploited as therapeutic targets. For example, necrosis inducers
can be used to target apoptosis-resistant tumors (19, 67). In the context of drug discovery, pCC can be used
in a multiplex fashion to both assess cell survival and study cell death mechanism. Besides excess growth,
established viability biomarkers, such as membrane integrity (e.g., propidium idodide staining) and
apoptosis (e.g., Annexin V staining), can also be probed simultaneously to provide information about
cytotoxic levels as well as cell death modalities (data not shown).
In the broad context of chemical toxicity testing, the bottleneck of in vitro cell-based assays is
biotransformation (68). Biotransformation is the process whereby a foreign substance (xenobiotic) is
modified in the body to form metabolites, which can be transported to systemic circulation (47). Therefore,
in vitro assays need to account for the toxic effects of both the parent chemicals and their metabolites (68).
By incorporating MCL-5 cells, which have stable expressions of critical metabolic enzymes (23), ptCC can
provide a rapid and sensitive platform for primary toxicity screens that overcomes the bottleneck of in vitro
assays.
ptCC's compatibility with the microtiter plate format is potentially adaptable for high-throughput
screening (HTS) for chemical safety testing in the context of environmental health. Due to the large number
of chemicals that come in contact with humans and the environment, governmental agencies, such as the
U.S. National Toxicology Program (NTP) and the EU's Registration, Evaluation, Authorisation, and
Restriction of Chemicals (REACH), have heavily invested in large-scale chemical safety studies. Cell
sensitivity is a critical endpoint in these studies, and microtiter plate viability assays are often the top choice
due to their compatibility with HTS.
Because of its high-throughput capacity and its multi-log sensitivity, we anticipate that the pCC
platform can be applied to detect subtle differences between people in population studies. Information about
inter-individual variability in sensitivity to toxic exposures is useful in developing personalized disease
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treatment as well as in understanding risk factors for environmentally-induced diseases. For example,
studies have shown a wide range of variation in sensitivity toward different DNA damaging agents in
lymphoblastoid cell lines derived from genetically diverse healthy individuals (31, 69). Many studies have
also observed differences in radiosensitivity among mitogen-stimulated T lymphocytes obtained from
different individuals (70). We anticipate that pCC is well suited to study dividing cells, such as mitogen-
stimulated lymphocytes, because of its ability to yield sensitive measurements after only a few days in
culture.
In this work, we focus on lymphoblastoid cells, which can grow in suspension. Further work is
needed to demonstrate tCC's utility for other cell types. Although many cells can be grown in a non-
adherent fashion (making it possible to grow them in the pCC agarose microwells), many other cell types
are anchorage dependent and require a charged surface or a biological ligand for binding (71, 72). We have
begun to explore several approaches for growing adherent cells on the pCC. For example, cells loaded into
the agarose microwells can be overlaid with low melting point agarose mixed with collagen type 1. We
found that HeLa cells and HepG2 cells appear to attach to the collagen ligands and form adherent
microcolonies (Fig. 3-S5, top and middle). A limitation of this approach is that not all cells stay confined
to the microwells, as they appear to elongate and spread during microcolony formation (Fig. 3-S5, bottom).
To optimize the assay, it is ideal for the microcolonies to be compact so that there is not significant
microcolony overlap. To overcome this limitation, further development to modify the growth conditions to
foster growth within the microwell, rather than growth by attachment to the ligands in the upper layer, is
necessary. Other ECM component proteins including laminin 1, fibronectin, vitronectin and various
collagens (73) can also be added to the pCC. Additionally, varying microwell diameters and distances
between the microwells can potentially acommodate different cell types. For example, for larger cells, a
microwell with a larger diameter may be desireable, and for cells that migrate away from the microcolony,
an increase in the inter-microwell distance may be advantageous.
In conclusion, we have described ptCC, a rapid and sensitive cell survival assay that combines the
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advantages of commonly used viability assays. With the short assay time and large dynamic range, the ptCC
platform provides an efficient alternative to the colony formation assay, which continues to be the gold
standard in cell survival testing. The companion in-house software enables automated image analysis of
thousands of microcolonies in a few minutes, making it easy for a new user to learn and use the assay.
Finally, the high-throughput and potential multiplexing capacity make ptCC a powerful tool for applications
including screens for drug development, epidemiological studies, and chemical safety studies.
3.6. SUPPLEMENTARY PROCEDURES
Correlation of F/M values with cell numbers per microwell
We loaded TK6 cells into an array of 40-tm wells and immediately stained the cells with Vybrant@
DyeCycle Green (see Methods). The microwells provide physical spaces with a defined volume that only
allows a maximum number of -7-8 TK6 cells per well. Fluorescent images of TK6 microcolonies were
captured and analyzed using our in-house MATLAB program (see Methods). Because the cells had not
been given time to grow after loading, the fluorescent nucleus of each cell in a microcolony can be clearly
distinguished by eyes in the fluorescent images. The number of distinct nuclei was counted manually and
compared to the F/M value of that microwell.
Calculation of Excess Microcolonies and Excess Growth
We can calculate the Excess Growth (EG) value for each treatment condition and compare to a
negative control EG (unexposed cells) to obtain a toxicity measurement. To calculate EG, we first estimate
Excess Microcolonies (EM), the portion of microcolonies that have grown in excess of the starting
population, by subtracting the microcolony size distribution of the final population by that of the starting
population. EG is the sum of the number of cells in these EM. To illustrate the calculation process, suppose
a starting population has 100 microcolonies with the following distribution: 25 microcolonies have I cell
each, 50 have 2 cells each, and 25 have 3 cells each (Fig. 3- SIB - light green). After growth, the final
population of 100 microcolonies consists of 25 microcolonies with 2 cells each, 50 with 3 cells each, and
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25 with 4 cells each (Fig. 3- SIB - dark green). For each microcolony size, we subtract the number of
microcolonies in the final population by the starting population:
1-cell microcolonies: 0 - 25 = -25 microcolonies < 0
2-cell microcolonies: 25 - 50 = -25 microcolonies <0
3-cell microcolonies: 50 - 25 = 25 microcolonies >0
4-cell microcolonies: 25 - 0 = 25 microcolonies >0
We define the positive values of the subtractions to be the EM. In this case, EM consist of 25 of
the 3-cell microcolonies and 25 of the 4-cell microcolonies. By our definition, the total number of cells in
these microcolonies is EG:
EG = 25 microcolonies x 3 cells + 25 microcolonies x 4 cells = 175 cells.
In practice, the numbers of microcolonies collected for starting and final populations can differ. A
normalization by the total number of microcolonies for each population is therefore required, and the
subtraction is performed between the relative frequencies of microcolonies and not between the actual
numbers of microcolonies.
Excess Growth
To quantify cell survival, we can compare different measures of growth between the treated
population and the untreated. The median colony size of the 3-Gy is ~1/9 that of the untreated. In contrast,
the 3-Gy's EG is only ~1/50, indicating a higher level of toxicity than revealed by the median colony size
comparison. Exposure of TK6 microcolonies to a range of yIR doses reveals that toxicity measured by
median colony size comparison plateaus around 10% of untreated. On the other hand, EG displays an
exponential killing curve with a superior dynamic range of more than two orders of magnitude (Fig. 3- 3D).
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Figure 3-1. Construction of Microcolony Chip (ptCC) and quantification of total DNA content. A.
Steps in micropatterning cells in ptCC. 1. PDMS stamp with microposts is pressed into molten agarose. 2.
Agarose is allowed to cool and solidify. 3. Stamp is lifted off to reveal patterned microwells on agarose
chip. 4. Cell suspension is placed directly onto agarose chip. 5. Cells settle into microwells via gravity.
Excess cells are washed off to reveal micropatterned cells. 6. Cells are kept in microwells by an overlay
layer of 0.3% low-melting point agarose. B. Phase-contrast pictures of example patterned TK6
microcolonies taken at 40X magnification. Left: empty agarose microwell array. Day 0: micropatterned
cells after loading. Day 1 - Day 4: growth of patterned microcolonies during 4 days in culture. C. Example
calculation of integrated fluorescence intensity per microcolony (F/M) for one TK6 microcolony. Left:
phase-contrast image of one TK6 microcolony after 4 days in culture. Middle: fluorescent image of a
different TK6 microcolony stained with Vybrant@ DyeCycleTM Green. Right: a plot of the average
fluorescence intensity of each pixel column from the left to the right of the Middle image after background
correction (binary mask using Otsu thresholding method). F/M is the total area under the curve.
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Figure 3-2. Total DNA content as a measure of microcolony size. A. Example calculation of F/M for
microwells with one cell (left) and five cells (right). Top: fluorescent images of TK6 cells in microwells
stained with Vybrant® DyeCycle'TM Green. Bottom: Fluorescence intensity plots of the corresponding
fluorescent images after background correction (binary mask using Otsu thresholding method). F/M is the
total area under the curve. B. Average F/M values for 1 to 7 TK6 cells. F/M for a single cell, or fluorescence
intensity per cell (F/C), is calculated to be 2300 500 (arbitrary fluorescence unit). Each data point is an
average of 3. independent experiments. Error bars are standard errors of the means. C. Fold change of
median F/M for TK6 microcolonies in piCC (green line) and TK6 cell density in liquid culture (red line)
during 4 days of culture. Each data point is an average of at least 3 independent experiments. Error bars are
standard errors of the means. D. Example of TK6 microcolony size distributions obtained from ptCC during
4 days in culture. F/M values of >700 microcolonies were analyzed for each distribution and converted to
cell numbers by dividing by the value of 1 F/C. y-axis for each plot is individually scaled.
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Figure 3-3. A. Illustrative example of microcolony size distributions before (starting population in light
green) and after growth (final population in dark green). Excess Microcolonies (blue-outlined) are
microcolonies in the final population that have grown beyond the starting population in size. Excess Growth
(EG) is defined as the total number of cells in Excess Microcolonies. B. Example of microcolony size
distributions derived from F/M values of TK6 cells. Left: distribution before yIR ("Starting population",
light green) overlaying with untreated distribution after 3 days in culture ("Untreated", dark green). Right:
distribution before yIR ("Starting population", light green) overlaying with y-irradiated distribution after 3
days in culture ("3 Gy", dark green). C. yIR-induced toxicity (% Untreated) derived from normalization of
y-irradiated microcolonies by "Untreated" using median microcolony sizes (light green line) or Excess
Growth values (dark green line).
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Figure 3-4. Compare p1CC with other assays in measuring yIR-induced toxicity in TK6 cells. Toxicity is
expressed as percent of y-irradiated cells relative to untreated control cells. A. The colony formation assay
data (light blue line, see Methods) were obtained 3 weeks after y-irradiation. ptCC data (dark green) were
obtained 3 days post irradiation. B. Colony formation data from *Wenz F. et al, 1998 (black line, (36))
were reproduced with permission from Radiation Research journal. pCC data (dark green) were obtained
3 days post irradiation. C. XTT data (dark blue line) were obtained 3 days after exposure (see Methods).
pCC data (dark green) were obtained 3 days post irradiation. D. yIR-induced toxicity in TK6 cells measured
by CTG® with different cell seeding densities (legend: number of cells per 96-well) after a recovery period
of 4 days. E. yIR-induced toxicity in TK6 cells measured by ptCC with different cell loading densities
(legend: number of cells per macrowell) after a recovery period of 4 days. n > 3, error bars are standard
errors of the means.
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Figure 3-5. ptCC analyses to measure toxicity presented as percent of treated cells relative to untreated
control cells (% Control). A. y radiation treatment (see Methods) for TK6 cells (blue) and TK6 + MGMT
cells (pink). B. N,N'-bis (2-chloroethyl)-N-nitrosourea (BCNU) treatment (1 hour at 370C) for TK6 cells
(blue) and TK6 + MGMT cells (pink). *p < 0.05, Student's t-test, 2-tailed, unequal variance. C. Aflatoxin
BI (AFB 1) exposure (24 hours at 37"C) for TK6 cells (blue) and MCL-5 cells (light purple). * p < 0.05,
Student's t-test, 2-tailed, unequal variance. D. Parallel treatment of MCL-5 cells with AFBI or AFBI in
conjunction with ketoconazole (KET). * p < 0.05, Student's t-test, 2-tailed, paired. All data points are
means of ;> 3 independent experiments. Error bars are standard errors of the means.
142
A 1 100 *
* *
*
10
TK6+MGMT
1
TK6
0.1 .
0 20 40 60 80100
BCNU (pM)
0
L-.
0
0.
C 1004
10.
1-
L..
0
0.
A
W 301 7% of allA)
microcolonies
o have -6 cells
0
, 0 10
0.
1 2 3 4 5 6 7 8 910
Microcolony size
(in unit of F/C, where 1 = 1 cell)
B
,
-0
So
00
E 0
Z
0S Starting population
60 M Final population
40.
20 L
01
1 2 3 4
Microcolony size
(in unit of number of cells)
Figure 3-S1. A. We sorted microcolonies into F/M bins with equal widths of 2300 (arbitrary fluorescence
unit) (1 F/C). These bins range from the expected F/M for ~one cell (1 F/C) to the expected F/M for -150
cells (150 F/C's). We then derived the microcolony size distribution by quantifying the relative frequency
of microcolonies with F/M values that fall within each specific F/M bin (example in Fig. S2). Illustration
of the construction of a microcolony size distribution. Data are from untreated TK6 microcolonies after one
day in culture. Each bin represents one microcolony size in unit of F/C (~number of cells). y-axis is the
relative frequency of microcolonies with the same size. B. Simplified illustrative size distributions for 100
starting microcolonies (light green) and 100 final microcolonies (dark green). See Supplementary
Procedures for step-by-step calculations for Excess Mircocolonies and Excess Growth.
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Figure 3-S2. Example of F/M distributions for TK6 cells on ptCC at different times in culture (see Fig. 3-
2D). y-axes for all distributions are set to the same scale.
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Figure 3-S3. Example bright-field pictures of wells with TK6 cells (untreated or y-irradiated with 4 Gy)
cultured in U-bottom 96-well plates over 18 days (DO = immediately after exposure, D9 = 9 days after
exposure, D14 = 14 days after, and D18 = 18 days after) (see Methods). Pictures are taken from the same
24 wells for each condition. Obvious colonies appear at different times across the wells. Red-circled wells
represent examples of colonies that are not obvious until day 18 (D18).
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Figure 3-S4. A. yIR-induced toxicity in TK6 cells measured by CTG® with different cell seeding densities
(legend: number of cells per 96-well) and 2 different recovery periods (left: 3 days; right: 4 days). B. yIR-
induced toxicity in TK6 cells measured by gCC with different cell loading densities (legend: number of
cells per macrowell) and 2 different recovery periods (left: 3 days; right: 4 days). n > 3, error bars are
standard errors of the means.
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Figure 3-S5. Growth of adherent cells on modified pCC. A layer of Collagen I gel was sandwiched between
the cells and the overlay agarose layer. Modified pCC with embedded cells was submerged in culture
medium and monitored for cell growth. Phase-contrast pictures of HeLa cells, HepG2 cells, and human
fibroblasts cells on modified gCC were taken at 40X magnification.
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Chapter 4
Application of CometChip and Human Lymphocytes to Study Population
Variation in DNA Repair Capacity
4.1. ABSTRACT
There is a high variability in how an individual responds to DNA damaging agents. Many lines of
evidence point toward an association between aberrant DNA repair capacity and risk of cancer as well as
sensitivity to anti-cancer treatment. Over the past two decades, there is mounting evidence showing
significant interindividual variations in DNA repair capacity, which are associated with differences in
disease risk and treatment outcomes. The evidence has been contributed by methods that indirectly or
directly measure DNA repair capacity. Therefore, the ability to measure DNA capacity may allow for
predictions of how an individual responds to a DNA damaging agent, enable more accurate assessment of
cancer risk, and provide useful information to design tailored treatment regimens in order to minimize side
effects while maximizing treatment effectiveness. CometChip, a high-throughput comet assay platform,
can process -3-4 orders of magnitude more samples than the conventional comet assay, opening doors to
large population studies. In this study, we demonstrated how CometChip can be used to measure DNA
repair kinetics of oxidative damage induced by y ionizing radiation (yIR) and hydrogen peroxide (H 2 02 ),
alkylation damage induced by methyl methanesulfonate (MMS), cyclobutane pyrimidine dimers induced
by ultraviolet (UV) light, and double-strand breaks (DSBs) formed upon yIR in human primary
lymphocytes. We also conducted a small pilot study with primary lymphocytes isolated from 56 healthy
volunteers, which shows a sevenfold variation in repair rates.
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4.2. INTRODUCTION
Environmental DNA damaging agents, such as air pollution, tobacco smoke, and UV radiation,
represent major causes of cancer, yet therapeutic DNA damaging agents, such as y radiation and
temozolomide, are standard cancer therapies. The health effects of exposure to DNA damaging agents vary
greatly across populations. Among heavy smokers, only ~10% develop lung cancer (1), and among patients
undergoing similar courses of cancer therapy, treatment outcomes highly diverge (2). The ability to identify
individuals who are most susceptible to the health effects of DNA damage would open doors for
personalized strategies for early detection or prevention of cancer and individualized dosing regimens that
could make treatment more effective while minimizing its harmful side effects. Genetic and functional
analyses indicate that cancer susceptibility and clinical treatment sensitivity can be associated with
inefficient DNA repair (3-8), raising the possibility of tailoring individual treatment and prevention by
measuring DNA repair capacity.
Despite the important role of DNA repair in modulating the health effects of DNA damage, clinical
applications of DNA repair capacity have been limited to diagnostics via genetic testing of known
polymorphisms in genes associated with DNA repair defects and diseases (9). Certain cell-based assays,
such as chromosomal aberration and UV-induced unscheduled DNA synthesis, are occasionally used as
confirmation tests (10, 11). Importantly, although genetic defects in DNA repair proteins have been
exploited to improve cancer treatment outcomes (12, 13), interindividual variation in DNA repair capacity
has not been considered in cohort selection for clinical trials or in designing treatment regimens.
More studies are needed to further elucidate the relationship between DNA repair capacity and
health outcomes. Larger and more prospective studies are especially crucial since it is unclear whether the
altered DNA repair capacity associated with cancer risk and treatment response variability is the cause or
the effect. The extensive crosstalk and competition between the major DNA repair pathways also needs to
be taken into account in these studies (14). To these ends, high-throughput assays capable of measuring
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multiple repair pathways in parallel are essential. Recent examples include a multiplexed fluorescence-
based flow cytometric host cell reactivation assay (FM-HCR) (15, 16) and CometChip (17, 18).
Developed in 1984 (19), the comet assay has since become a classic tool in a number of fields,
including environmental biomonitoring, DNA repair studies, and genotoxicity testing (20, 21). The key
advantages of the comet assay include simple procedures and sensitivity to a wide range of DNA damage.
Importantly, only a small number of cells are required, making the assay particularly suitable for population
studies where samples are usually rare and valuable. On the other hand, the conventional comet assay
suffers from several major drawbacks, including low-throughput and high experimental variability. Only
about 600 comets can be imaged within one hour, which limits the number of slides scored per day to 50
even when automated imaging systems are used (20). This practical challenge severely limits the use of the
comet assay in large-scale sample size and is especially prohibitive in DNA repair kinetics studies where
multiple time points are analyzed for several types of DNA damage.
CometChip, a high-throughput comet assay platform, was developed to overcome the limitations
of the conventional comet assay (17, 18). The underlying principle of CometChip is based upon arraying
cells in a grid on an agarose chip so that the resulting comets are on the same focal plane and are spaced at
a fixed distance from one another. As a consequence, as many as 100 comets can be imaged in one field.
In addition, a bottomless 96-well plate can be imposed on the agarose chip to create 96 isolated macrowells,
each of which contains up to 300 comets. Each chip, therefore, corresponds to ~96 slides in the conventional
comet assay, and one full chip can be imaged within ~15 minutes by automated systems. Finally, a
companion in-house software enables automated analysis of more than 100 comet images per second. As a
result, CometChip can process -3-4 orders of magnitude more samples than the conventional comet assay,
opening doors to large-scale population studies of DNA repair kinetics across multiple pathways.
This study focuses on establishing experimental CometChip conditions to measure DNA repair
kinetics of multiple types of DNA damage in human peripheral blood lymphocytes. Human peripheral
blood mononuclear cells (PBMCs) were isolated from fresh whole blood, and T-lymphocyte activation was
150
stimulated for three days with the mitogen phytohemagglutinin-L (PHA-L) (22, 23). The alkaline comet
assay was used to study oxidative damage induced by yIR and HO2 and alkylation damage induced by
MMS. An additional incubation step with T4 endonuclease V was included in the alkaline comet assay to
create nicks at CPDs formed upon short wavelength UV irradiation (UV-C). Finally, the repair of DSBs
caused by yIR was monitored with the neutral comet assay. All five measures were conducted in parallel
using the same sample of PHA-stimulated T-lymphocytes.
In a pilot study, we investigated CometChip's sensitivity and reproducibility to measure small
differences in oxidative repair kinetics between individuals. Blood samples were taken from ten healthy
volunteers on multiple visits in order to compare the variability within an individual and across the
population. A larger study was also conducted with 46 healthy volunteers, each of whom had one single
blood draw. Oxidative repair kinetics curves were obtained for the population, showing a sevenfold
variation in repair rate.
4.3. MATERIALS AND METHODS
CometChip fabrication
Materials. SylgarTM 184 silicone elastomer kit (102092-312) and bottomless 96-well plates (82050-
714) were purchased from VWR, Radnor, PA. GelBond® Film (53761) was obtained from Lonza,
Portsmouth, NH. UltraPure TM agarose (16500100) and UltraPureTM low melting point agarose (16520100)
were purchased from ThermoFisher Scientific, Waltham, MA.
Procedure. The microwells were fabricated as described previously (17, 18, 24, 25). Briefly, 1%
w/v agarose solution in DPBS was prepared. A polydimethylsiloxane (PDMS) stamp with an array of
micropegs was fabricated using the SylgarTM 184 kit as described previously (18). The stamp was pressed
into the molten agarose solution on top of the hydrophilic side of a sheet of GelBond® Film. The agarose
was allowed to gel at room temperature for ~15 minutes. The stamp was removed to reveal an array of
151
microwells with -40-50 ptm in both diameter and depth. The microwells were spaced 240 pm apart. A
bottomless 96-well plate was pressed on top of the agarose chip to form 96 macrowells. The bottom of each
macrowell was an array of -300 microwells.
To load cells into microwells, -2,000 - 200,000 cells in suspension were placed into each
macrowell, and the chip was incubated at 37"C in the presence of 5% CO2 for 15 minutes. This time is
sufficient for most cell types to have fully loaded into the microwells by gravity. Excess cells were then
washed off with DPBS by shear force. The chip was covered with a layer of overlay agarose (1% w/v low-
melting point agarose solution in DPBS, kept molten at 43'C until use). For complete solidification of the
overlay agarose, the chip was kept at room temperature for 2 minutes followed by 2 minutes at 4*C.
Alkaline CometChip assay
Chemicals. Sodium chloride (NaCl, 7581), disodium EDTA (Na2EDTA, 4931), and sodium
hydroxide pellets (NaOH, 7708) were purchased from VWR, Radnor, PA. Trizma® base (T 1503), Trizma@
HCI (T5941), and Triton X-100 (X-100) were obtained from MilliporeSigma, St. Louis, MO. 10,000X
SYBRTM Gold nucleic acid gel stain was obtained from ThermoFisher Scientific, Waltham, MA.
Buffers. The alkaline lysis buffer (pH ~ 10) was a solution of 2.5 M NaCl, 100 mM Na2EDTA, 10
mM Trizma® base, and 1% v/v Triton X-100 dissolved in de-ionized H20 (dI H20). The alkaline unwinding
buffer (pH ~ 13.5) was prepared by diluting NaOH and Na2EDTA stock solutions in dI H2 0 to final
concentrations of 0.3 M and 1 mM, respectively. The neutralization buffer (pH - 7.5) was prepared by
dissolving Trizma@ HCl in distilled H20 to a final concentration of 0.4 M.
Procedure. Cells encapsulated in CometChip were lysed in the alkaline lysis buffer overnight at
4'C. The nuclei were unwound in the alkaline unwinding buffer for 40 minutes at 4'C, and the DNA was
electrophoresed in the same buffer at the same temperature for 30 minutes at 1 V/cm and -300 mA. The
CometChip was then washed three times in the neutralization buffer by submerging for five minutes each
time.
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Afterward, the DNA on ComeChip was stained for 15 minutes at room temperature with IX of
SYBRTM Gold diluted in DPBS, protected from light. Fluorescent images of the comets were captured at
40X magnification using an epifluorescence microscope (Nikon Eclipse 80i, Nikon Instruments, Inc.,
Melville, NY) with a 480 nm excitation filter. Image acquisition was achieved by automatic scanning using
a motorized XY stage. Comet images were automatically analyzed using Guicometanalyzer, a custom
software developed in MATLAB (The MathWorks Inc., Natick, MA) as previously described (18). Outputs
from Guicometanalyzer were processed and imported to a spreadsheet (Microsoft Excel, Microsoft Office
Suite 2016) using Comet2Excel, an in-house software developed in Python (Python Software Foundation,
Python version 2.7.10).
Neutral CometChip assay
Chemicals. Sodium chloride (NaCl, 7581), disodium EDTA (Na2EDTA, 4931), and sodium
hydroxide pellets (NaOH, 7708) were purchased from VWR, Radnor, PA. N-lauroylsarcosine sodium salt
(L9150), Trizma@ base (T1503), Trizma® HCI (T5941), Triton X-100 (X-100), 100% dimethyl sulfoxide
(DMSO, D8418) were obtained from MilliporeSigma, St. Louis, MO. 1 0,OOOX SYBRTM Gold nucleic acid
gel stain was obtained from ThermoFisher Scientific, Waltham, MA. Boric acid (M139) was purchased
from AMRESCO LLC, Solon, OH.
Buffers. The neutral lysis buffer (pH ~ 9.5) was prepared as a solution of 2.5 M NaCl, 100 mM
Na2EDTA, 10 mM Trizma@ base, 1% N-lauroylsarcosine sodium salt, 0.5% v/v Triton X-100, and 10%
DMSO in de-ionized H20 (dl H 2 0). The neutral electrophoresis buffer (TBE, pH ~ 8.5) comprised of 2
mM Na2EDTA, 90 mM Trizma@ base, and 90 mM boric acid in dl H 20. The neutralization buffer (pH ~
7.5) was prepared by dissolving Trizma® HCl in distilled H2 0 to a final concentration of 0.4 M.
Procedure. Cells encapsulated in CometChip were lysed in the neutral lysis buffer overnight at
43'C. The CometChip was then washed vigorously three times by submerging in TBE and placed on an
orbital shaker for 30 minutes at a slow speed (-50 rpm). Afterward, the chip was incubated in fresh TBE at
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4'C for 60 minutes, and the DNA was electrophoresed in the same buffer at the same temperature for 60
minutes at a constant 0.6 V/cm and 6 mA. The CometChip was then washed three times in the neutralization
buffer by submerging for five minutes each time.
Afterward, the DNA on CometChip was stained for 15 minutes at room temperature with IX of
SYBRTM Gold diluted in DPBS, protected from light. Fluorescent images of the comets were captured at
40X magnification using an epifluorescence microscope (Nikon Eclipse 80i, Nikon Instruments, Inc.,
Melville, NY) with a 480 nm excitation filter. Image acquisition was achieved by automatic scanning using
a motorized XY stage. Comet images were automatically analyzed using Guicometanalyzer, a custom
software developed in MATLAB (The MathWorks Inc., Natick, MA) as previously described (18). Outputs
from Guicometanalyzer were processed and imported to a spreadsheet (Microsoft Excel, Microsoft Office
Suite 2016) using Comet2Excel, an in-house software developed in Python (Python Software Foundation,
Python version 2.7.10).
Culture of cell lines
Reagents. Dulbecco's phosphate-buffered saline (DPBS), high-glucose Dulbecco's Modified
Eagle's Medium (DMEM, high glucose, 11965092), RMPI-1640 (11875093), 200 mM L-glutamine
(A2916801), 10,000 U/ml Pen-Strep (15140), 0.25% Trypsin-EDTA with phenol red (25200) were
purchased from ThermoFisher Scientific, Waltham, MA. Fetal bovine serum (FBS) was obtained from
Atlanta Biologicals, Inc., Flowery Branch, GA.
Culture conditions. All the cells were cultured in an incubator set at 370 C with 5% CO2 .
Cell lines. TK6 (26, 27), a human B-lymphoblastoid cell line, was a gift from W. Thilly. TK6 was
cultured in RPMI 1640 with GlutaMAX TM supplemented with 100 U/ml Pen-Strep. TK6 cell suspension
was directly obtained from the suspension culture.
The XPG cell lines were gifts from 0. Scharer. These include XPG-deficient, XPG/WT, and
XPG/E791 A. The XPG-deficient cell line was obtained from SV40-transformation of the primary human
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skin fibroblasts from patient XPCS1RO (28). XPG/WT and XPG/E791A cells were obtained from the
stable transfection of the lentiviral vector containing XPG WT cDNA or XPG-E791A cDNA in the XPG-
deficient cell line (29). The XPG cell lines were cultured in high-glucose DMEM supplemented with 10%
FBS, 2 mM L-glutamine, and 100 U/ml Pen-Strep. To obtain cell suspension for the XP-G cell lines, the
monolayer culture was incubated with 0.25% Trypsin-EDTA for 1-2 minutes at 370 C. Detached cells were
then suspended in complete working media. Cell viability and cell number were analyzed using an
automated Trypan Blue exclusion system [Vi-CELLTM cell counter (Beckman Coulter Life Sciences, Brea,
CA)].
Peripheral blood mononuclear cells (PBMCs)
Reagents. Ficoll-Paque PLUS solution (17144002) was purchased from GE Healthcare Bio-
Sciences, Pittsburgh, PA. RMPI-1640 (11875093) and 10,000 U/ml Pen-Strep (15140) were purchased
from ThermoFisher Scientific, Waltham, MA. Heat-inactivated fetal bovine serum (HI-FBS, 100-106) was
obtained from Gemini Bio-Products, West Sacramento, CA. Phytohemagglutinin-L (PHA-L, L4144) and
100% dimethyl sulfoxide (DMSO, D8418) were obtained from MilliporeSigma, St. Louis, MO. D-Glucose
(dextrose, BDH9230) was purchased from VWR, Radnor, PA.
Human whole blood. For assay optimization and internal controls, fresh whole blood from two
anonymous healthy donors collected in sodium heparin Vacutainer collection tubes was purchased from
Research Blood Components, Brighton, MA. For our population study, fresh whole blood from 56 healthy
volunteers was collected in sodium heparin Vacutainer collection tubes by a clinical professional at the
Clinical Research Center at Massachusetts Institute of Technology, Cambridge, MA. Ten of the 56
volunteers had multiple blood draws (up to five visits) while the remaining 46 had one single blood draw
per person.
PBAJC isolation. PBMCs were isolated using the standard Ficoll gradient density centrifugation
(23, 30, 31 ). Briefly, 10 mL of fresh whole blood was diluted with 10 mL of warm RPMI-1640 solution. 8
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mL of the Ficoll-Paque PLUS solution was gently injected underneath the diluted blood sample without
mixing the two solutions. The whole tube was then centrifuged at 400 g for 40 minutes at 18'C with brakes
off. The upper layer containing plasma and platelets was aspirated off, providing access to the PBMC layer
(buffy coat). PBMCs were transferred to a new centrifuge tube. Cells isolated from the same original blood
sample were pooled in one tube. PBMCs were washed by diluting in warm RPMI-1640 solution to a final
volume of 50 mL and centrifuged at 600 g for 20 minutes at 18'C. The supernatant was aspirated, and the
pellet was resuspended in 20 mL of warm RPMI-1640 solution. Cells from 10 ptL of the suspension were
stained with crystal violet, and the number of mononuclear cells were counted with a hemocytometer. The
remaining suspension was centrifuged at 400 g for 15 minutes at 18'C. The supernatant was aspirated, and
the pellet was suspended in the freezing medium (40% RPMI-1640 + 50% HI-FBS + 10% DMSO). The
volume for the freezing medium was one-tenth the volume of the original blood sample (i.e. I mL freezing
medium to suspend a pellet isolated from 10 mL of fresh whole blood). The average cell density was
~10x106 cells/mL.
PBMC cryopreservation and storage. I mL aliquots of PBMCs suspended in the freezing medium
were transferred to separate cryovials. The vials were stored in a Styrofoam container and placed in a -80'C
freezer. After 24 hours, the frozen vials were transferred to a Dewar containing liquid nitrogen.
PBMC recovery and T-lymphocyte stimulation. Cryopreserved PBMCs were rapidly thawed by
placing the vial containing the cells in a 37'C water bath for -one minute. Cells were transferred to a
centrifuge tube containing 9 mL warm thawing medium (40% RPMI-1640 + 50% HI-FBS + 10% D-
glucose) and centrifuged at 600 g for 5 minutes at room temperature. Supernatant was aspirated, and the
pellet was resuspended in 10 mL of stimulation medium (RMPI- 1640 + 20 % HI-FBS + 100 U/mL Pen-
Strep + 5 ptg/mL PHA-L). 500 ptL of the suspension was analyzed for cell viability using an automated
Trypan Blue exclusion system (Vi-CELLTM cell counter). The recovery procedure typically yielded more
than 85% viable cells. T-lymphocytes were stimulated for three days by placing the remaining suspension
in a tissue-culture incubator (37'C, 5% C0 2 ).
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CometChip cell loading. For each experiment, 1 Ox 10' of PHA-stimulated T-lymphocytes were
harvested and suspended in 5 mL of complete medium (RPMI-1640 + 20% HI-FBS + 100 U/mL Pen-
Strep). Cells were loaded into microwells by placing 50 ptL of the suspension into a macrowell and
incubating for 15 minutes at 370 C.
y radiation treatment
Cells embedded in CometChip were irradiated with y-rays from a 137Cesium source delivered at -1
Gy/min (Gammacell 40 Exactor, Best Theratronics Model C-440) for the alkaline comet assay. For the
neutral comet assay, the y-rays were delivered from a 60Cobalt source at an approximate rate of 60 Gy/min
(Gammacell 220 Excel, MDS Nordion). Cells were kept on ice during irradiation.
Hydrogen peroxide (H 20 2)
Chemical. 30% w/w hydrogen peroxide (H 202 ) solution was obtained from MilliporeSigma, St.
Louis, MO (H 1009) and was stored at 4'C, protected from light. H2 0 2 dilutions were freshly prepared from
the 30% stock immediately before use.
H2O2 treatment. Doses of H 202 were prepared immediately before use by diluting 30% stock
solution (10 M) with cold PBS. Suspension of TK6 cells was obtained directly from exponentially growing
culture and loaded onto CometChip (see "CometChip fabrication"). A new bottomless 96-well was placed
on top of the CometChip. 100 pL of H 202 solution was pipetted into each well, and the CometChip was
incubated at 4'C for 20 minutes, protected from light. Afterward, the H2O 2 solution was aspirated, and the
bottomless plate was taken off. The CometChip was rinsed by submerging in cold PBS.
DNA damage and repair. To analyzed DNA damage immediately after treatment, the CometChip
was placed in cold alkaline lysis buffer and processed following the remaining steps of the alkaline comet
assay. To study repair kinetics, the CometChip was cut into ~5 cm x 5 cm pieces using a pair of sterile
surgical scissors and incubated in culture medium at 370 C for up to two hours. At each time point, a piece
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of CometChip was removed and placed in cold alkaline lysis buffer. The remaining steps followed the
alkaline comet assay procedure.
Methyl methanesulfonate (MMS)
Chemical. 99% methyl methanesulfonate (MMS) solution was obtained from MilliporeSigma, St.
Louis, MO (129925) and was stored at room temperature. MMS dilutions were freshly prepared from the
99% stock less than 15 minutes before use.
MMS treatment. Doses of MMS were prepared ~15 minutes before use by diluting 99% stock
solution (11.8 M) with warm serum-free media (pre-warmed by incubation at 37C). Suspension of TK6
cells was obtained directly from exponentially growing culture, and 1 mL of cell suspension was placed in
a 15 mL conical tube. The tube was centrifuged (200 x g, 5 minutes), and the supernatant was aspirated.
The cell pellet in each well was re-suspended in 1 mL of MMS solution, and the tube was incubated for 30
minutes or one hour at 370 C. Next, the tube was again centrifuged (200 x g, 5 minutes), and MMS
supernatant was aspirated. Each cell pellet was washed three times by re-suspending in 1 mL PBS, spinning
down (200 x g, 5 minutes), and aspirating the supernatant. After the last wash, each pellet was re-suspended
in 1 mL culture medium.
DNA damage and repair analysis. To analyzed DNA damage immediately after treatment, 50 PL
of cell suspension was transfer to a macrowell on CometChip. After the cells loaded into the microwells
(see "CometChip fabrication"), they were immediately placed in cold alkaline lysis buffer and processed
following the remaining steps of the alkaline CometChip assay. To analyze repair kinetics, remaining cells
in the tube were incubated at 370 C for up to 24 hours. At each time point, 50 gL of cell suspension was
transfer to a macrowell on CometChip and processed as above.
Ultraviolet (UV)
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Chemical. Reduced L-glutathione (GSH, G6013) was obtained from MilliporeSigma, St. Louis,
MO. IX GSH solution (10 mM) was prepared by dissolving GSH powder in warm culture medium and
used immediately within 30 minutes of preparation.
UV irradiation. Prior to UV irradiation, cells embedded in CometChip were incubated for 40
minutes at 37'C in working medium supplemented with 10 mM GSH. Exposure to 254 nm UV light
radiation (UVC) was administered via a handheld UV lamp that had a dose-rate of 14 J/m 2/s at a distance
of 7.6 cm (UVP 95001614, ThermoFisher Scientific, Waltham, MA). The UV irradiation procedure was
carried out in the dark at 4'C.
NER kinetics of CPDs. To study NER efficiency, we examined the repair rate of cyclobutane
pyrimidine dimers (CPDs) induced by UV irradiation. The bacterial T4 endonuclease V (M0308S, New
England BioLabs, Ipswich, MA) was used in combination with the alkaline CometChip assay to query the
level of CPDs (32) over 24 hours of repair. Briefly, UV-exposed cells were incubated in working medium
supplemented with 10 mM GSH for one hour, four hours, and 24 hours. Cells embedded in CometChip
were lysed overnight in the alkaline lysis buffer. The CometChip was then washed three times with the
enzyme reaction buffer (1 mM EDTA, 100 mM NaCl, 25 mM Na2HPO4, 100 pig/mL BSA, pH 7.2) by
submerging for 15 minutes each time. The enzyme reaction was performed by incubating the CometChip
with 50 U/mL T4 Endonuclease V in the enzyme reaction buffer for 15 minutes at 37'C. Afterward, the
CometChip was placed in the alkaline unwinding buffer and processed following the remaining steps of the
alkaline comet assay.
Data analysis of repair kinetics
Multiple comparisons between individuals. One-way ANOVA followed by Tukey-Kramer's multiple
comparison test was performed using the Real Statistics Resource Pack software (Release 5.1). Copyright
(2013-2017) Charles Zaiontz. www.real-statistics.com.
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Mathematical modeling. Background-corrected data were obtained by subtracting the DNA damage level
at each repair time point by the baseline level. Non-linear regression was performed using GraphPad Prism
version 7.01 for Windows (GraphPad Software, La Jolla, CA, www. graphpad.com.) to fit the background-
corrected data to a biphasic exponential decay model:
f (t) = F. ekf.t + S. e-ks.t
where f(t) is the level of DNA damage at time t, kf and ks are two rate constants corresponding to the
fast and the slow phases of the repair kinetics, and f(0) = F + S is the initial DNA damage level.
Therefore, if t1 / 2 is the time required to repair half of the initial damage (half-time), then
F. e kf -t1/2 + S. e-s~tiz _ = 0.
2
The value of t1/2 was approximated using the Solver add-in in Microsoft Excel (Microsoft Office Suite
2016).
4.4. RESULTS
CometChip assays for PBMC repair kinetics
We aimed to optimize CometChip assay conditions to measure repair kinetics of lymphocytes
against five different types of DNA damage: oxidative damage induced by H202, oxidative damage induced
by yIR, alkylation damage induced by MMS, bulky lesions induced by UV light, and DSBs induced by yIR.
PBMCs were isolated from purchased fresh whole blood collected from healthy individuals via Ficoll
density gradient centrifugation (23, 30, 31 ) (Fig. 4-1). In whole blood, the total number of leukocytes varies
between 4x10 6 and 16x 106 cells/mL, with an average of 7x10 6 cells/mL. The PBMC isolation procedure
yields an average cell density of 1.4 x 106 cells/mL. After isolation, PBMCs were immediately suspended
in media supplemented with 50% FBS and 10% DMSO and slowly cooled down to -80*C using insulated
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containers. For long-term storage, cryopreserved cells were transferred to a liquid nitrogen tank and kept
there until experiments. To recover PBMCs from cryopreservation, cells were rapidly thawed and
transferred to warm media supplemented with 50% serum and 10% dextrose. On average, more than 85%
of recovered PBMCs are viable. The recovered PBMCs were cultured with the mitogen PHA-L for three
days to stimulate T-cell activation and proliferation (23) and then harvested for CometChip assays (Fig. 4-
1).
Oxidative damage repair
Oxidative damage is the most common type of DNA damage, primarily caused endogenously by
reaction of DNA with reactive oxygen species (ROS) that are byproducts of cellular metabolisms. In
addition, external exposures to physical and chemical agents, such as y-radiation, have also been shown to
induce ROS, including superoxide (02' ), hydroxyl radical ('OH), and hydrogen peroxide (H 202) (33). ROS
can react with the sugar phosphate backbone and directly cause single-strand breaks (SSBs) (33). In
addition, reactions of ROS with nucleobases result in a wide range of oxidative base lesions, such as
8oxoguanine, thymine glycol, 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) (33).
The base excision repair pathway (BER) is involved in rejoining SSBs as well as correcting the
majority of oxidative base lesions (34, 35). The first step in BER is damage recognition and base removal
by DNA glycosylases (36). Monofunctional glycosylases remove the damaged base by cleaving the N-
glycosidic linkage between the base and the sugar, leaving behind an abasic site (AP). On the other hand,
bifunctional glycosylases not only remove the damaged base but also cleave the AP site, generating a SSB
(35). Following N-glycosidic cleavage by a monofunctional glycosylase, AP endonuclease 1 (APEl)
catalyzes the hydrolysis of the phosphodiester bond 5' of the AP site, creating a SSB flanked by a 5'-
deoxyribose-5-phosphate (5'-dRP) and a 3'-hydroxyl (3'-OH) termini (37). In short-patch BER, DNA
polymerase p (Pol P) fills in the single-nucleotide gap by extending from the 3'-OH terminus. Pol P also
possesses lyase activity that removes the 5'-dRP intermediate. The nick is then sealed by DNA ligase I or
ligase IIla/XRCC1 (35, 38). In long-patch BER, the replicative polymerases 6/ E or Pol k take over from
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Pol P (35, 36, 38). Because a longer repair patch is synthesized, the damage-containing strand is displaced
and is removed by the flap endonuclease FENI. The nick is sealed by ligase 1 (35, 36, 38).
Because a number of steps in BER result in SSBs as intermediates, it is possible to measure the
repair of oxidative damage using the alkaline CometChip (18, 24, 25). In addition to SSB intermediates,
AP sites left behind by monofunctional glycosylases are alkali-labile and can be converted to nicks in the
alkaline CometChip assay (pH >13) (39). We exposed cells to y-radiation (yIR) and H2 02 to induce
oxidative damage. Using the alkaline CometChip assay, we measured the levels of SBs immediately after
treatment as well as after different periods of repair in order to study the kinetics.
To study yIR-induced damage, we irradiated TK6 cells embedded in CometChip with TIR doses
between 1 and 14 Gy while keeping the cells on ice to prevent repair activity. Cells were immediately lysed
and analyzed for SBs. As shown in Fig. 4-2A, TK6 cells display a linear dose-response to yIR (R2 = 0.95)
with the highest dose inducing about five times more SBs than the basal level. To study repair kinetics,
cells embedded in CometChip were submerged in warm media following irradiation to enable DNA repair.
SB levels were analyzed at multiple repair time points to yield a repair kinetic curve. Our results show that
both TK6 and PHA-stimulated T-lymphocytes are able to rapidly rejoin SBs induced by 8 Gy with similar
kinetics (Fig. 4-2B), where more than 70% of initial SBs are rejoined after 15 minutes of repair.
Furthermore, we also studied the repair of oxidative damage induced by H 202 . Stimulated
lymphocytes embedded in CometChip were challenged with a range of H 2 02 doses (between 10 and 100
pM) via a short incubation at 4*C to prevent repair activity. SB levels analyzed immediately after the
challenge show a linear dose-response to H202 (Fig. 4-2C). Half of the exposed cells were incubated in
warm media for two hours to allow DNA repair. Analysis of their SB levels reveals a complete clearance
of H202-induced SBs for all H 202 doses (Fig. 4-2C). We analyzed SB levels at different repair time points
prior to two hours to further explore the kinetics. Both TK6 and PHA-stimulated T-lymphocytes display
similar initial levels of SBs after being challenged with 100 ptM H202 and are able to reduce the induced
damage to near the basal level after two hours of repair (Fig. 4-2D). However, the rate of repair appears to
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be faster in TK6 cells. For example, -60% of the initial damage is corrected after 30 minutes in TK6 cells
whereas the stimulated T-lymphocytes retain -70% of the initial damage at this time. This observation
further supports that it is necessary to examine multiple time points in order to study variation in repair.
Alkylation damage repair
MMS
Alkylating agents are one of the major classes of chemotherapeutics (40). Their reactions with
nucleobases form a range of alkylating lesions, some of which are highly cytotoxic and mutagenic (41).
Methyl methanesulfonate (MMS) is an SN2 alkylating agent, whose targets are primarily the ring nitrogen
(N) atoms on the nucleobases (42). Among the lesions induced by MMS, 7-methylguanine (7meG) is the
most abundant (~80%), followed by 3-methyladenine (3meA), which accounts for -10% of the total lesions
(41-43). 7meG appears to be innocuous, being neither mutagenic nor cytotoxic. However, 7meG can rapidly
hydrolyze to form abasic sites, which are both cytotoxic and able to mispair during replication (41). On the
other hand, 3meA blocks replication and is highly cytotoxic. The alkyladenine glycosylase (AAG) is the
primary mammalian glycosylase that recognizes and excises alkylated bases as part of BER.
We used the alkaline CometChip (18) to study the levels of SBs induced by MMS. TK6 and PHA-
stimulated T-lymphocytes were exposed to a range of MMS doses. Both cell types exhibit strong linear
dose-responses to MMS between 0.5 to 2 mM (Fig. 4-2E). When challenged with 2 mM MMS, the levels
of SBs for both cell types reach -77% DNA in tail, which is ~seven times higher than the background level.
4 mM MMS does not appear to induce further SBs likely because ~77% is the saturation limit for the comet
assay. When cells were allowed to repair in warm media following MMS exposure up to I mM, both TK6
and the stimulated lymphocytes were able to partially reduce their SB levels after four hours. Beyond 1
mM, the DNA became highly fragmented, resulting in comets with a small fraction of normal DNA
fluorescence that could no longer be accurately scored. It is likely that the level of DNA damage induced
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at high MMS doses (2 and 4 mM) is sufficient to trigger cell death, resulting in extreme DNA fragmentation
(39).
Because four hours of repair appears to be insufficient for complete clearance of MMS-induced
damage, we extended the total repair time for both TK6 and the stimulated lymphocytes to 24 hours and
analyzed SB levels at multiple earlier time points. While oxidative damage is rapidly repaired by both cell
types (Fig. 4-2B and D), alkylation damage induced by MMS requires an extended repair duration.
Specifically, -55% of the initial damage induced by 0.5 mM MMS remains after four hours of repair, and
~30% of the induced damage persists after 24 hours in both cell types (Fig. 4-2F).
Cyclobutane pyrimidine dimer repair by NER
Nucleotide excision repair (NER) is the most versatile pathway that can recognize and repair a
diverse set of structurally unrelated DNA lesions (44). Good NER substrates disrupt base pairing, distort
the double helix, and are generally bulky in size (45). Deficiency in NER proteins are associated with
debilitating disorders (46). Genetic defects in XP proteins cause xeroderma pigmentosum (XP), an
autosomal recessive disorder characterized by hypersensitivity to UV radiation, accompanied by a ~2,000-
fold increased risk of skin cancer. In addition to cancer induced by sunlight exposure, XP patients are also
at risk for cancers at sites that are not exposed to UV light (46-48). There is a ~12-fold increase in frequency
of internal neoplasms in all sites not exposed to sunlight for XP patients under 20. Notably, cancers of the
brain and oral cavity are disproportionately increased (47). In addition, about ~25% of XP patients develop
neurological abnormalities caused by progressive neurological degeneration. Mutations in some NER
genes, such as XPB and XPD, also underlie trichothiodystrophy (TTD). TTD patients exhibit developmental
abnormalities but do not show heightened risk of sunlight-induced skin cancer. Patients with defects in
CSA or CSB exhibit yet another disorder, Cockyane syndrome (CS), which manifests as photosensitivity
and severe developmental defects. CS, however, is not associated with a higher risk of sunlight-induced
skin cancer. In addition, several mutations in XPB, XPD, and XPG genes lead to a severe disorder with
combined symptoms of both XP and CS patients.
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We aimed to measure NER variation in human lymphocytes using UV radiation to induce
cyclobutane pyrimidine dimers (CPDs), which account for the majority of UV-induced lesions and are
efficiently repaired by NER (49). Using the alkaline CometChip (18), we incorporated the use of T4
endonuclease V (32), a bacterial enzyme that possesses both glycosylase and endonuclease activity specific
to CPDs (50). Cells embedded in CometChip Were irradiated with UV-C and allowed to repair in warm
media for up to 24 hours. After repair, cells were lysed overnight following the alkaline CometChip
procedure to expose nuclear DNA, which was then incubated with T4 endonuclease V. The enzyme excises
the dimers and creates a nick in the sugar phosphate backbone, contributing to the comet tail formation
under electrophoresis.
In order to verify that the UV-lesions recognized by T4 endonuclease V are specifically repaired
by NER, we compared a cell line deficient in the 3' endonuclease XPG (XPG--) (28) and a version of the
same cell line with a stable expression of the wildtype XPG (XPG/WT) (29). XPG is essential for the
complete assembly of the NER preincision complex (44), and the XPG- cells have been shown to be
deficient in NER activity (28). Without incubation with T4 endonuclease V, both XPG/WT and XPG-
display minimal SBs upon UV irradiation and during repair (Fig. 4-3A). On the other hand, incubation with
the T4 enzyme results in high levels of SBs (~four times higher than the background level) in both cell lines
immediately after UV exposure. While the XPG/WT cells are able to repair ~20% of the initial CPDs by
four hours and most of the lesions by 24 hours, XPG-- show no reduction in CPDs at any time point (Fig.
4-3B). These results support that T4 endonuclease V can be used in CometChip to study NER kinetics.
We demonstrated in this work that incubation with T4 endonuclease V can be applied to PHA-
stimulated T-lymphocytes in order to study NER variation among people. In a preliminary study, we
exposed PHA-stimulated T-lymphocytes and TK6 cells to UV-C doses ranging from 0.11 to 3.2 J/m 2 and
analyzed their CPD levels immediately after irradiation or after 24 hours of repair (Fig. 4-3C). The CPD
levels in both cell types increase linearly with the UV-C doses and reach a plateau at 0.8 J/M 2, where the
comet assay reaches the saturation level of -77% DNA in tail. After 24 hours, TK6 cells show complete
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repair for UV doses lower than 0.8 J/m2 and about 50% of repair for 0.8 J/m 2 and higher (Fig. 4-3C). On
the other hand, the stimulated lymphocytes display complete repair for most UV doses except for the highest
dose, where DNA becomes too fragmented for the comets to be quantifiable.
NER kinetics of CPDs were further investigated for both TK6 cells and the stimulated lymphocytes.
Following 0.2 J/m2 UV irradiation, CPD levels at multiple time points prior to 24 hours were analyzed by
incubation with T4 endonuclease V (Fig. 4-3D). Consistent with prior results (Fig. 4-3C), both cell types
are able to repair the majority of CPDs by 24 hours. The repair kinetic curves for both cell types are also
similar. In contrast with the slow repair rate of the XPG/WT cells, both TK6 and the stimulated lymphocytes
are able to repair ~50% of CPDs after four hours.
DSB repair
Double-strand breaks (DSBs) are the most deleterious type of DNA damage, capable of triggering
cell death and large genomic alterations (51, 52). Mammalian cells use two main mechanisms to repair
DSBs, non-homologous end joining (NHEJ) and homologous recombination (HR). NHEJ is a low-fidelity
DSB repair pathway, where broken DNA ends are rejoined to restore the chromosome structure, often at
the cost of sequence changes at the junction (53). NHEJ is highly flexible, capable of processing diverse
DNA end structures at DSBs (53), and is involved in the repair of most DSBs, including those generated
by V(D)J recombination and class-switch recombination (54). HR is another major DSB repair pathway,
and unlike NHEJ, HR is highly accurate. HR is involved in repair of both DSBs and interstrand crosslinks
where maintenance of genomic integrity is critical, such as collapsed replication forks, incomplete
telomeres, and crossovers during meiosis (55). Deficiency in one of these pathways results in
hypersensitivity to yIR (56-58).
The neutral comet assay is a commonly used method for detection of DSBs (20), and a neutral
CometChip version has been developed (17). In this work, we applied the neutral CometChip to measure
the repair of DSBs in PHA-stimulated T-lymphocytes. TK6 cells and stimulated lymphocytes were
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irradiated with 75 Gy and analyzed with the neutral CometChip assay (Fig. 4-3E). Both cell types display
DSB levels about three times the background level immediately after irradiation and able to rejoin the
majority of DSBs after four hours of repair. On the other hand, analysis of earlier time points reveal a slight
difference in the repair rates between the two cell types. While two hours is sufficient for a complete repair
in TK6, about 20% of the induced DSBs persist in the stimulated lymphocytes (Fig. 4-3E).
Application of H2 0 2 repair assays on PBMCs from healthy volunteers
In a pilot study, we applied the alkaline CometChip procedure to measure and analyze oxidative
damage repair kinetics of PBMCs isolated from blood draws from a small population of healthy volunteers.
Blood draws were obtained from 56 healthy volunteers, including 29 females and 27 males who were
between 21 and 66 years old. Lifestyle information, such as weight, height, medication history, dietary and
exercise habits, was also obtained via an optional survey.
Isolated PBMCs from each blood sample were cryopreserved in four separate vials and stored in
liquid nitrogen until use. For each experiment, cells from one vial were thawed, and T-lymphocytes were
stimulated with PHA-L for three days before treatment with H202 and analysis with the alkaline CometChip
assay. Three independent experiments, corresponding to three vials of PBMCs, were conducted for each
blood sample.
Repair kinetics of internal controls
We included TK6 cells as an internal control for the CometChip assay. To control for PBMC
processing procedures (e.g. thawing, PHA-stimulation), we also included PBMCs from one individual
(code name: #00) in all of the experiments. In preparation for the study, TK6 cells were cultured,
cryopreserved in multiple vials, and stored in liquid nitrogen. 440 mL of whole blood from #00 was
purchased and processed for PBMC isolation. The isolated PBMCs were also cryopreserved in multiple
vials and stored in liquid nitrogen until use. For all experiments with PBMCs isolated from the 56
volunteers, one vial of TK6 cells and one vial of #00 PBMCs were thawed and analyzed in parallel.
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As shown in Fig. 4-Si A, both TK6 cells and PHA-stimulated lymphocytes from #00 rapidly repair
H202-induced damage within the first 30 minutes. Afterward, the repair activity appears to continue at a
slower rate. To approximate the repair rate, we performed non-linear regression and fitted a biphasic
exponential decay model to the data. We then used the resulting equations to calculate the repair half-times
for both cell types. Notably, TK6's half-time is -24 minutes, which is >1.5 times faster than #00's (Fig. 4-
SIB).
Multiple-visit study revels lower intra-individual variation compared to inter-individual variation
Before investigating inter-individual variation in repair capacity, we first studied the variability
within individuals in comparison to the variability among people. Ten volunteers from our pilot study (code
names: #01, #02, #05, #06, #09, #11, #12, #18, #19, and #23) had their blood drawn in multiple visits on
different days. PBMCs were isolated from the serial blood draws, stimulated with PHA-L, and analyzed
with the alkaline CometChip assay as described above. The PHA-stimulated lymphocytes were embedded
in CometChip, exposed to 100 ptM H2 02 , and analyzed for SBs immediately after treatment or after different
repair time points up to two hours.
Different visits of #01, #02, #05, #06, #09, #11, #12, #18, #19, and #23 display a range of repair
kinetic curves (Fig. 4-4A). The variability (%CV) between visits for each individual is less than 15% across
all time points including background (Fig. 4-4B). Notably, we observe a larger variability across the
individuals than within the individuals (Fig. 4-4B). Statistically significant differences (p<0.05, one-way
ANOVA) are observed for the baseline damage level as well as all repair time points except for 0 minute
(Fig. 4-4C). We performed post-hoc analysis (Tukey's honest significant test) to compare each pair of the
individuals. Only one person (#23) displays no difference from anyone else. Interestingly, only one pair of
individuals (#05 and #09) show significant difference at the baseline damage level whereas six pairs differ
significantly at the latest repair time point.
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Furthermore, we investigated the rate of repair for each individual. Similar to TK6 and #00, the
repair kinetics data for all ten individuals follow biphasic exponential decay equations (Fig. 4-4D), enabling
calculations of the repair half-times. The average time is -40 minutes, and there is a difference of ~24
minutes between the fastest and the slowest individuals. Notably, stimulated lymphocytes from all of the
ten individuals appear to be slower at repair than TK6 cells. The slowest (#19) takes ~56 minutes to repair
half of the damage (Fig. 4-4D), which is more than twice the time by TK6 cells (Fig. 4-S IB).
Oxidative damage repair kinetics from single-visit individuals
While serial blood draws yield valuable information about intra-individual variability, a single
blood draw would significantly simplify the sample collection procedure and enable larger studies. To
investigate whether one visit per person is sufficient to discern differences between individuals, we obtained
one single blood draw for the remaining 46 volunteers in our pilot study. Isolated PBMCs were again
stimulated with PHA-L, treated with 100 ptM H202, and analyzed with the alkaline CometChip assay.
Similar to the multi-visit study, a wide range of curve shapes for H 2O2-induced damage repair
kinetics is observed for the single-visit 46 volunteers (Fig. 4-5). The repair kinetic curve for each individual
is an average of three independent experiments using three separate portions of PBMCs isolated from one
single blood sample. The variability (%CV) between experiments ranges between 20% and 27%. Despite
the relatively high level of experimental noise, a larger variability across people is observed for all time
points except for the baseline and initial damage levels (Fig. 4-S2A). However, only the differences at the
30-minute and 60-minute time points show statistical significance (p < 0.05, one-way ANOVA) (Table 4-
SI) (Fig. 4-S2B). In addition, when the damage level at each time point is corrected for background by
subtracting the baseline, the differences at 30-minute and 6-minute time points are no longer statistically
significant (p 0.05, one-way ANOVA) (Table 4-S 1).
On the other hand, the variation in the shapes of the kinetic curves suggests that the repair rate may
vary among people and can be used as a measure of repair capacity. For example, #03, #04, and #38 rapidly
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repair most of the initial damage within the first 30 minutes, but there appears to be no further reduction of
SBs after 30 minutes. On the other hand, #24 and #26 display a gradual reduction in SBs over the entire
120 minutes of repair. To quantify the repair rates, we parameterized the kinetic curves by fitting the data
to a biphasic exponential decay model. The time it takes to repair 50% of the initial damage (repair half-
time) is calculated from the resulting equation as a measure of the repair rate. Results from the 46 volunteers
show a broad range of repair half-times with more than seven-fold difference between the fastest (16
minutes) and the slowest (114 minutes) (Fig. 4-5B).
The repair half-times can be divided into quartiles, representing individuals with "very fast", "fast",
"medium", and "slow" repair (Fig. 4-5B). Interestingly, #03, #04, and #38 all belong to the "very fast"
group. A closer examination of the other members of the group reveals a common trend where most of the
initial DNA damage is rapidly reduced during the first 30 minutes (rapid phase) while any further reduction
of SBs afterward appears to be much slower (slow phase) (Fig. 4-5C). In contrast, the transition from the
rapid phase to the slow phase for the "fast" group appears to be at 60 minutes instead of 30 (Fig. 4-5D).
Furthermore, both the "medium" and the "slow" groups appear to have a relatively consistent rate for SB
reduction over the entire 120 minutes (Fig. 4-5E and F). Notably, both #24 and #26 belong to the "slow
repair" group with #24 being the slowest of the 46 people. Fig. 4-5G shows representatives from different
groups to further illustrate the variation in the kinetic curves. A comparison between #24 and #43 highlights
the difference between the "medium" and the "slow repair" groups. While both samples have comparable
SB levels for most of the repair time points (30 minutes and later), #43 has -1.5 times higher initial damage
level compared to #24, resulting in a steeper repair slope for #43 and a repair rate ~twice as fast (60 minutes
vs 114 minutes half-time).
4.5. DISCUSSION
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DNA damage has broad academic, drug safety, drug discovery, and diagnostic relevance. There
remains a significant gap in clinical applications of DNA repair capacity variation. More extensive evidence
supporting a causal relationship between DNA repair capacity and health outcomes is needed. There is a
major lack of studies that take into account the complex interactions between different repair pathways,
mainly stemming from the lack of available technologies for rapid assessment of multiple pathways in
parallel. In this work, we demonstrated the use of CometChip to measure DNA repair kinetics of multiple
types of damage as integrated outcomes of some of the major repair pathways in primary human
lymphocytes. Further, pilot studies with a small population of healthy volunteers highlight the sensitivity
of the CometChip platform and provide important insights into the variation in oxidative damage repair
kinetics in the population.
The use of the same sample of stimulated lymphocytes enables a comparison of repair activities
across multiple types of DNA damage. A key observation is that the stimulated lymphocytes are capable of
repairing most damage, including oxidative, alkylation, CPDs, and DSBs. However, the rates of repair for
damage induced by different agents vary widely. For example, most of the oxidative damage induced by
H20 2 repairs within -30-60 minutes while CPDs require up to 24 hours. Significantly, the repair rates of
different types of damage induced by the same agent also vary. For example, most of SSBs induced by yIR
is repaired within 15 minutes while it takes -2-4 hours for most of yIR-induced DSB removal. Taken
together, these results highlight the significance of studying multiple repair processes in parallel for a
complete understanding of DNA repair capacity.
Elevated oxidative damage has been shown to correlate with higher cancer risk and the pathology
for conditions associated with oxidative stress, such as post-ischemic brain and heart damage (59).
Therefore, the oxidative damage repair capacity may provide a sensitive predictor of disease outcomes.
This study demonstrated that the CometChip assay can be used to discern small differences in oxidative
damage repair between people, evidenced in the lower variability in PBMCs isolated from serial blood
draws compared to PBMCs from different individuals.
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A key advantage of kinetics analysis is that it allows for estimates of repair rates, which exhibit
different degrees of variation depending on the types of DNA damage (5, 60). Reduced repair rates have
been show to correlate with elevated cancer risk (60, 61) and treatment outcomes (62, 63). In PBMCs
isolated from 46 healthy volunteers, we observed a sevenfold variation in repair half-times of H202-induced
damage, which is in the same order as shown in other studies (5, 60). Interestingly, there are subtle but
noticeable differences in the shapes of the average repair kinetics curves for different quartiles. Larger
studies are needed to confirm the range of repair rates and the different curve shapes characteristic of the
quartiles.
There are a few challenges that need to be addressed going forward. First, the experimental
variability in PBMCs isolated from the same blood sample is relatively high, which potentially masks the
differences between individuals and reduces the sensitivity of the assay. Because intraindividual variation
is relatively low, future studies should consider using serial blood draws to improve reproducibility. In
addition, a significant trend toward higher DNA damage levels over time (batch effect) is observed during
the course of the study in both TK6 cells and PBMCs from #00 (data not shown), indicating systematic
variation that may contribution to some of the differences observed in PBMCs isolated from the volunteers.
Further analyses are warranted to examine potential correlations between the batch effect and other
experimental factors, such as time of day and culture conditions. Trend correction may be necessary, which
will require a thorough re-analysis of the data.
In conclusion, the ability of CometChip to examine the repair of multiple types of DNA damage in
parallel presents an exciting opportunity to further shed light on the relationship between DNA repair
capacity and human health. Initial studies with human primary lymphocytes reveal significant differences
between individuals and provide an important basis to ask specific questions about health outcomes in
relation to repair kinetics. The repertoire of DNA damage detection can be further expanded to include
specific types of base lesions and interstrand crosslinks, facilitating a more comprehensive understanding
of how an individual responds to potential genotoxic agents.
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Figure 4-1. Schematic for CometChip analysis of human lymphocytes. Step 1. Fresh whole blood is
centrifuged with a density gradient solution, Ficoll-Paque PLUS, to separate red blood cells and
granulocytes from the peripheral blood mononuclear cells (PBMCs). PBMCs form a white band above the
Ficoll layer after centrifugation (see arrow) and can be extracted. Isolated PBMCs are cryopreserved by
slow freezing (about -I 'C/minute) to -80*C and then transferred to a liquid nitrogen (LN 2) Dewar. Step 2.
Cryopreserved PBMCs are rapidly thawed at 37*C to recover viable cells. Resting T-lymphocytes are
stimulated to proliferate by incubation with 5 pg/mL PHA-L for three days. Step 3. PHA-stimulated T-
lymphocytes are collected from culture, exposed to DNA damaging agents, and analyzed for DNA damage
levels with CometChip. Cells are analyzed at multiple time points following exposure for DNA repair
kinetic studies.
179
80 -
60 -
40 -
20
0 . . . . . .
0 2 4 6 8 10 12 14
yIR (Gy)
80 8 Gy
60
40
20
0
UT 0 30 60 90 120
Repair time (min)
C E
80
C 60
Z < 40
o 20
) 0 10 20 40 80 100
H 20 2 (pM)
D
a)
CD
c
-)
80 . 2 2
60 -
40 -
20
0
UT 0 30 60 90 120
Repair time (min)
a)
Cu
E
0
0
80
60-
40
0
e 20
0
F
CU
Cu
E::-.
QZ
~40
a1)
-J
Lymphocytes TK6
III Ill
ElI~
0 0.5 1 2 4 0 0.5 1
MMS (mM)
0.5mM MMS
2 4
ov80 -
60 -
40 -
20
0
UT 0 4 8 12 16 20 24
Repair time (hours)
Figure 4-2. Analysis of oxidative damage and alkylation damage by alkaline CometChip. A. Dose-
response of TK6 cells to yIR. TK6 cells are irradiated with yIR and immediately analyzed for DNA strand
breaks. B. Repair kinetics of 8 Gy-induced damage by TK6 (gray) and PHA-stimulated T-lymphocytes
(pink). C. Repair of H202-induced damage by PHA-stimulated T-lymphocytes. Green bars represent cells
analyzed immediately after exposure. Yellow bars show cells after two hours of repair following H202
treatment. D. Repair kinetics of DNA damage induced by 100 ptM H2 02 . E. Repair of MMS-induced
damage by PHA-stimulated T-lymphocytes and TK6. Green bars denote DNA damage levels immediately
after challenge, and yellow bars represent cells after four hours of repair. F. Repair kinetics of DNA damage
induced by 0.5 mM MMS. Error bars represent standard errors of the means (SEMs) of independent
experiments (biological replicates) or technical triplicates. A, B, and D. Biological triplicates. F. Biological
duplicates. C and E. Technical triplicates. Background DNA damage levels are represented as untreated
cells (UT). Gray lines: TK6. Pink lines: PHA-stimulated T-lymphocytes.
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Figure 4-3. A and B. Repair kinetics of cyclobutane pyrimidine dimers (CPDs) induced by UV radiation
in human skin fibroblast cell lines, XPG-1- and XPG/WT (see Methods for more details). Cells are irradiated
with 0.2 J/m2 254 nm UV light (UVC) to induce CPDs. Cells are lysed overnight, and exposed nuclear
DNA is incubated in a T4 endonuclease V reaction buffer without the enzyme (A) or with the enzyme (B)
to create DNA nicks specific to CPD sites. SBs are then analyzed following the alkaline CometChip
procedure. C and D. Repair of CPDs in TK6 and PHA-stimulated T-lymphocytes. UV-irradiated cells are
lysed and incubated with T4 endonuclease V enzyme and analyzed with the alkaline CometChip assay. C.
Green bars represent CPD levels immediately after UVC exposure. Yellow bars show CPD levels after 24
hours of repair. D. Repair kinetics of CPDs induced by 0.2 J/m 2 UVC. E. Repair of DNA double-strand
breaks induced by 75 Gy yIR and measured by the neutral CometChip assay. Error bars represent standard
errors of the means (SEMs) of independent experiments (biological replicates) or technical triplicates. A,
B, and D. Biological triplicates. E. Biological duplicates. C. Technical triplicates. Background DNA
damage levels are represented as untreated cells (UT). Gray lines: TK6. Pink lines: PHA-stimulated T-
lymphocytes.
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Figure 4-4. Oxidative damage repair of lymphocytes isolated from serial blood draws measured by
alkaline CometChip. #01, #02, #05, #06, #09, #11, #12, #18, #19, and #23 represent ten healthy volunteers
having blood draws on multiple visits. PBMCs isolated from each visit are cultured and stimulated with 5
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pg/mL PHA-L for three days to activate T-lymphocyte proliferation. The stimulated T-lymphocytes are
exposed to 100 pM H202 and analyzed for SBs immediately or after different periods of repair. A. Repair
kinetics from cells obtained from different visits for each individual. The axis labels for "Visit 2" of #01
are applied to all the other plots. The first data point from the left represents DNA damage level from
untreated cells (background damage). Error bars are SEMs from three independent experiments performed
with three separate portions of PBMCs isolated from the same blood sample. B. Coefficient of variation
(%CV) between visits for each person (intra-individual; gray bars) and among the ten volunteers (inter-
individual; orange bars). C. Comparison of repair kinetics between the ten volunteers. Error bars are SEMs
of all the visits from each individual. *p<0.05, one-way ANOVA. D. The DNA damage levels for all repair
time points are corrected for background damage and fitted to a biphasic exponential decay model.
Goodness-of-fit is represented by R2 values. Repair half-times (t1 /2) are approximated from the model
equations (see Methods for more details). Error bars are SEMs of all the visits from each individual.
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Figure 4-5. Oxidative damage repair of lymphocytes isolated from single blood draws measured by
alkaline CometChip. 46 healthy volunteers each had one single blood draw. PBMCs isolated from each
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blood sample are cultured and stimulated with 5 pg/mL PHA-L for three days to activate T-lymphocyte
proliferation. The stimulated T-lymphocytes are exposed to 100 p.M H2 0 2 and analyzed for SBs
immediately or after different periods of repair. A. Repair kinetics from cells obtained from 46 volunteers
who are identified by "#" followed by a unique combination of two digits. The axis labels for #03 are
applied to all the other plots. B. Rank-ordered repair half-times for the 46 volunteers. See Methods for more
details on the calculation of repair half-times. The half-times are divided into quartiles, where the first
quartile corresponds to the fastest repair rates of the population ("Very fast") and the fourth is comprised
of the slowest rates ("Slow"). C, D, E, and F. Background-corrected DNA repair kinetic curves for
individuals belonging to each quartile. Black lines represent the average of each quartile. G. Representative
background-corrected DNA repair kinetic curves from different quartiles. #35 is the fastest of the
population, and #24 is the slowest. Error bars are SEMs from three independent experiments performed
with three separate portions of PBMCs isolated from the same blood sample.
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Figure 4-Si. Oxidative damage repair of internal control cells (TK6 and PHA-stimulated T-
lymphocytes from #00). Samples of TK6 and PBMCs from #00 are processed in the same way as PBMCs
isolated from the 56 volunteers except that TK6 cells are not stimulated with PHA-L during culture. A.
Repair kinetics of oxidative damage repair. TK6 and lymphocytes from #00 are treated with 100 ptM H 202
and analyzed for SBs immediately or after different periods of repair using alkaline CometChip. B.
Background-corrected repair kinetics are fitted to a biphasic exponential decay model. R2 values reflect
goodness-of-fit. Half-times (t 12 ) are calculated from the model equations (see Methods for more details).
Error bars are SEMs of 29 independent experiments for TK6 and 30 for #00.
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Figure 4-S2. Statistical analysis of results from Figure 4-5A. A. Coefficient of variation (%CV) between
triplicate experiments for each volunteer (gray bars) and among the 46 volunteers (orange bars). C.
Comparison of repair kinetics among the 46 volunteers. Error bars are SEMs of triplicate experiments
performed with three separate aliquots of PBMCs isolated from the same blood sample. *p<O. 05, one-way
ANOVA.
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Table 4-S1. One-way ANOVA for H 202 repair kinetics of 46 single-visit individuals (Figure 4-5A)
Raw %DNA in tail
F-statistic
0.64
0.58
1.15
2.03
1.92
1.03
p-value
0.95
0.98
0.28
< 0.05
< 0.05
0.44
Background corrected
%DNA in tail
F-statistic p-value
0.64
1.08
1.44
1.30
0.92
0.95
0.36
0.07
0.15
0.62
Sources
Between people
Between repeat
experiments
Total
A
Repair
time
Untreated
0 min
15 min
30 min
60 min
120 min
B Degree of
freedom
45
92
137
188
Chapter 5
Conclusions and Future Work
5.1. GENOTOXICITY TESTING
One of the blind spots in cell-based genotoxicity testing is the lack of a sensitive and rapid method
to detect bulky DNA lesions, many of which are induced by metabolic activation of environmental
carcinogens. One of the most commonly used methods for DNA damage detection is the comet assay,
which is based on electrophoretic migration of nuclear DNA in the presence of DNA strand-breaks (SBs)
(1). CometChip is a recently developed platform for comet assays, increasing throughput by 10' to 104 fold
as well as improving assay reproducibility.
Bulky DNA lesions are corrected primarily by nucleotide excision repair (NER), which generates
a number of DNA SBs as repair intermediates. Based on this observation, we adopt the use of the DNA
repair synthesis inhibitors hydroxyurea (HU) and l-f-D-arabinofuranosyl cytosine (ara-C) to induce
accumulation of SBs and analyzed with CometChip for rapid SB detection. To provide physiologically
relevant metabolisms, HepaRGTM, a human hepatocyte cell line with high levels of liver-specific functions,
is incorporated into the assay. The result is a platform tailored to the rapid assessment of bulky DNA adducts
induced by chemical agents and/or their bioactivated metabolites. An additional advantage of the platform
is that HU/ara-C also inhibits the repair of oxidative and alkylation damage, two of the most common types
of DNA damage, enabling an overall improvement in assay sensitivity toward DNA damage detection.
Importantly, significant improvement in sensitivity for genotoxic agents is observed in a small chemical
screen.
Some questions still need to be addressed for the assessment of the platform as an in vitro
genotoxicity testing method. Most important is the question of specificity. With the constantly expanding
chemical libraries, false positives can be very costly by creating large number of unnecessary follow-up
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animal studies (2, 3). Therefore, a validation study needs to be conducted to assess both the false negative
and the false positive rates of the assay. Another question pertains to the certainty of a positive genotoxic
result. Dose studies were conducted for the small chemical screen, and only the highest doses of many
agents induce significant DNA damage. A three-day repeated dosing regimen has been implemented by our
collaborators at Integrated Laboratory Systems, Inc. to enhance the effect of metabolic activation.
Potentially, we can adapt this approach to confirm our findings.
Future works can capitalize on the advantages of the platform to expand the capacity for different
types of DNA damage as well as include conditions that elucidate the test compound's molecular
mechanism. Specifically, the use of site-specific endonucleases should be simple to incorporate into the
assay. In cases where no significant increase in SBs is observed even at cytotoxic doses, the presence of
interstrand crosslinks (ICLs) should be checked by irradiation with y-rays to induce direct breaks and
follow-up analysis for evidence of DNA migration inhibition by ICLs. Small molecule inhibitors can be
used to probe for the role of specific molecular processes in response to a DNA damaging challenge. In
addition, the advent of CRISPR/Cas systems, a versatile genome editing toolkit (4), suggest the possibility
of generating libraries of genetically altered HepaRG TM cell lines to study the role of different pathways in
the formation and repair of certain DNA damage.
5.2. CELL SURVIVAL QUANTIFICATION
One of the most critical decisions for proliferating cells under stresses is to divide, senesce, or die.
Therefore, cell survival quantification is essential in many branches of biology and is particularly pertinent
in chemical safety assessment. The colony formation assay developed more than 60 years ago (5, 6) still
remains the gold standard because it is the only method that directly measures the ability of a cell to divide.
The long incubation time and large culture dishes render the gold standard incapable of meeting the current
challenge of toxicity testing where the massive libraries of existing chemicals are constantly expanded with
thousands of new ones every year. To overcome these limitations, we adopt the agarose microarray
developed in CometChip to grow microcolonies in a grid and quantify microcolony sizes by DNA
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fluorescent staining and automated image analysis. The resulting platform is a miniaturized colony
formation assay that [MicroColonyChip (iCC)] is compatible with high-throughput (HT) screening
equipment and requires only ~20% of the original incubation time.
Results from validation studies shown in this work highlight key advantages of pCC. Most
importantly, pCC is capable of a multi-log dynamic range of measurement and similar sensitivity to the
colony formation assay. Direct comparisons with two of the most popular cell viability assays, a tetrazolium
salt-based (XTT) and an ATP-based (CellTiter-Glo@) assay, reveal superior performance of the pCC in
sensitivity and reproducibility, respectively. Lastly, the incorporation of MCL-5, a metabolically competent
cell line, creates a platform suitable for primary screens for toxicity.
Further optimization and development of ptCC is necessary to address several concerns. A current
limitation of providing collagen type 1 in pCC is that not all cells stay confined to the microwells, as they
appear to elongate and spread during microcolony formation. To optimize the assay, it is ideal for the
microcolonies to be compact so that there is not significant microcolony overlap. To overcome this
limitation, we propose to modify the growth conditions to foster growth within the microwell, rather than
growth by attachment to the ligands in the upper layer. Additionally, we will explore varied microwell
diameters and inter-colony distances to accommodate different cell types. For example, for larger cells, a
microwell with a larger diameter may be desireable, and for cells that migrate away from the microcolony,
an increase in the inter-microwell distance may be advantageous. In addition, for adherent cells that can
form colonies with collagen 1 (e.g. HepG2 and HeLa), experiments need to carry out to test the sensitivity
and robustness of ptCC in measuring toxicity in these cell types.
Another possibility for future work is optimization for multiplexing capacity. The goal is to gain
mechanistic insights into the cell survival or cell death response. Information about cell death mechanisms,
for example, can inform candidate drug design and may also aid in the drug discovery process. Preliminary
results show the feasibility of fluorescent staining for a number of biomarkers, such as membrane
permeability, apoptosis, and intracellular esterase activity. The versatility of the staining capability on pCC
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should be explored. Importantly, computational routines should be developed to enable quantification and
interpretation of multiple endpoints.
Finally, a robust and efficient method for single-cell loading should be established. A chief
advantage would be a much closer imitation of the colony formation assay, which may potentially further
improve assay sensitivity as well as make it easier for new users to be willing to adopt. Colonies from
single-cell microwells will be significantly smaller compared to colonies that start with multiple cells in
one microwell. The benefit would be significant reduction in required growth area, enabling the use of a
new microarray with much smaller distances between the microwells. To facilitate single-cell loading, the
microwell dimensions should be such that one cell can fit comfortably but there will be no room for two or
more. In addition, if the distance between two microwells is sufficiently small, then the number of off-grid
excess cells can be significantly reduced. Potentially, the washing step can then be eliminated, reducing a
major source of experimental noise.
5.3. INTERINDIVIDUAL VARIATION IN DNA REPAIR KINETICS
In order to fully assess the impact of DNA damaging agents on human health, how an individual
responds also needs to be accounted for. Although there is substantial evidence linking variation in DNA
repair capacity to cancer risk and response to treatment, most studies lack a comprehensive survey across
multiple major repair pathways, potentially missing valuable information. In addition, there are practical
challenges of large population studies that many current assays are either too slow or too noisy to meet.
With the capacity to process up to 96 samples in one chip and its scalability using HT screening equipment,
CometChip has the potential to overcome these limitations.
In this work, we showed optimal conditions for CometChip to measure repair kinetics of five
different types of DNA damage in human primary lymphocytes. The rates of repair vary considerably
depending on the types of damage, reflecting the dissimilarities between multiple repair pathways. We
investigated the assay's reproducibility and sensitivity using lymphocytes isolated from blood samples from
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56 healthy volunteers and showed that there are relatively small but significant differences in oxidative
damage repair kinetics among people. Based upon the observation of a sevenfold variation in repair rates,
the population is tentatively divided into groups with "very fast", "fast", "medium", or "slow" repair.
A key limitation of this study is the high variability between experiments using PBMCs isolated
from the same blood sample. A significant trend toward higher DNA damage during the course of the study
is observed in both TK6 and #00 and may contribute to the high experimental noise. Closer examination of
the trend and changes in experimental conditions (e.g. time of day, new culture media) may yield insights
into the potential cause of this batch effect. In addition, each experiment requires the recovery of
cryopreserved PBMCs via thawing and the activation of T-lymphocytes via mitogen stimulation, both of
which are highly noisy processes.
Future works to expand the capacity of CometChip for DNA repair measurement should
incorporate the use of more site-specific enzymes and whenever possible include a genetic cell model
carrying a defect in a major repair pathway in order to assess the contribution of the pathway. Potential
correlations between the results in the current population study and the demographic as well as lifestyle
information from each volunteer (e.g. age, weight, diet and exercise habits) should be explored.
Collaborators in this project also used stimulated T-lymphocytes from the same cultures to analyze for the
repair of plasmid reporters carrying ten different types of repair substrates using the FM-HCR assay.
Comparisons of oxidative damage repair kinetics and repair capacity profile may potentially shed light into
the role of each pathway in the repair of oxidative damage. In the next population study, the repair of all
five types of DNA damage should be measured in parallel to provide a more complete understanding of
DNA repair capacity.
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